<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0812223001
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rinvoq
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        UPADACITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5655.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AbbVie Ireland" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AbbVie Ireland
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>RINVOQ contains the active substance upadacitinib. It belongs to a group of medicines called Janus kinase inhibitors. By reducing the activity of an enzyme called &lsquo;Janus kinase&rsquo; in the body, RINVOQ lowers inflammation in the following</p><p>diseases:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atopic dermatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcerative colitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&rsquo;s disease</p><p>&nbsp;</p><p><u>Atopic dermatitis</u></p><p>RINVOQ is used to treat adults and adolescents 12 years and older with moderate to severe atopic</p><p>dermatitis, also known as atopic eczema. RINVOQ may be used with eczema medicines that you apply to the skin or it may be used on its own.</p><p>&nbsp;</p><p>Taking RINVOQ can improve the condition of your skin, and reduce itching and flares. RINVOQ can help improve symptoms of pain, anxiety and depression that people with atopic dermatitis may have. RINVOQ can also help improve your sleep disturbance and overall quality of life.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p>Ulcerative colitis is an inflammatory disease of the large bowel. RINVOQ is used to treat adults with ulcerative colitis who did not respond well enough or did not tolerate previous therapy.</p><p>&nbsp;</p><p>RINVOQ can help to reduce the signs and symptoms of the disease including bloody stools, abdominal pain and the need to rush to and the number of times you go to the toilet. These effects can enable your normal daily activities and reduce fatigue.</p><p>&nbsp;</p><p><u>Crohn&rsquo;s disease</u></p><p>Crohn&rsquo;s disease is an inflammatory disease that may involve any part of the digestive tract, but most commonly affects the bowel. RINVOQ is used to treat adults with Crohn&rsquo;s disease who did not respond well enough or did not tolerate previous therapy.</p><p><u>&nbsp;</u></p><p>RINVOQ can help to reduce the signs and symptoms of the disease including the need to rush to and the number of times you go to the toilet, abdominal pain, and the inflammation of your intestinal lining. These effects can enable your normal daily activities and reduce fatigue.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take RINVOQ</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to upadacitinib or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection (such as pneumonia or bacterial skin infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have active tuberculosis (TB)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant (see section Pregnancy, breast-feeding and contraception)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before and during treatment with RINVOQ if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an infection or if you often get infections. Tell your doctor if you get symptoms such as fever, wounds, feeling more tired than usual or dental problems as these can be signs of infection. RINVOQ can reduce your body&rsquo;s ability to fight infections and may make an existing infection worse or increase the chance of you getting a new infection. If you have diabetes or are 65 years of age or older you may have an increased chance of getting infectionsyou have had tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting RINVOQ and may retest during treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a herpes zoster infection (shingles), because RINVOQ may allow it to come back. Tell your doctor if you get a painful skin rash with blisters as these can be signs of shingles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had hepatitis B or C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have recently had or plan to have a vaccination (immunisation) - this is because live vaccines are not recommended while using RINVOQ</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or had in the past cancer, smoke or have smoked in the past, because your doctor will discuss with you if RINVOQ is appropriate for you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-melanoma skin cancer has been observed in patients taking RINVOQ. Your doctor may recommend that you have regular skin examinations while taking RINVOQ. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have, or have had, heart problems, because your doctor will discuss with you if RINVOQ is appropriate for you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your liver does not work as well as it should</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) or have an increased risk for developing this (for example: if you had recent major surgery, if you use hormonal contraceptives\hormonal replacement therapy, if a blood clotting disorder is identified in you or your close relatives). Your doctor will discuss with you if RINVOQ is appropriate for you. Tell your doctor if you get sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discolouration in the leg or arm as these can be signs of blood clots in the veins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have unexplained stomach (abdominal) pain, have or have had diverticulitis (painful inflammation of small pockets in the lining of your intestine) or ulcers in your stomach or intestines, or are taking non-steroidal anti-inflammatory medicines.</p><p>&nbsp;</p><p>&nbsp;If you notice any of the following serious side effects, tell a doctor straight away:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms such as a rash (hives), trouble breathing, or swelling of your lips, tongue, or throat, you may be having an allergic reaction. Some people taking RINVOQ had serious allergic reactions. If you have any of these symptoms during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help straight away</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe stomach pain especially accompanied by fever, nausea, and vomiting.</p><p><strong>&nbsp;</strong></p><p><strong>Blood tests</strong></p><p>You will need blood tests before you start taking RINVOQ, or while you are taking it. This is to check for a low red blood cell count (anaemia), low white blood cell count (neutropaenia or lymphopaenia), high blood fat (cholesterol) or high levels of liver enzymes. The tests are to check that treatment with RINVOQ is not causing problems.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>There is a higher rate of infection in patients 65 years of age and older. Tell your doctor as soon as you notice any signs or symptoms of an infection.</p><p>&nbsp;</p><p>Patients 65 years of age and older may be at increased risk of infections, heart problems including heart attack, and some types of cancer. Your doctor will discuss with you if RINVOQ is appropriate for you.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>RINVOQ is not recommended for use in children under 12 years of age or adolescents weighing less than 30&nbsp;kg with atopic dermatitis. This is because it has not been studied in these patients.</p><p>&nbsp;</p><p>RINVOQ is not recommended for use in children and adolescents under 18 years of age with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis),ulcerative colitis, or Crohn&rsquo;s disease. This is because it has not been studied in this age group.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and RINVOQ</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines may reduce how well RINVOQ works or may increase the risk of getting side effects. It is very important to talk to your doctor or pharmacist if you are taking any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat fungal infections (such as itraconazole, posaconazole or voriconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat bacterial infections (such as clarithromycin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat Cushing&rsquo;s syndrome (such as ketoconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat tuberculosis (such as rifampicin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat seizures or fits (such as phenytoin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect your immune system (such as azathioprine, 6-mercaptopurine, ciclosporin and tacrolimus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may increase your risk of gastrointestinal perforation or diverticulitis such as non-steroidal anti-inflammatory medicines (usually used to treat painful and/or inflammatory conditions of muscle or joints), and/or opioids (used to treat severe pain), and/or corticosteroids (usually used to treat inflammatory conditions) &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>If any of the above apply to you or you are not sure, talk to your doctor or pharmacist before taking RINVOQ.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and contraception</strong></p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>RINVOQ must not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor before taking this medicine. You should not use RINVOQ while breast-feeding as it is not known if this medicine passes into breast milk. You and your doctor should decide if you will breast-feed or use RINVOQ. You should not do both.</p><p>&nbsp;</p><p><u>Contraception </u></p><p>If you are a woman of child-bearing potential, you must use effective contraception to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose of RINVOQ. If you become pregnant during this time, you must talk to your doctor straight away.</p><p>&nbsp;</p><p>If your child has her first menstrual period while taking RINVOQ, you should inform the doctor.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>RINVOQ has no effect or limited effect on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you.</strong> Check with your doctor or pharmacist if you are not sure.</p><p><u>&nbsp;</u></p><p><strong>How much to take</strong></p><p><u>&nbsp;</u></p><p><u>If you have</u><u> </u><u>a</u><u>topic dermatitis</u></p><p><em>&nbsp;</em></p><p><em>Adults</em>:</p><p>The recommended dose is 15&nbsp;mg or 30&nbsp;mg as prescribed by your doctor, as one tablet once a day.</p><p>Your doctor may increase or decrease your dose depending on how well the medicine is working.</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>If you are 65 years of age or older, the recommended dose is 15&nbsp;mg once a day.</p><p>&nbsp;</p><p><em>Adolescents (from 12 to 17 years of age) weighing at least 30&nbsp;kg:</em></p><p>The recommended dose is one 15&nbsp;mg tablet once a day.</p><p>&nbsp;</p><p><u>If you have ulcerative colitis</u></p><p>&nbsp;</p><p>The recommended dose is one 45&nbsp;mg tablet once a day for 8 weeks. Your doctor may decide to extend the initial 45&nbsp;mg dose for another 8 weeks (for 16 weeks total). This will be followed by one 15&nbsp;mg or one 30&nbsp;mg tablet once a day for your long-term treatment. Your doctor may increase or decrease your dose depending on how you respond to the medicine.</p><p><em>&nbsp;</em></p><p><em>Elderly:</em></p><p>If you are 65 years of age or older, the recommended dose is 15&nbsp;mg once a day for your long-term treatment.</p><p>&nbsp;</p><p>Your doctor may reduce your dose if you have kidney problems, or you are prescribed certain other medicines.</p><p><strong>&nbsp;</strong></p><p><u>If you have Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>The recommended dose is one 45&nbsp;mg tablet once a day for 12 weeks. This will be followed by one 15&nbsp;mg or one 30&nbsp;mg tablet once a day for your long-term treatment. Your doctor may increase or decrease your dose depending on how you respond to the medicine.</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>If you are 65 years of age or older, the recommended dose is 15&nbsp;mg once a day for your long-term treatment.</p><p>&nbsp;</p><p>Your doctor may reduce your dose if you have kidney problems, or you are prescribed certain other medicines.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>How to take</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with water. Do not split, crush, chew or break the tablet before swallowing as it may change how much medicine gets into your body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To help you remember to take RINVOQ, take it at the same time every day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets can be taken with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not swallow the desiccant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid food or drink containing grapefruit whilst you are taking (or being treated with) RINVOQ as these may make side effects more likely, by increasing the amount of medicine in your body.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more RINVOQ than you should</strong></p><p>If you take more RINVOQ than you should, contact your doctor. You may get some of the side effects listed in section 4.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take RINVOQ</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose, take it as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget your dose for an entire day, just skip the missed dose and take only a single dose as usual the following day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p><strong>If you stop taking RINVOQ</strong></p><p>Do not stop taking RINVOQ unless your doctor tells you to stop taking it.</p><p>&nbsp;</p><p><strong>How to open the bottle</strong></p><p>&nbsp;</p><p><img alt="" width="602" height="580" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, RINVOQ can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects</strong></p><p>Talk to your doctor or get medical help straight away if you get any signs of infection such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shingles or painful skin rash with blisters (herpes zoster) &ndash; common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the lung (pneumonia), which may cause shortness of breath, fever, and a cough with mucus &ndash; common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection in the blood (sepsis) &ndash; uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (chest tightness, wheezing, swelling of the lips, tongue or throat, hives) &ndash; uncommon (may affect up to 1 in 100 people)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Talk to your doctor<strong> </strong>if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat and nose infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-melanoma skin cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cold sores (herpes simplex)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick in the stomach (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in an enzyme called creatine kinase, shown by blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell counts shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of cholesterol (a type of fat in the blood) as shown in tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of liver enzymes, shown by blood tests (sign of liver problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation (swelling) of the hair follicles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu (influenza)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your belly (abdomen)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue (feeling unusually tired and weak)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrush in the mouth (white patches in the mouth)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of triglycerides (a type of fat) in the blood, as shown in tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diverticulitis (painful inflammation of small pockets in the lining of your intestine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal perforation (a hole in the bowel)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister label and carton after &lsquo;EXP&rsquo;.</p><p>&nbsp;</p><p>Store in original bottle with the lid tightly closed to protect from moisture.</p><p>&nbsp;</p><p>&nbsp;</p><p>Store below 30˚C</p><p>&nbsp;</p><p>Do not split, crush, or chew the tablet.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>RINVOQ 30&nbsp;mg prolonged-release tablets</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30&nbsp;mg upadacitinib.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Core tablet: microcrystalline cellulose, mannitol, tartaric acid, hypromellose, silica colloidal anhydrous, magnesium stearate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coating: poly(vinyl alcohol), macrogol, talc, titanium dioxide (E171), iron oxide red (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	RINVOQ 30 mg prolonged-release tablets

	RINVOQ 30 mg prolonged-release tablets are red, oblong, biconvex tablets imprinted on one side with ‘a30’.

RINVOQ is available in bottles with desiccant containing 30 prolonged-release tablets, each pack contains 1 bottle (30 tablet pack) or 3 bottles (90 tablet pack).
	
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>AbbVie Deutschland GmbH &amp; Co. KG</p><p>Knollstrasse</p><p>67061 Ludwigshafen</p><p>Germany</p><p><strong>Manufacturer</strong></p><p>AbbVie Ireland NL B.V.</p><p>Sligo, Ireland</p><p>Batch releaser:</p><p>AbbVie S.r.l.</p><p>04011 Campoverde di Aprilia, (Latina), Italy</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2023

To reporting of side effects

•	Saudi Arabia
The National Pharmacovigilance and Drug Safety Centre (NPC)

Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa 
Website: https://ade.sfda.gov.sa/ 


•	Other GCC States:

-	Please contact the relevant competent authority.


Council of Arab Health Ministries

The following statement issued by the Council of Arab Health Ministries should be printed in PIL
-	This is a medicament
-	Medicament is a product which affects your health and its consumption contrary to
-	instructions is dangerous for you.
-	Follow strictly the doctor’s prescription, the method of use and the instructions of the
-	pharmacist who sold the medicament.
-	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-	Do not by yourself interrupt the period of treatment prescribed for you.
-	Do not repeat the same prescription without consulting your doctor.
-	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacist




            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>رينفوك</strong> على المادة الفعالة يوباداسيتينيب، ينتمي إلى مجموعة من الأدوية تسمى مثبطات لجانوس كيناز (JAK) من خلال تقليل نشاط إنزيم يسمى لجانوس كيناز في الجسم ، يقلل <strong>رينفوك</strong> من الالتهاب في الأمراض التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد التأتبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كرون</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التهاب الجلد التأتبي</strong><strong> :</strong></p><p dir="RTL">يستخدم <strong>رينفوك</strong> لعلاج البالغين والمراهقين بعمر 12 عامًا فما فوق المصابين بحالات التهاب الجلد التأتبي المتوسطة إلى الشديدة، المعروف أيضًا باسم الأكزيما التأتبية. يمكن استخدام <strong>رينفوك</strong> مع أدوية الأكزيما الموضعية على الجلد أو يمكن استخدامه بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي تناول <strong>رينفوك</strong> إلى تحسين حالة بشرتك وتقليل الحكة والتهيج، يمكن أن يساعد <strong>رينفوك</strong> في تحسين أعراض الألم والقلق والاكتئاب التي قد يعاني منها الأشخاص المصابون بالتهاب الجلد التأتبي، يمكن أن يساعد <strong>رينفوك</strong> أيضًا في تحسين اضطرابات النوم وتحسين نوعية الحياة بشكل عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب القولون التقرحي:</strong></p><p dir="RTL">التهاب القولون التقرحي هو مرض التهابي يصيب الأمعاء الغليظة. يستخدم <strong>رينفوك</strong> لعلاج البالغين المصابين بالتهاب القولون التقرحي الذين لم يستجيبوا بشكل جيد بما فيه الكفاية أو لم يتحملوا العلاج السابق.</p><p dir="RTL">يمكن أن يساعد <strong>رينفوك</strong> في تقليل علامات وأعراض المرض بما في ذلك البراز الدموي وآلام البطن والحاجة إلى التسرع وعدد مرات الذهاب إلى المرحاض. هذه التأثيرات يمكن أن تساعد على ممارسة أنشطتك اليومية العادية وتقليل التعب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرض كرون:</strong></p><p dir="RTL">داء كرون هو مرض التهابي قد يصيب أي جزء من الجهاز الهضمي ، ولكنه يؤثر بشكل شائع على الأمعاء. يستخدم <strong>رينفوك</strong> لعلاج البالغين المصابين بداء كرون والذين لم يستجيبوا جيدًا أو لم يتحملوا العلاج السابق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يساعد <strong>رينفوك</strong> في تقليل علامات وأعراض المرض بما في ذلك الحاجة إلى التسرع وعدد المرات التي تذهب فيها إلى المرحاض وآلام البطن والتهاب بطانة الأمعاء. هذه التأثيرات يمكن أن تساعد على ممارسة أنشطتك اليومية العادية وتقليل التعب.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتلقى رينفوك:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;إذا كنت مصابا بالحساسية تجاه يوباداسيتينيب أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;إذا كنت مصاب بالعدوى الشديد (مثل الالتهاب الرئوي أو عدوى الجلد البكتيرية)</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;إذا كنت مصابا بالسل النشط.</p><ul><li dir="RTL">إذا كنت تعاني من مشاكل الكبد.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ امرأة حاملا (انظر قسم الحمل والرضاعة ومنع الحمل)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تحذيرات واحتياطات</u></strong></p><p dir="RTL">تحدث إلى طبيبك، الصيدلاني أو الممرضة قبل وأثناء استعمال <strong>رينفوك</strong> إذا:</p><p dir="RTL">₋&nbsp;&nbsp; إذا كان لديك عدوى أو إذا كنت تصاب بالعدوى في كثير من الأحيان. أخبر طبيبك إذا ظهرت عليك أعراض مثل: الحمى أو الجروح أو الشعور بالتعب أكثر من المعتاد أو مشاكل الأسنان حيث يمكن أن تكون هذه علامات للإصابة بالعدوى. يمكن أن يقلل رينفوك من قدرة جسمك على مكافحة العدوى وبالتالي قد يؤدي إلى تفاقم العدوى التي لديك بالفعل، أو يزيد من احتمالية إصابتك بعدوى جديدة. إذا كنت مصابًا بداء السكري أو تبلغ من العمر 65 عامًا أو أكثر، فقد تزداد فرصة الإصابة بالعدوى</p><p dir="RTL">₋&nbsp;&nbsp; أصبت بالسل أو كنت على اتصال وثيق بشخص مصاب بالسل. سيقوم طبيبك بفحصك لمرض السل قبل بدء <strong>رينفوك</strong> وقد يعيد الاختبار أثناء العلاج</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp; لقد أصبت بعدوى الهربس النطاقي (القوباء المنطقية)، لأن <strong>رينفوك</strong> قد يسمح لهذه العدوى بالعودة. أخبر طبيبك إذا أصبت بطفح جلدي مؤلم مصحوب ببثور حيث يمكن أن تكون هذه علامات على القوباء المنطقية</p><p dir="RTL">₋&nbsp;&nbsp; عانيت في أي وقت مضى من التهاب الكبد B أو C</p><p dir="RTL">₋&nbsp;&nbsp; &nbsp;تلقيت مؤخرًا أو تخطط للحصول على لقاح (تطعيم) - هذا بسبب أن للقاحات الحية أثناء استخدام <strong>رينفوك</strong> غير موصى بها</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالسرطان أو أصبت به في الماضي أو دخنت أو كنت مدخنًا في الماضي، لأنه سيتعين على طبيبك أن يقرر ما إذا كان لا يزال من الممكن إعطاؤك رينفوك</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ سرطان الجلد غير الميلانيني في المرضى الذين يتناولون رينفوك. قد يوصي طبيبك بإجراء فحوصات جلدية منتظمة أثناء تناول رينفوك. تحدث إلى طبيبك إذا أصبت بآفة جلدية جديدة أثناء العلاج أو أي تغيير في الآفات الموجودة على الجلد</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك الآن، أو في السابق، مشاكل في القلب، لأنه سيتعين على طبيبك أن يقرر ما إذا كان لا يزال من الممكن إعطاؤك رينفوك</p><p dir="RTL">₋&nbsp;&nbsp; لديك مشاكل بالكبد، كبدك لا يعمل كما ينبغي</p><p dir="RTL">₋&nbsp;&nbsp; إذا عانيت سابقًا من جلطات دموية في أوردة ساقيك (تخثر وريدي عميق (DVT)) أو في رئتيك (انسداد (انصمام) رئوي) أو لديك خطر متزايد للإصابة بالجلطة (على سبيل المثال: إذا أجريت جراحة كبرى مؤخرًا، أو إذا كنت تستخدمين موانع حمل هرمونية / العلاج الهرموني التعويضي (العلاج بالهرمونات البديلة)، إذا كان لديك اضطراب تخثر الدم أو لدى أقاربك المقربين). سيناقش طبيبك معك ما إذا كان رينفوك مناسبًا لك. أخبر طبيبك إذا كنت تعاني من ضيق مفاجئ في التنفس أو صعوبة في التنفس، أو ألم في الصدر أو ألم في الجزء العلوي من الظهر، أو تورم في الساق أو الذراع، أو ألم في الساق أو ليونة، أو احمرار أو تغير في لون الساق أو الذراع حيث يمكن أن تكون هذه علامات على جلطات دموية في الأوردة</p><p dir="RTL">₋&nbsp;&nbsp; لديك مشاكل في الكلى</p><p dir="RTL">₋&nbsp;&nbsp; إذا كان لديك ألم في المعدة (في البطن) غير مبرر، أو إذا كنت تعاني الآن أو في السابق من التهاب الرتج (التهاب مؤلم في الجيوب الصغيرة (الرتوج) في بطانة الأمعاء) أو تقرحات في معدتك أو أمعائك، أو تتناول مضادات التهاب غير ستيرويدية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الآثار الجانبية الخطيرة التالية ، أخبر الطبيب على الفور:</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مثل الطفح الجلدي (خلايا النحل أو الشرى) ، وصعوبة التنفس ، أو تورم الشفاه أو اللسان أو الحلق ، قد يكون لديك رد فعل تحسسي. كان لدى بعض الأشخاص الذين يتناولون <strong>رينفوك</strong> ردود فعل تحسسية خطيرة. إذا كان لديك أي من هذه الأعراض أثناء العلاج بـ <strong>رينفوك</strong>، فتوقف عن تناول <strong>رينفوك</strong> واحصل على مساعدة طبية طارئة على الفور</p><p dir="RTL">₋&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في المعدة خاصة المصحوبة بحمى وغثيان وقيء.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>اختبارات الدم</strong></p><p dir="RTL">ستحتاج لإجراء اختبارات الدم قبل البدء بتناول <strong>رينفوك</strong> أو في أثناء تناوله، وذلك لتحري وجود قلة عدد خلايا الدم الحمراء (فقر الدم)، قلة عدد خلايا الدم البيضاء (قلة العدلات أو قلة اللمفاويات)، ارتفاع معدل شحوم الدم (الكولسترول) أو ارتفاع معدل الخمائر الكبدية. تُجرى الاختبارات للتأكد من أن العلاج بواسطة <strong>رينفوك</strong> لا يسبب اضطرابات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>كبار السن </u></strong></p><p dir="RTL">هناك معدل إصابة أعلى لدى المرضى الذين تبلغ أعمارهم 65 عامًا فما فوق. أخبر طبيبك بمجرد أن تلاحظ أي علامات أو أعراض للعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون المرضى الذين تبلغ أعمارهم 65 عامًا وما فوق أكثر عرضة للإصابة بالعدوى ومشاكل القلب بما في ذلك النوبة القلبية وبعض أنواع السرطان. سيناقش طبيبك معك ما إذا كان رينفوك مناسبًا لك.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأطفال والمراهقون</u></strong></p><p dir="RTL">لا ينصح باستخدام<strong> رينفوك </strong>&nbsp;للأطفال دون سن ١٢ عامًا أو المراهقين الذين يقل وزنهم عن 30 كجم مع التهاب الجلد التأتبي. وهذا لأن <strong>رينفوك</strong> لم يدرس في هذه المجموعة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينصح باستخدام <strong>رينفوك</strong>&nbsp; في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا المصابين بالتهاب المفاصل الروماتويدي والتهاب المفاصل الصدفي والتهاب المفاصل الفقاري المحوري (التهاب الفقار الفقاري المحوري غير الشعاعي والتهاب الفقار اللاصق) ، التهاب القولون التقرحي، أو مرض كرون. هذا لأنه لم يتم دراسته في هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong><u>الأدوية الأخرى ورينفوك</u></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. وذلك لأن بعض الأدوية قد تقلل من فعالية <strong>رينفوك </strong>&nbsp;أو قد تزيد من خطر حدوث آثار جانبية. من المهم جدًا التحدث إلى طبيبك أو الصيدلي إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL"><strong>&bull; </strong>أدوية لعلاج الالتهابات الفطرية (مثل إيتراكونازول ، بوساكونازول أو فوريكونازول)</p><p dir="RTL">&bull; أدوية لعلاج الالتهابات البكتيرية (مثل كلاريثروميسين)</p><p dir="RTL">&bull; أدوية لعلاج متلازمة كوشينغ (مثل الكيتوكونازول)</p><p dir="RTL">&bull; أدوية لعلاج السل (مثل ريفامبيسين)</p><p dir="RTL">&bull; أدوية لعلاج النوبات أو النوبات المرضية (مثل الفينيتوين)</p><p dir="RTL">&bull; أدوية التي تؤثر على جهاز المناعة لديك (مثل الآزوثيوبرين،&nbsp; 6- مركابتوبورين ، والسيكلوسبورين والتاكروليموس)</p><p dir="RTL">&bull; الأدوية التي قد تزيد من خطر الإصابة بثقب الأمعاء أو بالتهاب الرتج مثل الأدوية المضادة للالتهابات غير الستيرويدية (تستخدم عادة لعلاج الحالات المؤلمة و / أو الالتهابية للعضلات أو المفاصل) ، و/ أو المواد الأفيونية (المستخدمة لعلاج الألم الشديد) ، و/ أو الكورتيكوستيرويدات (تستخدم عادة لعلاج الحالات الالتهابية) (انظر القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك أو لم تكن متأكدًا ، تحدث إلى طبيبك أو الصيدلي قبل تناول <strong>رينفوك </strong>&nbsp;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>رينفوك مع الطعام والشراب</strong></p><p dir="RTL">يجب تناول <strong>رينفوك</strong> عن طريق الفم مرة واحدة يوميا مع الطعام أو من دونه في أي وقت من اليوم.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>رينفوك والحمل، منع الحمل والإرضاع</u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب الامتناع عن استعمال <strong>رينفوك</strong> في أثناء الحمل.</p><p>&nbsp;</p><p dir="RTL"><u>الإرضاع</u></p><p dir="RTL">إن كنت مرضعا أو إن كنت تخططين للإرضاع تحدثي إلى طبيبك قبل استعمال هذا الدواء.</p><p dir="RTL">يجب أن لا تستعملي <strong>رينفوك</strong> في أثناء الإرضاع&nbsp; لأنه لا يعرف فيما إذا كان هذا الدواء ينتقل إلى حليب الأم. يجب أن تقرري أنت وطبيبك ما إذا كنت سترضع أم تستخدم <strong>رينفوك</strong>. يجب عدم القيام بالأمرين على حد سواء.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>منع الحمل </u></p><p dir="RTL">إذا كنت امرأة في سن الحمل، فيجب أن تستخدمي وسيلة موثوقة لمنع الحمل لكي تتفادي حدوث الحمل في أثناء تلقي <strong>رينفوك</strong> ، ولمدة ٤ اسابيع على الأقل بعد تناول آخر جرعة من <strong>رينفوك</strong>. إذا أصبحت حاملا في هذه الفترة، فيجب أن تخبري طيبك على الفور.</p><p dir="RTL">إذا كانت لطفلتك أول دورة شهرية لها أثناء تناول <strong>رينفوك</strong>، يجب عليك إبلاغ الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآلات</strong></p><p dir="RTL">يمتلك <strong>رينفوك</strong> تأثيرا ضئيلا أو تأثيراً محدوداً على القدرة على القيادة أو استعمال الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>إذا كان لديك مرض </u></strong><strong><u>التهاب الجلد التأتبي:</u></strong></p><p dir="RTL"><strong>البالغين:</strong></p><p dir="RTL">الجرعة الموصى بها من <strong>رينفوك</strong> هي ١٥ مجم أو ٣٠ مجم مرة واحدة يومياً بحسب إرشادات الطبيب</p><p dir="RTL">قد يزيد طبيبك أو ينقص جرعتك اعتمادًا على مدى عمل الدواء.</p><p dir="RTL"><strong>الكبار بالسن:</strong></p><p dir="RTL">إذا كان عمرك 65 عامًا أو أكبر، الجرعة الموصى بها من <strong>رينفوك</strong> هي 15 مجم مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراهقون (من 12 إلى 17 عامًا) الذين لا يقل وزنهم عن 30 كجم:</strong></p><p dir="RTL">الجرعة الموصى بها هي 15 مجم مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>إذا كان لديك مرض التهاب القولون التقرحي</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي 45 مجم مرة واحدة يوميًا لمدة 8 أسابيع. قد يقرر طبيبك تمديد الجرعة الأولية البالغة 45 مجم لمدة 8 أسابيع أخرى (لمدة 16 أسبوعًا إجمالاً). يتبع ذلك 15 مجم أو 30 مجم مرة واحدة يوميًا لعلاجك طويل الأمد. قد يزيد طبيبك أو ينقص جرعتك اعتمادًا على كيفية استجابتك للدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكبار بالسن</strong> :</p><p dir="RTL">إذا كان عمرك 65 عامًا أو أكثر ، فإن الجرعة الموصى بها هي 15 مجم مرة واحدة يوميًا لعلاجك طويل الأمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقوم طبيبك بتقليل جرعتك إذا كنت تعاني من مشاكل في الكلى ، أو إذا وصفت لك بعض الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>إ</u></strong><strong><u>ذا كنت تعاني من مرض كرون</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد 45 مجم مرة واحدة يوميًا لمدة 12 أسبوعًا. سيتبع ذلك قرص واحد 15 مجم أو 30 مجم مرة واحدة يوميًا لعلاجك طويل الأمد. قد يزيد طبيبك أو ينقص جرعتك اعتمادًا على كيفية استجابتك للدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكبار بالسن</strong> :</p><p dir="RTL">إذا كان عمرك 65 عامًا أو أكثر ، فإن الجرعة الموصى بها هي 15 مجم مرة واحدة يوميًا لعلاجك طويل الأمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقوم طبيبك بتقليل جرعتك إذا كنت تعاني من مشاكل في الكلى ، أو إذا تم وصف أدوية أخرى لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تتناول رينفوك:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص كاملاً مع الماء. لا تقم بتقسيم القرص أو سحقه أو مضغه أو كسره قبل البلع لأنه قد يغير كمية الدواء التي تدخل جسمك. لمساعدتك على تذكر تناول <strong>رينفوك</strong> ، خذها في نفس الوقت كل يوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول الأقراص مع الطعام أو بدونه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تبتلع كيس المجفف.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت أكثر مما ينبغي من رينفوك</strong></p><p dir="RTL">إذا تناولت أكثر مما ينبغي من <strong>رينفوك</strong> ، فاتصل بطبيبك. قد تصاب ببعض التأثيرات الجانبية المذكورة في القسم ٤.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>إذا نسيت أن تتناول رينفوك</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول إحدى الجرعات فعليك أن تتناولها بأقرب وقت ممكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت جرعتك طوال اليوم، فما عليك إلا تجاوز هذه الجرعة المنسية وتناول جرعة مفردة فقط كالمعتاد في اليوم التالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة للتعويض عن القرص الذي نسيت تناوله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الطعام أو الشراب الذي يحتوي على الجريب فروت أثناء تناولك (أو العلاج بـ) <strong>رينفوك</strong> لأن هذه قد تزيد من احتمال حدوث آثار جانبية ، عن طريق زيادة كمية الدواء في جسمك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول رينفوك</strong></p><p dir="RTL">لا تتوقف عن تناول <strong>رينفوك</strong> ما لم يشر عليك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>كيف تفتح القنينة</u></strong></p><p>&nbsp;</p><p><img alt="" width="670" height="821" src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب <strong>رينفوك</strong> تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة</strong></p><p dir="RTL">تحدث إلى طبيبك أو احصل على مساعدة طبية فورية إذا ظهرت أي من علامات العدوى مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس النطاقي (القوباء المنطقية) أو الطفح الجلدي المؤلم المترافق بنُفاطات: شائعة (قد تصيب حتى ١ من ١٠ أشخاص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; عدوى رئوية (ذات الرئة)، مما قد يسبب ضيق النفس، حمى، وسعال مترافق بمخاط : شائعة (قد تصيب حتى ١ من ١٠ أشخاص).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; العدوى في الدم (إنتان وتعفن الدم) &ndash; أعراض غير شائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; رد فعل تحسسي (ضيق في الصدر ، صفير عند التنفس ، تورم الشفتين ، اللسان أو الحلق ، خلايا النحل أو الشرى) - غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت حدوث أي من التأثيرات الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدا </strong>(قد تصيب أكثر من ١ من ١٠ أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى البلعوم والأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب حتى ١ من ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد غير الميلانيني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قروح البرد (الهربس أو العقبول البسيط)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بغثيان في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل إنزيم الكرياتين كيناز، حسب ما تظهر اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحفاض أعداد خلايا الدم البيضاء في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدلات الكولسترول (أحد أنواع شحوم الدم) حسب ما تظهر اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدلات الإنزيمات الكبدية، كما تظهر اختبارات الدم (علامة على اضطرابات الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب (انتفاخ) بصيلات الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;فقر دم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التعب (الشعور بالتعب والضعف بشكل غير عادي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتيكاريا (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى &nbsp;١ من ١٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلاق في الفم (بقع بيضاء في باطن الفم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل ثلاثيات الغليسيريد (أحد أنواع شحوم الدم) كما تظهر الاختبارات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرتج (التهاب مؤلم في الجيوب الصغيرة في بطانة الأمعاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب في الأمعاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التبليغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا عانيت من أي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية ، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على شريط الدواء والكرتون بعد &rsquo;EXP&lsquo;.</p><p>&nbsp;</p><p dir="RTL">احفظه ضمن درجة حرارة تقلّ عن ٣٠ درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">احفظه في عبوته الأصلية لتحميه من الرطوبة، واحرص على أن تكون القنينة مغلقة بإحكام.</p><p>&nbsp;</p><p dir="RTL">لا تقسم القرص أو تسحقه، أو تمضغه.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي مكونات رينفوك</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي كل قرص ممتد المفعول على يوباداسيتينيب هيميهايدرات ، أي ما يعادل 30 ملغ يوباداسيتينيب.</p><p dir="RTL">&bull; <strong>المكونات الأخرى هي:</strong></p><p dir="RTL">&bull; الأقراص الأساسية: مكروكريستالين سيللوز ، مانيتول ، حمض التارتار ، هيبروميلوز ، ثنائي أكسيد السيليكون الغرواني ، ستيرات المغنيسيوم.</p><p dir="RTL">&bull; غلاف القرص: كحول البولي فنيل ، ماكروغول ، التلك ، ثاني أكسيد التيتانيوم (E171) ، أكسيد الحديد الأحمر (E172).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو رينفوك ومحتويات العبوة</strong></p><p dir="RTL">أقراص <strong>رينفوك</strong> ٣٠ ملغ هي أقراص ممتدة المفعول ، حمراء ، متطاولة ، محدبة الوجهين مطبوعة على جانب واحد بـ &quot;a30&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر <strong>رينفوك</strong> في قناني تحتوي على مادة مجففة&nbsp; وتحتوي على 30 قرصًا ممتد المفعول ، تحتوي كل عبوة على قنينة واحدة (عبوة 30 قرصًا) أو 3 زجاجات (عبوة تحتوي على 90 قرصًا)</p><p>&nbsp;</p><p><strong>قد لا يتم تسويق كافة أحجام العبوات</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">آبفي دويتشلاند جي إم بي إتش وشركاه كي جي</p><p dir="RTL">نولستراس</p><p dir="RTL">٦٧٠٦١ لودفيغسهافن</p><p dir="RTL">ألمانيا</p><p>&nbsp;</p><p dir="RTL"><strong>الجهة الصانعة</strong></p><p dir="RTL">آبفي أيرلندا إن إل بي في</p><p dir="RTL">&nbsp;سليغو، إيرلندا</p><p>المصنع الذي &nbsp;صدر منه رقم التشغيلة :</p><p dir="RTL">آبفي إس آر إل&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">٠٤٠١١ كامبوفيردي دي أبريليا، (لاتينا)، إيطاليا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في ابريل ٢٠٢٣
	
	
	
	
	
	
	للإبلاغ عن التأثيرات الجانبية

•	المملكة العربية السعودية

المركز الوطني للتيقظ والسلامة الدوائية  
-	فاكس: 7662-205-11-966+
-	مركز الاتصال بهيئة الغذاء والدواء السعودية ١٩٩٩٩
-	البريد الالكتروني: npc.drug@sfda.gov.sa
-	الموقع الالكتروني:  /https://ade.sfda.gov.sa



•	بلدان مجلس التعاون الخليجي الأخرى:

-	الرجاء الاتصال بالجهات المختصة المسؤولة.



مجلس وزراء الصحة العرب  

إن هذا دواء 
-	 الدواء مستحضر يؤثر على صحّتك، واستهلاكه خلافاً للتعليمات يعرّضك للخطر. 
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك.
-	إن الطبيب والصيدلاني هما الخبيران في الدواء وبنفعه وضرره.  
-	لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك.
-	لا تكرر صرف الدواء بدون استشارة الطبيب.  
-	لا تترك الأدوية في متناول أيدي الأطفال. 

      مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب






        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RINVOQ 30 mg prolonged-release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RINVOQ 30 mg prolonged-release tablets

Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg of upadacitinib.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet

RINVOQ 30 mg prolonged-release tablets

Red 14 x 8 mm, oblong biconvex prolonged-release tablets imprinted on one side with ‘a30’.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Atopic dermatitis</u></p><p>&nbsp;</p><p>RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p>&nbsp;</p><p>RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with upadacitinib should be initiated and supervised by physicians experienced in the diagnosis and treatment of conditions for which upadacitinib is indicated.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p><u>Atopic dermatitis</u></p><p><em>&nbsp;</em></p><p><em><u>Adults</u></em></p><p>The recommended dose of upadacitinib is 15&nbsp;mg or 30&nbsp;mg once daily based on individual patient presentation.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 15&nbsp;mg is recommended for patients at higher risk of venous thromboembolism (VTE), major adverse cardiovascular events (MACE) and malignancy (see section 4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 30&nbsp;mg once daily may be appropriate for patients with high disease burden who are not at higher risk of VTE, MACE and malignancy (see section 4.4) or patients with an inadequate response to 15&nbsp;mg once daily.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The lowest effective dose to maintain response should be used.</p><p>&nbsp;</p><p>For patients 65 years of age and older, the recommended dose is 15&nbsp;mg once daily (see section 4.4).</p><p>&nbsp;</p><p><em><u>Adolescents (from 12 to 17 years of age)</u></em></p><p>The recommended dose of upadacitinib is 15&nbsp;mg once daily for adolescents weighing at least 30&nbsp;kg.</p><p>&nbsp;</p><p><em>Concomitant topical therapies</em></p><p>Upadacitinib can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used for sensitive areas such as the face, neck, and intertriginous and genital areas.</p><p>Consideration should be given to discontinuing upadacitinib treatment in any patient who shows no evidence of therapeutic benefit after 12 weeks of treatment.</p><p><em>&nbsp;</em></p><p><em><u>Ulcerative colitis</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Induction</em></p><p>The recommended induction dose of upadacitinib is 45&nbsp;mg once daily for 8 weeks. For patients who do not achieve adequate therapeutic benefit by week 8, upadacitinib 45&nbsp;mg once daily may be continued for an additional 8 weeks (see sections 4.8 and 5.1). Upadacitinib should be discontinued in any patient who shows no evidence of therapeutic benefit by week 16.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Maintenance</em></p><p>The recommended maintenance dose of upadacitinib is 15&nbsp;mg or 30&nbsp;mg once daily based on individual patient presentation:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 15&nbsp;mg is recommended for patients at higher risk of VTE, MACE and malignancy (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 30&nbsp;mg once daily may be appropriate for some patients, such as those with high disease burden or requiring 16‑week induction treatment who are not at higher risk of VTE, MACE and malignancy (see section 4.4) or who do not show adequate therapeutic benefit to 15&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The lowest effective dose to maintain response should be used.</p><p>&nbsp;</p><p>For patients 65 years of age and older, the recommended dose is 15&nbsp;mg once daily (see section 4.4).</p><p><em>&nbsp;</em></p><p>In patients who have responded to treatment with upadacitinib, corticosteroids may be reduced and/or discontinued in accordance with standard of care.</p><p>&nbsp;</p><p><em><u>Crohn&rsquo;s disease </u></em></p><p><em>&nbsp;</em></p><p><em>Induction </em></p><p>The recommended induction dose of upadacitinib is 45&nbsp;mg once daily for 12 weeks. For patients who have not achieved adequate therapeutic benefit after the initial 12-week induction, prolonged induction for an additional 12 weeks with a dose of 30&nbsp;mg once daily may be considered. For these patients, upadacitinib should be discontinued if there is no evidence of therapeutic benefit after 24 weeks of treatment.</p><p><em><u>&nbsp;</u></em></p><p><em>Maintenance </em></p><p>The recommended maintenance dose of upadacitinib is 15&nbsp;mg or 30&nbsp;mg once daily based on individual patient presentation:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 15&nbsp;mg is recommended for patients at higher risk of VTE, MACE and malignancy (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 30&nbsp;mg once daily may be appropriate for patients with high disease burden who are not at higher risk of VTE, MACE and malignancy (see section 4.4) or who do not show adequate therapeutic benefit to 15&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The lowest effective dose to maintain response should be used.</p><p>&nbsp;</p><p>For patients&nbsp;65 years of age and older, the recommended maintenance dose is 15&nbsp;mg once daily (see section 4.4).</p><p>&nbsp;</p><p>In patients who have responded to treatment with upadacitinib, corticosteroids may be reduced and/or discontinued in accordance with standard of care.</p><p><u>&nbsp;</u></p><p><u>Interactions</u></p><p>&nbsp;</p><p>For patients with ulcerative colitis and Crohn&rsquo;s disease receiving strong inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole, clarithromycin), the recommended induction dose is 30&nbsp;mg once daily and the recommended maintenance dose is 15&nbsp;mg once daily (see section 4.5).</p><p><em>&nbsp;</em></p><p><u>&nbsp;</u></p><p><u>Dose initiation</u></p><p><em>&nbsp;</em></p><p>Treatment should not be initiated in patients with an absolute lymphocyte count (ALC) that is &lt;&nbsp;0.5 x 10<sup>9</sup> cells/L, an absolute neutrophil count (ANC) that is &lt;&nbsp;1&nbsp;x&nbsp;10<sup>9</sup> cells/L or who have haemoglobin (Hb) levels that are &lt;&nbsp;8&nbsp;g/dL (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Dose interruption</u></p><p>&nbsp;</p><p>Treatment should be interrupted if a patient develops a serious infection until the infection is controlled.</p><p>Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 1.</p><p><strong>Table&nbsp;1. Laboratory measures and monitoring guidance</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Laboratory measure</strong></p></td><td style="vertical-align:bottom"><p><strong>Action</strong></p></td><td style="vertical-align:top"><p><strong>Monitoring </strong><strong>guidance</strong></p></td></tr><tr><td><p>Absolute Neutrophil Count (ANC)</p></td><td><p>Treatment should be interrupted if ANC is &lt;&nbsp;1 x&nbsp;10<sup>9</sup> cells/L and may be restarted once ANC returns above this value</p></td><td rowspan="3" style="vertical-align:top"><p>Evaluate at baseline and then no later than 12 weeks after initiation of treatment. Thereafter evaluate according to individual patient management.</p><p>&nbsp;</p></td></tr><tr><td><p>Absolute Lymphocyte Count (ALC)</p></td><td><p>Treatment should be interrupted if ALC is &lt;<sup>&nbsp; </sup>0.5 x 10<sup>9</sup> cells/L and may be restarted once ALC returns above this value</p></td></tr><tr><td><p>Haemoglobin (Hb)</p></td><td><p>Treatment should be interrupted if Hb is &lt;&nbsp;8&nbsp;g/dL and may be restarted once Hb returns above this value</p></td></tr><tr><td><p>Hepatic transaminases</p></td><td><p>Treatment should be temporarily interrupted if drug-induced liver injury is suspected</p></td><td style="vertical-align:top"><p>Evaluate at baseline and thereafter according to routine patient management.</p></td></tr><tr><td><p>Lipids</p></td><td><p>Patients should be managed according to international clinical guidelines for hyperlipidaemia</p></td><td style="vertical-align:top"><p>Evaluate 12 weeks after initiation of treatment and thereafter according to international clinical guidelines for hyperlipidaemia</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>&nbsp;</p><p><em>Atopic dermatitis</em></p><p>For atopic dermatitis, doses higher than 15&nbsp;mg once daily are not recommended in patients aged 65&nbsp;years and older (see section 4.8).</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p><em>Ulcerative colitis and Crohn&rsquo;s disease</em></p><p>For ulcerative colitis and Crohn&rsquo;s disease, doses higher than 15&nbsp;mg once daily for maintenance therapy are not recommended in patients 65&nbsp;years of age and older (see section 4.8). The safety and efficacy of upadacitinib in patients 75years of age and older have not yet been established.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>No dose adjustment is required in patients with mild or moderate renal impairment. There are limited data on the use of upadacitinib in subjects with severe renal impairment (see section 5.2). Upadacitinib</p><p>should be used with caution in patients with severe renal impairment as described in Table 2. The use of upadacitinib has not been studied in subjects with end stage renal disease and is therefore not recommended for use in these patients.</p><p>&nbsp;</p><p><strong>Table 2 </strong><strong>Recommended dose for severe renal impairment<sup>a </sup></strong>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:498px"><tbody><tr><td style="vertical-align:top"><p><strong>Therapeutic indication</strong></p></td><td style="vertical-align:top"><p><strong>Recommended once daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis</p></td><td style="vertical-align:top"><p>15&nbsp;mg</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ulcerative colitis, Crohn&rsquo;s disease</p></td><td style="vertical-align:top"><p>Induction: 30&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance: 15&nbsp;mg</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup>estimated glomerular filtration rate (eGFR) 15 to &lt; 30 ml/min/1.73m<sup>2</sup></p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No dose adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment (see section 5.2). Upadacitinib should not be used in patients with severe (Child-Pugh C) hepatic impairment (see section 4.3).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of RINVOQ in children with atopic dermatitis below the age of 12&nbsp;years have not been established. No data are available. No clinical exposure data are available in adolescents &lt;&nbsp;40&nbsp;kg (see section 5.2).</p><p>&nbsp;</p><p>The safety and efficacy of RINVOQ in children and adolescents with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and Crohn&rsquo;s disease aged 0&nbsp;to&nbsp;less than 18&nbsp;years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><em>&nbsp;</em></p><p>RINVOQ is to be taken orally once daily with or without food and may be taken at any time of the day. Tablets should be swallowed whole and should not be split, crushed, or chewed in order to ensure the entire dose is delivered correctly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Active tuberculosis (TB) or active serious infections (see section 4.4).
•	Severe hepatic impairment (see section 4.2).
•	Pregnancy (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Upadacitinib should only be used if no suitable treatment alternatives are available in patients:</p><p>-&nbsp; 65 years of age and older;</p><p>-&nbsp; patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);</p><p>- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Use in patients 65 years of age and older </u></p><p><u>&nbsp;</u></p><p>Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients 65 years of age and older, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), upadacitinib should only be used in these patients if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p>In patients 65&nbsp;years of age and older, there is an increased risk of adverse reactions with upadacitinib 30&nbsp;mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15&nbsp;mg once daily (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Immunosuppressive medicinal products</u></p><p>&nbsp;</p><p>Combination with other potent immunosuppressants such as azathioprine, 6-mercaptopurine, ciclosporin, tacrolimus, and biologic DMARDs or other JAK inhibitors has not been evaluated in clinical studies and is not recommended as a risk of additive immunosuppression cannot be excluded.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Serious infections</u></p><p><u>&nbsp;</u></p><p>Serious and sometimes fatal infections have been reported in patients receiving upadacitinib. The most frequent serious infections reported with upadacitinib included pneumonia and cellulitis (see section&nbsp;4.8). Cases of bacterial meningitis and sepsis have been reported in patients receiving upadacitinib. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, oral/oesophageal candidiasis, and cryptococcosis were reported with upadacitinib.</p><p>&nbsp;</p><p>Upadacitinib should not be initiated in patients with an active, serious infection, including localised infections.</p><p>&nbsp;</p><p>Consider the risks and benefits of treatment prior to initiating upadacitinib in patients:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with chronic or recurrent infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have been exposed to tuberculosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with a history of a serious or an opportunistic infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have resided or travelled in areas of endemic tuberculosis or endemic mycoses; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with underlying conditions that may predispose them to infection.</p><p>&nbsp;</p><p>Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with upadacitinib. Upadacitinib therapy should be interrupted if a patient develops a serious or opportunistic infection. A patient who develops a new infection during treatment with upadacitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and upadacitinib therapy should be interrupted if the patient is not responding to antimicrobial therapy. Upadacitinib therapy may be resumed once the infection is controlled.</p><p>&nbsp;</p><p>A higher rate of serious infections was observed with upadacitinib 30&nbsp;mg compared to upadacitinib 15&nbsp;mg.</p><p>&nbsp;</p><p>As there is a higher incidence of infections in the elderly and in the diabetic populations in general, caution should be used when treating the elderly and patients with diabetes. In patients 65 years of age and older, upadacitinib should only be used if no suitable treatment alternatives are available (see section 4.2).</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Tuberculosis </em></p><p><em>&nbsp;</em></p><p>Patients should be screened for tuberculosis (TB) before starting upadacitinib therapy. Upadacitinib should not be given to patients with active TB (see section 4.3). Anti-TB therapy should be considered prior to initiation of upadacitinib in patients with previously untreated latent TB or in patients with risk factors for TB infection.</p><p>&nbsp;</p><p>Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.</p><p>&nbsp;</p><p>Patients should be monitored for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.</p><p><u>Viral reactivation</u></p><p>&nbsp;</p><p>Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies (see section 4.8). The risk of herpes zoster appears to be higher in Japanese patients treated with upadacitinib. If a patient develops herpes zoster, interruption of upadacitinib therapy should be considered until the episode resolves.</p><p>&nbsp;</p><p>Screening for viral hepatitis and monitoring for reactivation should be performed before starting and during therapy with upadacitinib. Patients who were positive for hepatitis C antibody and hepatitis C virus RNA were excluded from clinical studies. Patients who were positive for hepatitis B surface antigen or hepatitis B virus DNA were excluded from clinical studies. If hepatitis B virus DNA is detected while receiving upadacitinib, a liver specialist should be consulted.</p><p><u>&nbsp;</u></p><p><u>Vaccination</u></p><p>&nbsp;</p><p>No data are available on the response to vaccination with live vaccines in patients receiving upadacitinib. Use of live, attenuated vaccines during or immediately prior to upadacitinib therapy is not recommended. Prior to initiating upadacitinib, it is recommended that patients be brought up to date with all immunisations, including prophylactic zoster vaccinations, in agreement with current immunisation guidelines (see section 5.1 for data on inactivated pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) and concomitant use with upadacitinib).</p><p><u>&nbsp;</u></p><p><u>Malignancy</u></p><p>&nbsp;</p><p>Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including upadacitinib.</p><p>&nbsp;</p><p>In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.</p><p>&nbsp;</p><p>A higher rate of malignancies was observed with upadacitinib 30&nbsp;mg compared to upadacitinib 15&nbsp;mg.</p><p>&nbsp;</p><p>In patients 65 years of age and older, patients who are current or past long-time smokers, or with other malignancy risk factors (e.g., current malignancy or history of malignancy) upadacitinib should only be used if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p><em>Non-melanoma skin cancer</em></p><p><em>&nbsp;</em></p><p>NMSCs have been reported in patients treated with upadacitinib (see section 4.8). A higher rate of NMSC was observed with upadacitinib 30&nbsp;mg compared to upadacitinib 15&nbsp;mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.</p><p>&nbsp;</p><p><u>Haematological abnormalities</u></p><p>&nbsp;</p><p>Absolute Neutrophil Count (ANC) &lt;&nbsp;1&nbsp;x&nbsp;10<sup>9</sup> cells/L, Absolute Lymphocyte Count (ALC) &lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L and haemoglobin &lt;&nbsp;8&nbsp;g/dL were reported in &le;1&nbsp;% of patients in clinical trials (see section 4.8). Treatment should not be initiated, or should be temporarily interrupted, in patients with an ANC &lt;&nbsp;1 x&nbsp;10<sup>9</sup> cells/L, ALC &lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L or haemoglobin &lt;&nbsp;8&nbsp;g/dL observed during routine patient management (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Gastrointestinal perforations</u></p><p><u>&nbsp;</u></p><p>Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post‑marketing sources (see section 4.8).</p><p>&nbsp;</p><p>Upadacitinib should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn&rsquo;s disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.</p><p>&nbsp;</p><p><u>Major adverse cardiovascular events </u></p><p><u>&nbsp;</u></p><p>Events of MACE were observed in clinical studies of upadacitinib.</p><p>&nbsp;</p><p>In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>Therefore, in patients 65 years of age and older, patients who are current or past long-time smokers, and patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors, upadacitinib should only be used if no suitable treatment alternatives are available.</p><p><u>&nbsp;</u></p><p><u>Lipids</u></p><p>&nbsp;</p><p>Treatment with upadacitinib was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol (see section 4.8). Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy, although evidence is limited. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined (see section 4.2 for monitoring guidance).</p><p>&nbsp;</p><p><u>Hepatic transaminase elevations</u></p><p>&nbsp;</p><p>Treatment with upadacitinib was associated with an increased incidence of liver enzyme elevation compared to placebo.</p><p>&nbsp;</p><p>Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.</p><p>&nbsp;</p><p>If increases in ALT or AST are observed during routine patient management and drug-induced liver injury is suspected, upadacitinib therapy should be interrupted until this diagnosis is excluded.</p><p><u>Venous thromboembolism</u></p><p>&nbsp;</p><p>Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for upadacitinib.</p><p>&nbsp;</p><p>In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>In patients with cardiovascular or malignancy risk factors (see also section 4.4 &ldquo;Major adverse cardiovascular events&rdquo; and &ldquo;Malignancy&rdquo;) upadacitinib should only be used if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p>In patients with known VTE risk factors other than cardiovascular or malignancy risk factors, upadacitinib should be used with caution. VTE risk factors other than cardiovascular or malignancy<u> </u>risk factors include previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder. Patients should be re-evaluated periodically during upadacitinib treatment to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue upadacitinib in patients with suspected VTE, regardless of dose.</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving upadacitinib. If a clinically significant hypersensitivity reaction occurs, discontinue upadacitinib and institute appropriate therapy (see sections 4.3 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicinal products to affect the pharmacokinetics of upadacitinib</u></p><p>&nbsp;</p><p>Upadacitinib is metabolised mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medicinal products that strongly inhibit or induce CYP3A4.</p><p>&nbsp;</p><p><em>Coadministration with CYP3A4 inhibitors</em></p><p><em>&nbsp;</em></p><p>Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, and grapefruit). In a clinical study, coadministration of upadacitinib with ketoconazole resulted in 70% and 75% increases in upadacitinib C<sub>max</sub> and AUC, respectively. Upadacitinib 15&nbsp;mg once daily should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors. Upadacitinib 30&nbsp;mg once daily dose is not recommended for patients with atopic dermatitis receiving chronic treatment with strong CYP3A4 inhibitors. For patients with ulcerative colitis or Crohn&rsquo;s disease using strong CYP3A4 inhibitors, the recommended induction dose is 30&nbsp;mg once daily and the recommended maintenance dose is 15&nbsp;mg once daily (see section 4.2). Alternatives to strong CYP3A4 inhibitor medications should be considered when used in the long-term. Food or drink containing grapefruit should be avoided during treatment with upadacitinib.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Coadministration with CYP3A4 inducers</em></p><p><em>&nbsp;</em></p><p>Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin and phenytoin), which may lead to reduced therapeutic effect of upadacitinib. In a clinical study, co-administration of upadacitinib after multiple doses of rifampicin (strong CYP3A inducer) resulted in approximately 50% and 60% decreases in upadacitinib C<sub>max</sub> and AUC, respectively. Patients should be monitored for changes in disease activity if upadacitinib is co-administered with strong CYP3A4 inducers.</p><p>&nbsp;</p><p>Methotrexate and pH modifying medicinal products (e.g., antacids or proton pump inhibitors) have no effect on upadacitinib plasma exposures.</p><p>&nbsp;</p><p><u>Potential for upadacitinib to affect the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>Administration of multiple 30&nbsp;mg or 45&nbsp;mg once daily doses of upadacitinib to healthy subjects had a limited effect on midazolam (sensitive substrate for CYP3A) plasma exposures (24-26% decrease in midazolam AUC and C<sub>max</sub>), indicating that upadacitinib 30&nbsp;mg or 45 mg once daily may have a weak induction effect on CYP3A. In a clinical study, rosuvastatin and atorvastatin AUC were decreased by 33% and 23%, respectively, and rosuvastatin C<sub>max</sub> was decreased by 23% following the administration of multiple 30&nbsp;mg once daily doses of upadacitinib to healthy subjects. Upadacitinib had no relevant effect on atorvastatin C<sub>max</sub> or on plasma exposures of ortho-hydroxyatorvastatin (major active metabolite for atorvastatin). Administration of multiple 45&nbsp;mg once daily doses of upadacitinib to healthy subjects led to a limited increase in AUC and C<sub>max</sub> of dextromethorphan (sensitive CYP2D6 substrate) by 30% and 35%, respectively, indicating that upadacitinib 45&nbsp;mg once daily has a weak inhibitory effect on CYP2D6. No dose adjustment is recommended for CYP3A substrates, CYP2D6 substrates, rosuvastatin or atorvastatin when coadministered with upadacitinib.</p><p>&nbsp;</p><p>Upadacitinib has no relevant effects on plasma exposures of ethinylestradiol, levonorgestrel, methotrexate, or medicinal products that are substrates for metabolism by CYP1A2, CYP2B6, CYP2C9, or CYP2C19.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should be advised to use effective contraception during treatment and for 4 weeks following the final dose of upadacitinib. Female paediatric patients and/or their parents/caregivers should be informed about the need to contact the treating physician once the patient experiences menarche while taking upadacitinib.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited data on the use of upadacitinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Upadacitinib was teratogenic in rats and rabbits with effects in bones in rat foetuses and in the heart in rabbit foetuses when exposed <em>in utero</em>.</p><p>&nbsp;</p><p>Upadacitinib is contraindicated during pregnancy (see section 4.3).</p><p>&nbsp;</p><p>If a patient becomes pregnant while taking upadacitinib the parents should be informed of the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether upadacitinib/metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk (see section 5.3).</p><p>&nbsp;</p><p>A risk to newborns/infants cannot be excluded.</p><p>&nbsp;</p><p>Upadacitinib should not be used during breast-feeding. A decision must be made whether to discontinue breast-feeding or to discontinue upadacitinib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of upadacitinib on human fertility has not been evaluated. Animal studies do not indicate effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Upadacitinib has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>In the placebo-controlled clinical trials for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, the most commonly reported adverse reactions (&ge;2% of patients in at least one of the indications with the highest rate among indications presented) with upadacitinib 15&nbsp;mg were upper respiratory tract infections (19.5%), blood creatine phosphokinase (CPK) increased (8.6%), alanine transaminase increased (4.3%), bronchitis (3.9%), nausea (3.5%), neutropaenia (2.8%), cough (2.2%), aspartate transaminase increased (2.2%), and hypercholesterolaemia (2.2%).</p><p>&nbsp;</p><p>In the placebo-controlled atopic dermatitis clinical trials, the most commonly reported adverse reactions (&ge;2% of patients) with upadacitinib 15&nbsp;mg or 30&nbsp;mg were upper respiratory tract infection (25.4%), acne (15.1%), herpes simplex (8.4%), headache (6.3%), CPK increased (5.5%), cough (3.2%), folliculitis (3.2%), abdominal pain (2.9%), nausea (2.7%), neutropenia (2.3%), pyrexia (2.1%), and influenza (2.1%).</p><p>&nbsp;</p><p>In the placebo-controlled ulcerative colitis and Crohn&rsquo;s disease induction and maintenance clinical trials, the most commonly reported adverse reactions (&ge;3% of patients) with upadacitinib 45&nbsp;mg, 30&nbsp;mg or 15&nbsp;mg were upper respiratory tract infection (19.9%), pyrexia (8.7%), blood CPK increased (7.6%), anemia (7.4%), headache (6.6%), acne (6.3%), herpes zoster (6.1%), neutropaenia (6.0%), rash (5.2%), pneumonia (4.1%), hypercholesterolemia (4.0%), bronchitis (3.9%), aspartate transaminase increased (3.9%), fatigue (3.9%), folliculitis (3.6%), alanine transaminase increased (3.5%), herpes simplex (3.2%), and influenza (3.2%).</p><p>&nbsp;</p><p>The most common serious adverse reactions were serious infections (see section 4.4).</p><p>&nbsp;</p><p>The safety profile of upadacitinib with long‑term treatment was generally similar to the safety profile during the placebo‑controlled period across indications.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following list of adverse reactions is based on experience from clinical studies.</p><p>The frequency of adverse reactions listed below is defined using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1000&nbsp;to&nbsp;&lt;&nbsp;1/100). The frequencies in Table 3 are based on the higher of the rates for adverse reactions reported with RINVOQ in clinical trials of rheumatologic disease (15&nbsp;mg), atopic dermatitis (15&nbsp;mg and 30&nbsp;mg), ulcerative colitis (15&nbsp;mg, 30&nbsp;mg and 45&nbsp;mg), or Crohn&rsquo;s disease (15 mg, 30 mg, and 45 mg). When notable differences in frequency were observed between indications, these are presented in the footnotes below the table.</p><p>&nbsp;</p><p><strong>Table 3 Adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:bottom"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:bottom"><p><strong>Very common</strong></p></td><td style="vertical-align:bottom"><p><strong>Common</strong></p></td><td style="vertical-align:bottom"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Upper respiratory tract infections (URTI)<sup>a</sup></p></td><td style="vertical-align:top"><p>Bronchitis<sup>a,b&nbsp; </sup></p><p>Herpes zoster<sup>a</sup></p><p>Herpes simplex<sup>a</sup></p><p>Folliculitis</p><p>Influenza</p><p>Urinary tract infection</p><p>Pneumonia<sup>a,h</sup></p></td><td style="vertical-align:top"><p>Oral candidiasis</p><p>Diverticulitis</p><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer<sup>f</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia<sup>a</sup></p><p>Neutropaenia<sup>a</sup></p><p>Lymphopaenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria<sup>c,g</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Serious hypersensitivity reactions<sup>a,e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>a,b</sup></p><p>Hyperlipidaemia<sup>a,b</sup></p></td><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain<sup>a,d</sup></p><p>Nausea</p></td><td style="vertical-align:top"><p>Gastrointestinal perforation<sup>i</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Acne<sup>a,c,d,g</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood CPK increased</p><p>ALT increased<sup>b</sup></p><p>AST increased<sup>b</sup></p><p>Weight increased<sup>g</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> Presented as grouped term</p><p><sup>b</sup> In atopic dermatitis trials, the frequency of bronchitis, hypercholesterolaemia, hyperlipidaemia, ALT increased, and AST increased was uncommon.</p><p><sup>c </sup>In rheumatologic disease trials, the frequency was common for acne and uncommon for urticaria.</p><p><sup>d </sup>In ulcerative colitis trials, the frequency was common for acne; abdominal pain was less frequent for upadacitinib than for placebo.</p><p><sup>e</sup> Serious hypersensitivity reactions including anaphylactic reaction and angioedema<sup> </sup></p><p><sup>f</sup> Most events reported as basal cell carcinoma and squamous cell carcinoma of skin</p><p><sup>g </sup>In Crohn&rsquo;s disease, the frequency was common for acne, and uncommon for urticaria and weight increased.</p><p><sup>h </sup>Pneumonia was common in Crohn&rsquo;s disease and uncommon across other indications.</p><p><sup>i </sup>Frequency is based on Crohn&rsquo;s disease clinical trials.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Atopic dermatitis</u></em></p><p><em>Infections</em></p><p><em>&nbsp;</em></p><p>In the placebo-controlled period of the clinical studies, the frequency of infection over 16 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 39% and 43% compared to 30% in the placebo group, respectively. The long-term rate of infections for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 98.5 and 109.6 events per 100 patient-years, respectively.</p><p>&nbsp;</p><p>In placebo-controlled clinical studies, the frequency of serious infection over 16 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 0.8% and 0.4% compared to 0.6% in the placebo group, respectively. The long-term rate of serious infections for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 2.3 and 2.8 events per 100&nbsp;patient-years, respectively.</p><p><em>&nbsp;</em></p><p><em>Opportunistic infections (excluding tuberculosis)</em></p><p><em>&nbsp;</em></p><p>In the placebo-controlled period of the clinical studies, all opportunistic infections (excluding TB and herpes zoster) reported were eczema <em>herpeticum.</em> The frequency of eczema <em>herpeticum</em> over 16 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 0.7% and 0.8% compared to 0.4% in the placebo group, respectively. The long-term rate of eczema <em>herpeticum</em> for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 1.6 and 1.8 events per 100 patient-years, respectively. One case of esophageal candidiasis was reported with upadacitinib 30&nbsp;mg.</p><p>&nbsp;</p><p>The long-term rate of herpes zoster for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 3.5 and 5.2 events per 100 patient-years, respectively. Most of the herpes zoster events involved a single dermatome and were non-serious.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Laboratory abnormalities</em></p><p><em>&nbsp;</em></p><p>Dose-dependent changes in ALT increased and/or AST increased (&ge; 3 x ULN), lipid parameters, CPK values (&gt; 5 x ULN), and neutropaenia<em> (</em>ANC&nbsp;&lt;&nbsp;1&nbsp;x&nbsp;10<sup>9</sup> cells/L) associated with upadacitinib treatment were similar to what was observed in the rheumatologic disease clinical studies.</p><p>&nbsp;</p><p>Small increases in LDL cholesterol were observed after week 16 in atopic dermatitis studies.</p><p><u>&nbsp;</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Ulcerative colitis</u></em></p><p><em>&nbsp;</em></p><p>The overall safety profile observed in patients with ulcerative colitis was generally consistent with that observed in patients with rheumatoid arthritis.</p><p>&nbsp;</p><p>A higher rate of herpes zoster was observed with an induction treatment period of 16 weeks vs 8&nbsp;weeks.</p><p><em>&nbsp;</em></p><p><em>Infections</em></p><p>In the placebo‑controlled induction studies, the frequency of infection over 8 weeks in the upadacitinib 45&nbsp;mg group compared to the placebo group was 20.7% and 17.5%, respectively. In the placebo‑controlled maintenance study, the frequency of infection over 52 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 38.4% and 40.6%, respectively, compared to 37.6% in the placebo group. The long-term rate of infections for upadacitinib 15&nbsp;mg and 30&nbsp;mg was 73.8 and 82.6 events per 100 patient-years, respectively.</p><p>&nbsp;</p><p>In the placebo‑controlled induction studies, the frequency of serious infection over 8 weeks in both the upadacitinib 45&nbsp;mg group and the placebo group was 1.3%. No additional serious infections were observed over 8-week extended treatment with upadacitinib 45&nbsp;mg. In the placebo‑controlled maintenance study, the frequency of serious infection over 52 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 3.2% and 2.4%, respectively, compared to 3.3% in the placebo group. The long-term rate of serious infections for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 4.1 and 3.9 events per 100 patient-years, respectively. The most frequently reported serious infection in the induction and maintenance phases was COVID‑19 pneumonia.</p><p>&nbsp;</p><p><em>Opportunistic infections (excluding tuberculosis)</em></p><p>In the placebo‑controlled induction studies over 8 weeks, the frequency of opportunistic infection (excluding tuberculosis and herpes zoster) in the upadacitinib 45&nbsp;mg group was 0.4% and 0.3% in the placebo group. No additional opportunistic infections (excluding tuberculosis and herpes zoster) were observed over 8‑week extended treatment with upadacitinib 45&nbsp;mg. In the placebo‑controlled maintenance study over 52 weeks, the frequency of opportunistic infection (excluding tuberculosis and herpes zoster) in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 0.8% and 0.4%, respectively, compared to 0.8% in the placebo group. The long‑term rate of opportunistic infections (excluding tuberculosis and herpes zoster) for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 0.6 and 0.3 events per 100 patient-years, respectively.</p><p>&nbsp;</p><p>In the placebo-controlled induction studies over 8 weeks, the frequency of herpes zoster in the upadacitinib 45&nbsp;mg group was 0.6% and 0% in the placebo group. The frequency of herpes zoster was 3.9% over 16-week treatment with upadacitinib 45&nbsp;mg. In the placebo‑controlled maintenance study over 52 weeks, the frequency of herpes zoster in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 4.4% and 4.0%, respectively, compared to 0% in the placebo group. The long‑term rate of herpes zoster for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 5.7 and 6.3 events per 100 patient-years, respectively.</p><p>&nbsp;</p><p><em>Laboratory abnormalities</em></p><p>In the induction and maintenance clinical studies, the laboratory changes in ALT increased and/or AST increased (&ge;&nbsp;3&nbsp;x&nbsp;ULN), CPK values (&gt;&nbsp;5&nbsp;x&nbsp;ULN), and neutropaenia<em> </em>(ANC&nbsp;&lt;&nbsp;1&nbsp;x&nbsp;10<sup>9</sup> cells/L) associated with upadacitinib treatment were generally similar to what was observed in the rheumatologic disease and atopic dermatitis clinical studies. Dose-dependent changes for these laboratory parameters associated with 15&nbsp;mg and 30&nbsp;mg upadacitinib treatment were observed<s>.</s></p><p>&nbsp;</p><p>In the placebo‑controlled induction studies for up to 8 weeks, decreases in lymphocyte counts below 0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L in at least one measurement occurred in 2.0% and 0.8% of patients in the upadacitinib 45&nbsp;mg and placebo groups, respectively. In the placebo-controlled maintenance study, for up to 52 weeks, decreases in lymphocyte counts below 0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L in at least one measurement occurred in 1.6%, 0.8% and 0.8% of patients in the upadacitinib 15&nbsp;mg, 30&nbsp;mg and placebo groups, respectively. In clinical studies, treatment was interrupted in response to ALC&nbsp;&lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L (see section 4.2). No notable mean changes of lymphocyte counts were observed during upadacitinib treatment over time.</p><p>&nbsp;</p><p>Elevations in lipid parameters were observed at 8 weeks of treatment with upadacitinib 45&nbsp;mg and remained generally stable with longer-term treatment with upadacitinib 15&nbsp;mg and 30&nbsp;mg. Among patients in the placebo-controlled induction studies with baseline values below the specified limits, the following frequencies of patients were observed to shift to above the specified limits on at least one occasion during 8 weeks (including patients who had an isolated elevated value):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total cholesterol &ge;&nbsp;5.17&nbsp;mmol/L (200&nbsp;mg/dL): 49% vs. 11%, in the upadacitinib&nbsp;45&nbsp;mg and placebo groups, respectively</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LDL cholesterol &ge;&nbsp;3.36&nbsp;mmol/L (130&nbsp;mg/dL): 27% vs. 9%, in the upadacitinib&nbsp;45&nbsp;mg and placebo groups, respectively</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HDL cholesterol &ge;&nbsp;1.03&nbsp;mmol/L (40&nbsp;mg/dL): 79% vs. 36%, in the upadacitinib&nbsp;45&nbsp;mg and placebo groups, respectively</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triglycerides &ge;&nbsp;2.26&nbsp;mmol/L (200&nbsp;mg/dL): 6% vs 4% in the upadacitinib&nbsp;45&nbsp;mg and placebo groups, respectively</p><p><u>&nbsp;</u></p><p><em><u>Crohn&rsquo;s disease</u></em></p><p><em><u>&nbsp;</u></em></p><p>Overall, the safety profile observed in patients with Crohn&rsquo;s disease treated with upadacitinib was consistent with the known safety profile for upadacitinib.</p><p>&nbsp;</p><p><em>Serious infections </em></p><p>&nbsp;</p><p>In the placebo‑controlled induction studies, the frequency of serious infection over 12 weeks in the upadacitinib 45&nbsp;mg group and the placebo group was 1.9% and 1.7%, respectively. In the placebo‑controlled maintenance study, the frequency of serious infection over 52 weeks in the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups was 3.2% and 5.7%, respectively, compared to 4.5% in the placebo group. The long-term rate of serious infections for the upadacitinib 15&nbsp;mg and 30&nbsp;mg groups in patients who responded to upadacitinib 45&nbsp;mg as induction treatment was 5.1 and 7.3 events per 100 patient-years, respectively. The most frequently reported serious infection in the induction and maintenance studies was gastrointestinal infections.</p><p><em>&nbsp;</em></p><p><em>Gastrointestinal Perforations</em></p><p><em>&nbsp;</em></p><p>During the placebo-controlled period in the Phase 3 induction clinical studies, gastrointestinal perforation was reported in 1 patient (0.1%) treated with upadacitinib 45&nbsp;mg and no patients on placebo through 12 weeks. In all patients treated with upadacitinib 45&nbsp;mg (n=938) during the induction studies, gastrointestinal perforation was reported in 4 patients (0.4%).</p><p>&nbsp;</p><p>In the long-term placebo-controlled period, gastrointestinal perforation was reported in 1 patient each treated with placebo (0.7 per 100 patient-years), upadacitinib 15&nbsp;mg (0.4 per 100 patient-years), and upadacitinib 30&nbsp;mg (0.4 per 100 patient-years). In all patients treated with rescue upadacitinib 30&nbsp;mg (n=336), gastrointestinal perforation was reported in 3 patients (0.8 per 100 patient-years) through long-term treatment.</p><p><strong>&nbsp;</strong></p><p><em>Laboratory abnormalities</em></p><p><em>&nbsp;</em></p><p>In the induction and maintenance clinical studies, the laboratory changes in ALT increased and/or AST increased (&ge;&nbsp;3 x ULN), CPK values (&gt;&nbsp;5 x ULN), neutropaenia (ANC&nbsp;&lt;&nbsp;1 x 10<sup>9</sup> cells/L), and lipid parameters associated with upadacitinib treatment were generally similar to what was observed in the rheumatologic disease, atopic dermatitis and ulcerative colitis clinical studies. Dose-dependent changes for these laboratory parameters associated with 15&nbsp;mg and 30&nbsp;mg upadacitinib treatment were observed.</p><p>&nbsp;</p><p>In the placebo‑controlled induction studies for up to 12 weeks, decreases in lymphocyte counts below 0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L in at least one measurement occurred in 2.2% and 2.0% of patients in the upadacitinib 45&nbsp;mg and placebo groups, respectively. In the placebo-controlled maintenance study, for up to 52 weeks, decreases in lymphocyte counts below 0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L in at least one measurement occurred in 4.6%, 5.2% and 1.8% of patients in the upadacitinib 15&nbsp;mg, 30&nbsp;mg and placebo groups, respectively. In clinical studies, treatment was interrupted in response to ALC&nbsp;&lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup> cells/L (see section 4.2). No notable mean changes of lymphocyte counts were observed during upadacitinib treatment over time.</p><p>&nbsp;</p><p>In the placebo‑controlled induction studies for up to 12 weeks, decreases in haemoglobin concentration to below 8 g/dL in at least one measurement occurred in 2.7% and 1.4% of patients in the upadacitinib 45&nbsp;mg and placebo groups, respectively. In the placebo-controlled maintenance study, for up to 52 weeks, decreases in haemoglobin concentration below 8 g/dL in at least one measurement occurred in 1.4%, 4.4% and 2.8% of patients in the upadacitinib 15&nbsp;mg, 30&nbsp;mg and placebo groups, respectively. In clinical studies, treatment was interrupted in response to Hb&nbsp;&lt;&nbsp;8 g/dL (see section 4.2). No notable mean changes of haemoglobin concentration were observed during upadacitinib treatment over time.</p><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>Based on limited data in atopic dermatitis patients 65 years of age and older, there was a higher rate of overall adverse reactions<s> </s>with the upadacitinib 30&nbsp;mg dose compared to the 15&nbsp;mg dose.</p><p><em>&nbsp;</em></p><p>Based on the limited data in ulcerative colitis and Crohn&rsquo;s disease patients 65 years of age and older, there was a higher rate of overall adverse reactions with the upadacitinib 30&nbsp;mg dose compared to the 15&nbsp;mg dose with maintenance treatment (see section 4.4).</p><p><em>&nbsp;</em></p><p><u>Paediatric</u><u> population </u></p><p>&nbsp;</p><p>A total of 343 adolescents aged 12 to 17 years with atopic dermatitis were treated in the Phase 3 studies, of whom 167 were exposed to 15&nbsp;mg. The safety profile for upadacitinib 15&nbsp;mg in adolescents was similar to that in adults. The safety and efficacy of the 30&nbsp;mg dose in adolescents are still being investigated.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National Pharmacovigilance Center (NPC)</p><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Upadacitinib was administered in clinical studies up to doses equivalent in daily AUC to 60&nbsp;mg prolonged-release once daily. Adverse reactions were comparable to those seen at lower doses and no specific toxicities were identified.<em> </em>Approximately 90% of upadacitinib in the systemic circulation is eliminated within 24 hours of dosing (within the range of doses evaluated in clinical studies). In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants ATC code: L04AA44</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit cytokine or growth factor signals involved in a broad range of cellular processes including inflammatory responses, hematopoiesis and immune surveillance. The JAK family of enzymes contains four members, JAK1, JAK2, JAK3 and TYK2 which work in pairs to phosphorylate and activate signal transducers and activators of transcription (STATs). This phosphorylation, in turn, modulates gene expression and cellular function. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function.</p><p>&nbsp;</p><p>In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Atopic dermatitis is driven by pro-inflammatory cytokines (including IL-4, IL-13, IL-22, TSLP, IL-31 and IFN-&gamma;) that transduce signals via the JAK1 pathway. Inhibiting JAK1 with upadacitinib reduces the signaling of many mediators which drive the signs and symptoms of atopic dermatitis such as eczematous skin lesions and pruritus. Pro‑inflammatory cytokines (primarily IL‑6, IL‑7, IL‑15 and IFN&gamma;) transduce signals via the JAK1 pathway and are involved in the pathology of inflammatory bowel diseases. JAK1 inhibition with upadacitinib modulates the signalling of the JAK-dependent cytokines underlying the inflammatory burden and signs and symptoms of inflammatory bowel diseases.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Inhibition of IL-6 induced STAT3 and IL-7 induced STAT5 phosphorylation</em></p><p>&nbsp;</p><p>In healthy volunteers, the administration of upadacitinib (immediate-release formulation) resulted in a dose- and concentration-dependent inhibition of IL-6 (JAK1/JAK2) - induced STAT3 and IL-7 (JAK1/JAK3)-induced STAT5 phosphorylation in whole blood. The maximal inhibition was observed 1 hour after dosing which returned to near baseline by the end of dosing interval.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><u>Vaccine study</u></p><p><u>&nbsp;</u></p><p>The influence of upadacitinib on the humoral response following the administration of inactivated pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) was evaluated in 111 patients with rheumatoid arthritis under stable treatment with upadacitinib 15 mg (n=87) or 30 mg (n=24). 97% of patients (n=108) were on concomitant methotrexate. The primary endpoint was the proportion of patients with satisfactory humoral response defined as &ge; 2-fold increase in antibody concentration from baseline to week 4 in at least 6 out of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Results at week 4 demonstrated a satisfactory humoral response in 67.5% (95% CI: 57.4, 77.5) and 56.5% (95% CI: 36.3, 76.8) of patients treated with upadacitinib 15 mg and 30 mg, respectively.</p><p><u>Clinical efficacy and safety</u></p><p><em>&nbsp;</em></p><p><em>Atopic dermatitis</em></p><p>&nbsp;</p><p>The efficacy and safety of upadacitinib 15&nbsp;mg and 30&nbsp;mg once daily was assessed in three Phase 3 randomised, double‑blind, multicentre studies (MEASURE UP 1, MEASURE UP 2 and AD UP) in a total of 2584 patients (12&nbsp;years of age and older). Upadacitinib was evaluated in 344 adolescent and 2240 adult patients with moderate to severe atopic dermatitis (AD) not adequately controlled by topical medication(s). At baseline, patients had to have all the following: an Investigator&#39;s Global Assessment (vIGA‑AD) score &ge;&nbsp;3 in the overall assessment of AD (erythema, induration/papulation, and oozing/crusting) on an increasing severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score &ge;16 (composite score assessing extent and severity of erythema, oedema/papulation, scratches and lichenification across 4 different body sites), a minimum body surface area (BSA) involvement of &ge;&nbsp;10%, and weekly average Worst Pruritus Numerical Rating Scale (NRS) &ge;&nbsp;4.</p><p>&nbsp;</p><p>In all three studies, patients received upadacitinib once daily doses of 15&nbsp;mg, 30&nbsp;mg, or matching placebo for 16 weeks. In the AD UP study, patients also received concomitant topical corticosteroids (TCS). Following completion of the double blinded period, patients originally randomised to upadacitinib were to continue receiving the same dose until week 260. Patients in the placebo group were re-randomised in a 1:1 ratio to receive upadacitinib 15&nbsp;mg or 30&nbsp;mg until week 260.</p><p>&nbsp;</p><p><em>Baseline characteristics</em></p><p><em>&nbsp;</em></p><p>In the monotherapy studies (MEASURE UP 1 and 2), 50.0% of patients had a baseline vIGA-AD score of 3 (moderate) and 50.0% of patients had a baseline vIGA-AD of 4 (severe). The mean baseline EASI score was 29.3 and the mean baseline weekly average Worst Pruritus NRS was 7.3. In the concomitant TCS study (AD UP), 47.1% of patients had a baseline vIGA-AD score of 3 (moderate) and 52.9% of patients had a baseline vIGA-AD of 4 (severe). The mean baseline EASI score was 29.7 and the mean baseline weekly average Worst Pruritus NRS was 7.2.</p><p>&nbsp;</p><p><em>Clinical response</em></p><p><em>&nbsp;</em></p><p><em><u>Monotherapy (MEASURE UP 1 AND MEASURE UP 2) and Concomitant TCS (AD UP) studies</u></em></p><p><em><u>&nbsp;</u></em></p><p>A significantly greater proportion of patients treated with upadacitinib 15&nbsp;mg or 30&nbsp;mg achieved vIGA-AD 0 or 1, EASI 75, or a &ge; 4-point improvement on the Worst Pruritus NRS compared to placebo at week 16. Rapid improvements in skin clearance and itch were also achieved (see Table 4).</p><p>&nbsp;</p><p>Figure 1 shows the proportion of patients achieving an EASI 75 response and mean percent change from baseline in Worst Pruritus NRS, respectively up to week 16 for MEASURE UP 1 and 2.</p><p><strong>Table 4: Efficacy results of upadacitinib</strong></p><p><strong><s>&nbsp;</s></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MEASURE UP 1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MEASURE UP 2</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>AD UP</strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment Group</p></td><td style="vertical-align:top"><p>PBO</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg&nbsp;</p></td><td style="vertical-align:top"><p>UPA</p><p>30&nbsp;mg</p></td><td style="vertical-align:top"><p>PBO</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>UPA</p><p>30&nbsp;mg</p></td><td><p>PBO + TCS</p><p>&nbsp;</p></td><td><p>UPA 15&nbsp;mg + TCS</p></td><td><p>UPA 30&nbsp;mg + TCS</p></td></tr><tr><td style="vertical-align:top"><p>Number of subjects</p><p>randomised</p><p>&nbsp;</p></td><td><p>281</p></td><td><p>281</p></td><td><p>285</p></td><td><p>278</p></td><td><p>276</p></td><td><p>282</p></td><td><p>304</p></td><td><p>300</p></td><td><p>297</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><strong>Week 16 endpoints, % responders </strong><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>vIGA-AD 0/1<sup>a<strong>,</strong>b</sup></p><p>(co-primary)</p></td><td><p>8</p><p>(5,12)</p><p>&nbsp;</p></td><td><p>48<sup>d</sup></p><p>(42,54)</p><p>&nbsp;</p></td><td><p>62<sup>d</sup></p><p>(56,68)</p><p>&nbsp;</p></td><td><p>5</p><p>(2,7)</p><p>&nbsp;</p></td><td><p>39<sup>d</sup></p><p>(33,45)</p><p>&nbsp;</p></td><td><p>52<sup>d</sup></p><p>(46,58)</p><p>&nbsp;</p></td><td><p>11</p><p>(7,14)</p><p>&nbsp;</p></td><td><p>40<sup>d</sup></p><p>(34,45)</p><p>&nbsp;</p></td><td><p>59<sup>d</sup></p><p>(53,64)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EASI 75<sup>a</sup></p><p>(co-primary)</p></td><td style="vertical-align:top"><p>16</p><p>(12,21)</p></td><td style="vertical-align:top"><p>70<sup>d</sup></p><p>(64,75)</p></td><td style="vertical-align:top"><p>80<sup>d</sup></p><p>(75,84)</p></td><td style="vertical-align:top"><p>13</p><p>(9,17)</p></td><td style="vertical-align:top"><p>60<sup>d</sup></p><p>(54,66)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>73<sup>d</sup></p><p>(68,78)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>26</p><p>(21,31)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>65<sup>d</sup></p><p>(59,70)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>77<sup>d</sup></p><p>(72,82)</p></td></tr><tr><td style="vertical-align:top"><p>EASI 90<sup>a</sup></p></td><td style="vertical-align:top"><p>8</p><p>(5,11)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>53<sup>d</sup></p><p>(47,59)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>66<sup>d</sup></p><p>(60,71)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>5</p><p>(3,8)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>42<sup>d</sup></p><p>(37,48)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>58<sup>d</sup></p><p>(53,64)</p><p>&nbsp;</p></td><td><p>13</p><p>(9,17)</p><p>&nbsp;</p></td><td><p>43<sup>d</sup></p><p>(37,48)</p><p>&nbsp;</p></td><td><p>63<sup>d</sup></p><p>(58,69)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EASI 100<sup>a</sup></p></td><td style="vertical-align:top"><p>2</p><p>(0,3)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>17<sup>d</sup></p><p>(12,21)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>27<sup>d</sup></p><p>(22,32)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1</p><p>(0,2)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>14<sup>d</sup></p><p>(10,18)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>19<sup>d</sup></p><p>(14,23)</p><p>&nbsp;</p></td><td><p>1</p><p>(0,3)</p><p>&nbsp;</p></td><td><p>12<sup>e</sup></p><p>(8,16)</p><p>&nbsp;</p></td><td><p>23<sup>d</sup></p><p>(18,27)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Worst Pruritus NRS<sup>c</sup></p><p><em>(&ge; 4-point improvement)</em></p></td><td style="vertical-align:top"><p>12</p><p>(8,16)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>52<sup>d</sup></p><p>(46,58)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>60<sup>d</sup></p><p>(54,66)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>9</p><p>(6,13)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>42<sup>d</sup></p><p>(36,48)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>60<sup>d</sup></p><p>(54,65)</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>15</p><p>(11,19)</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>52<sup>d</sup></p><p>(46,58)</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>64<sup>d</sup></p><p>(58,69)</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><strong>Early onset endpoints, </strong><strong>% responders </strong><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>EASI 75<sup>a</sup></p><p><em>(Week 2)</em></p></td><td style="vertical-align:top"><p>4</p><p>(1,6)</p></td><td style="vertical-align:top"><p>38<sup>d</sup></p><p>(32,44)</p></td><td style="vertical-align:top"><p>47<sup>d</sup></p><p>(42,53)</p></td><td style="vertical-align:top"><p>4</p><p>(1,6)</p></td><td style="vertical-align:top"><p>33<sup>d</sup></p><p>(27,39)</p></td><td style="vertical-align:top"><p>44<sup>d</sup></p><p>(38,50)</p></td><td style="vertical-align:top"><p>7</p><p>(4,10)</p></td><td><p>31<sup>d</sup></p><p>(26,36)</p></td><td><p>44<sup>d</sup></p><p>(38,50)</p></td></tr><tr><td style="vertical-align:top"><p>Worst Pruritus NRS</p><p><em>(&ge; 4-point improvement at week 1)</em><sup>c,f</sup></p></td><td style="vertical-align:top"><p>0</p><p>(0,1)</p></td><td style="vertical-align:top"><p>15<sup>d</sup></p><p>(11,19)</p></td><td style="vertical-align:top"><p>20<sup>d</sup></p><p>(15,24)</p></td><td style="vertical-align:top"><p>1</p><p>(0,2)</p></td><td style="vertical-align:top"><p>7<sup>d</sup></p><p>(4,11)</p></td><td style="vertical-align:top"><p>16<sup>d</sup></p><p>(11,20)</p></td><td style="vertical-align:top"><p>3</p><p>(1,5)</p></td><td style="vertical-align:top"><p>12<sup>d</sup></p><p>(8,16)</p></td><td style="vertical-align:top"><p>19<sup>d</sup></p><p>(15,24)</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>Abbreviations: UPA= upadacitinib (RINVOQ); PBO = placebo</p><p>Subjects with rescue medication or with missing data were counted as non-responders. The number and percentage of subjects who were imputed as non-responders for EASI 75 and vIGA-AD 0/1 at Week 16 due to the use of rescue therapy in the placebo, upadacitinib 15 mg, and upadacitinib 30 mg groups, respectively, were 132 (47.0%), 31 (11.0%), 16 (5.6%) in MEASURE UP 1, 119 (42.8%), 24 (8.7%), 16 (5.7%) in MEASURE UP 2, and 78 (25.7%), 15 (5.0%), 14 (4.7%) in AD UP.</p><p><sup>a</sup> Based on number of subjects randomised</p><p><sup>b </sup>Responder was defined as a patient with vIGA-AD 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) with a reduction of &ge; 2 points on a 0-4 ordinal scale</p><p><sup>c</sup> Results shown in subset of patients eligible for assessment (patients with Worst Pruritus NRS &ge; 4 at baseline)</p><p><sup>d</sup> Statistically significant vs. placebo with p &lt; 0.001</p><p><sup>e</sup> p &lt; 0.001 vs placebo, without multiplicity control</p><p><sup>f</sup> Statistically significant improvements vs placebo were seen as early as 1 day after initiating upadacitinib 30&nbsp;mg and 2 days after initiating upadacitinib 15&nbsp;mg in MEASURE UP 1 and 2</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1:&nbsp; Proportion of patients achieving an EASI 75 response and mean percent change from baseline in Worst Pruritus NRS in </strong><strong>MEASURE UP 1 and MEASURE UP 2</strong></p><p><strong><img alt="" width="722" height="463" src="data:image/png;base64,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" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Treatment effects in subgroups (weight, age, gender, race, and prior systemic treatment with immunosuppressants) were consistent with the results in the overall study population.</p><p>&nbsp;</p><p>Results at week 16 continued to be maintained through week 52 in patients treated with upadacitinib 15&nbsp;mg or 30&nbsp;mg.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Quality of life/patient‑reported outcomes</em></p><p><strong>Table 5: </strong><strong>Patient-reported outcomes </strong><strong>results</strong><strong> of upadacitinib at week 16</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:578px"><thead><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MEASURE UP 1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MEASURE UP 2</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Treatment group</p></td><td style="vertical-align:top"><p>PBO</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>UPA</p><p>30&nbsp;mg</p></td><td style="vertical-align:top"><p>PBO</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>UPA</p><p>30&nbsp;mg</p></td></tr><tr><td><p>Number of subjects</p><p>randomised</p></td><td style="vertical-align:top"><p>281</p></td><td style="vertical-align:top"><p>281</p></td><td style="vertical-align:top"><p>285</p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>276</p></td><td style="vertical-align:top"><p>282</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>% responders (</strong><strong>95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ADerm-SS Skin Pain<sup> </sup></p><p><em>(&ge; 4-point improvement)</em><sup>a</sup></p></td><td style="vertical-align:top"><p>15</p><p>(10,20)</p></td><td style="vertical-align:top"><p>54<sup> e</sup></p><p>(47,60)</p></td><td style="vertical-align:top"><p>63<sup>e</sup></p><p>(57,69)</p></td><td style="vertical-align:top"><p>13</p><p>(9,18)</p></td><td style="vertical-align:top"><p>49<sup>e </sup>&nbsp;</p><p>(43,56)</p></td><td style="vertical-align:top"><p>65<sup>e</sup></p><p>(59,71)</p></td></tr><tr><td style="vertical-align:top"><p>ADerm-IS Sleep<sup> </sup></p><p><em>(&ge; 12-point improvement)</em><sup> a,b</sup></p></td><td style="vertical-align:top"><p>13</p><p>(9,18)</p></td><td style="vertical-align:top"><p>55<sup>e</sup></p><p>(48,62)</p></td><td style="vertical-align:top"><p>66<sup>e</sup></p><p>(60,72)</p></td><td style="vertical-align:top"><p>12</p><p>(8,17)</p></td><td style="vertical-align:top"><p>50<sup>e</sup></p><p>(44,57)</p></td><td style="vertical-align:top"><p>62<sup>e</sup></p><p>(56,69)</p></td></tr><tr><td style="vertical-align:top"><p>DLQI 0/1<sup>c</sup></p></td><td style="vertical-align:top"><p>4</p><p>(2,7)</p></td><td style="vertical-align:top"><p>30<sup>e</sup></p><p>(25,36)</p></td><td style="vertical-align:top"><p>41<sup>e</sup></p><p>(35,47)</p></td><td style="vertical-align:top"><p>5</p><p>(2,7)</p></td><td style="vertical-align:top"><p>24<sup>e</sup></p><p>(19,29)</p></td><td style="vertical-align:top"><p>38<sup>e</sup></p><p>(32,44)</p></td></tr><tr><td style="vertical-align:top"><p>HADS Anxiety &lt;8 and HADS Depression &lt; 8<sup>d</sup></p></td><td style="vertical-align:top"><p>14</p><p>&nbsp;(8,20)&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>46<sup>e</sup></p><p>(37,54)&nbsp;</p></td><td style="vertical-align:top"><p>49<sup>e</sup></p><p>(41,57)</p></td><td style="vertical-align:top"><p>11</p><p>&nbsp;(6,17)</p></td><td style="vertical-align:top"><p>46<sup>e</sup></p><p>(38,54)</p></td><td><p>56<sup>e</sup></p><p>(48,64)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: UPA= upadacitinib (RINVOQ); PBO = placebo; DLQI = Dermatology Life Quality Index; HADS = Hospital Anxiety and Depression Scale</p><p>Subjects with rescue medication or with missing data were counted as non-responders.</p><p>The threshold values specified correspond to the minimal clinically important difference (MCID) and was used to determine response.</p><p><sup>a&nbsp; </sup>Results shown in subset of patients eligible for assessment (patients with assessment score &gt; MCID at baseline).</p><p><sup>b</sup> ADerm-IS Sleep assesses difficulty falling asleep, sleep impact, and waking up at night due to AD.</p><p><sup>c</sup> Results shown in subset of patients eligible for assessment (patients with DLQI &gt; 1 at baseline).</p><p><sup>d</sup> Results shown in subset of patients eligible for assessment (patients with HADS Anxiety &ge; 8 or HADS Depression &ge; 8 at baseline)</p><p><sup>e</sup> Statistically significant vs. placebo with p &lt; 0.001</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Ulcerative colitis </em></p><p><em>&nbsp;</em></p><p>The efficacy and safety of upadacitinib was evaluated in three multicentre, double‑blind, placebo‑controlled Phase 3 clinical studies: two replicate induction studies, UC‑1 (U‑ACHIEVE Induction) and UC‑2 (U‑ACCOMPLISH), and a maintenance study UC‑3 (U‑ACHIEVE Maintenance).</p><p>&nbsp;</p><p>Disease activity was based on the adapted Mayo score (aMS, Mayo scoring system excluding Physician&#39;s Global Assessment), which ranged from 0 to 9 and has three subscores that were each scored 0 (normal) to 3 (most severe): stool frequency subscore (SFS), rectal bleeding subscore (RBS) and a centrally‑reviewed endoscopy subscore (ES).</p><p>&nbsp;</p><p><em><u>Induction studies (UC‑1 and UC‑2)</u></em></p><p>In UC‑1 and UC‑2, 988 patients (473 and 515 patients, respectively) were randomised to upadacitinib 45&nbsp;mg once daily or placebo for 8 weeks with a 2:1 treatment allocation ratio and included in the efficacy analysis. All enrolled patients had moderately to severely active ulcerative colitis defined as an aMS of 5 to 9 with an ES of 2 or 3 and demonstrated prior treatment failure including inadequate response, loss of response, or intolerance to prior conventional and/or biologic treatment. Prior treatment failure to at least 1 biologic therapy (prior biologic failure) was seen in 52% (246/473) and 51% (262/515) of patients, respectively. Previous treatment failure to conventional therapy but not biologics (without prior biologic failure) was seen in 48% (227/473) and 49% (253/515) of patients, respectively.</p><p>&nbsp;</p><p>At baseline in UC‑1 and UC‑2, 39% and 37% of patients received corticosteroids, 1.1% and 0.6% of patients received methotrexate and 68% and 69% of patients received aminosalicylates. Concomitant use of thiopurine was not allowed during the studies. Patient disease activity was moderate (aMS&nbsp;&ge;5, &le;7) in 61% and 60% of patients and severe (aMS&nbsp;&gt;7) in 39% and 40% of patients.</p><p>&nbsp;</p><p>The primary endpoint was clinical remission per aMS at week 8. Table 6 shows the primary and key secondary endpoints including clinical response,<sup> </sup>mucosal healing, histologic-endoscopic mucosal healing and deep mucosal healing.</p><p>&nbsp;</p><p><strong>Table 6 Proportion of patients meeting primary and key secondary efficacy endpoints at week 8 in the induction studies UC-1 and UC-2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>UC-1</strong></p><p><strong>(U-ACHIEVE) </strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>UC-2</strong></p><p><strong>(U-ACCOMPLISH)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Endpoint </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>PBO</strong></p><p><strong>N=154</strong></p></td><td style="vertical-align:bottom"><p><strong>UPA</strong></p><p><strong>45&nbsp;mg</strong></p><p><strong>N=319</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment Difference</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>PBO</strong></p><p><strong>N=174</strong></p></td><td style="vertical-align:bottom"><p><strong>UPA</strong></p><p><strong>45&nbsp;mg</strong></p><p><strong>N=341</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment Difference</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission<sup>a </sup></strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>4.8%</p></td><td style="vertical-align:top"><p>26.1%</p></td><td style="vertical-align:top"><p>21.6%*</p><p>(15.8, 27.4)</p></td><td style="vertical-align:top"><p>4.1%</p></td><td style="vertical-align:top"><p>33.5%</p></td><td style="vertical-align:top"><p>29.0%*</p><p>(23.2, 34.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>17.9%</p></td><td style="vertical-align:top"><p>17.5%</p></td><td style="vertical-align:top"><p>2.4%</p></td><td style="vertical-align:top"><p>29.6%</p></td><td style="vertical-align:top"><p>27.1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>9.2%</p></td><td style="vertical-align:top"><p>35.2%</p></td><td style="vertical-align:top"><p>26.0%</p></td><td style="vertical-align:top"><p>5.9%</p></td><td style="vertical-align:top"><p>37.5%</p></td><td style="vertical-align:top"><p>31.6%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical response<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>27.3%</p></td><td style="vertical-align:top"><p>72.6%</p></td><td style="vertical-align:top"><p>46.3%*</p><p>(38.4, 54.2)</p></td><td style="vertical-align:top"><p>25.4%</p></td><td style="vertical-align:top"><p>74.5%</p></td><td style="vertical-align:top"><p>49.4%*</p><p>(41.7, 57.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>12.8%</p></td><td style="vertical-align:top"><p>64.4%</p></td><td style="vertical-align:top"><p>51.6%</p></td><td style="vertical-align:top"><p>19.3%</p></td><td style="vertical-align:top"><p>69.4%</p></td><td style="vertical-align:top"><p>50.1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>42.1%</p></td><td style="vertical-align:top"><p>81.8%</p></td><td style="vertical-align:top"><p>39.7%</p></td><td style="vertical-align:top"><p>31.8%</p></td><td style="vertical-align:top"><p>79.8%</p></td><td style="vertical-align:top"><p>48.0%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mucosal healing<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>7.4%</p></td><td style="vertical-align:top"><p>36.3%</p></td><td style="vertical-align:top"><p>29.3%*</p><p>(22.6, 35.9)</p></td><td style="vertical-align:top"><p>8.3%</p></td><td style="vertical-align:top"><p>44.0%</p></td><td style="vertical-align:top"><p>35.1%*</p><p>(28.6, 41.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>1.7%</p></td><td style="vertical-align:top"><p>27.0%</p></td><td style="vertical-align:top"><p>25.3%</p></td><td style="vertical-align:top"><p>4.8%</p></td><td style="vertical-align:top"><p>37.1%</p></td><td style="vertical-align:top"><p>32.3%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>13.2%</p></td><td style="vertical-align:top"><p>46.8%</p></td><td style="vertical-align:top"><p>33.6%</p></td><td style="vertical-align:top"><p>12.0%</p></td><td style="vertical-align:top"><p>51.2%</p></td><td style="vertical-align:top"><p>39.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Histologic-endoscopic mucosal healing<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>6.6%</p></td><td style="vertical-align:top"><p>30.1%</p></td><td style="vertical-align:top"><p>23.7%*</p><p>(17.5, 30.0)</p></td><td style="vertical-align:top"><p>5.9%</p></td><td style="vertical-align:top"><p>36.7%</p></td><td style="vertical-align:top"><p>30.1%*</p><p>(24.1, 36.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>1.4%</p></td><td style="vertical-align:top"><p>22.7%</p></td><td style="vertical-align:top"><p>21.3%</p></td><td style="vertical-align:top"><p>4.6%</p></td><td style="vertical-align:top"><p>30.7%</p></td><td style="vertical-align:top"><p>26.1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>11.8%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>38.2%</p></td><td style="vertical-align:top"><p>26.4%</p></td><td style="vertical-align:top"><p>7.2%</p></td><td style="vertical-align:top"><p>42.9%</p></td><td style="vertical-align:top"><p>35.7%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Deep mucosal healing<sup>e</sup></strong></p></td><td style="vertical-align:top"><p>1.3%</p></td><td style="vertical-align:top"><p>10.7%</p></td><td style="vertical-align:top"><p>9.7%*</p><p>(5.7, 13.7)</p></td><td style="vertical-align:top"><p>1.7%</p></td><td style="vertical-align:top"><p>13.5%</p></td><td style="vertical-align:top"><p>11.3%*</p><p>(7.2, 15.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6.5%</p></td><td style="vertical-align:top"><p>6.5%</p></td><td style="vertical-align:top"><p>1.1%</p></td><td style="vertical-align:top"><p>9.2%</p></td><td style="vertical-align:top"><p>8.1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>15.4%</p></td><td style="vertical-align:top"><p>12.8%</p></td><td style="vertical-align:top"><p>2.4%</p></td><td style="vertical-align:top"><p>17.9%</p></td><td style="vertical-align:top"><p>15.5%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: PBO = placebo; UPA= upadacitinib; aMS = adapted Mayo Score, based on the Mayo Scoring system (excluding Physician&#39;s Global Assessment), which ranged from 0 to 9 and has three subscores that were each scored 0 (normal) to 3 (most severe): stool frequency subscore (SFS), rectal bleeding subscore (RBS) and a centrally‑reviewed endoscopy subscore (ES).</p><p><sup>+</sup>The number of &ldquo;Prior biologic failure&rdquo; patients in UC-1 and UC-2 are 78 and 89 in the placebo group, and 168 and 173 in the upadacitinib 45&nbsp;mg group, respectively; the number of &ldquo;Without prior biologic failure&rdquo; patients in UC-1 and UC-2 are 76 and 85 in the placebo group, and 151 and 168 in the upadacitinib 45&nbsp;mg group, respectively.</p><p><strong><sup>*</sup></strong>p &lt;0.001, adjusted treatment difference (95% CI)</p><p><sup>a </sup>Per aMS: SFS&le; 1 and not greater than baseline, RBS = 0, ES &le; 1 without friability</p><p><sup>b</sup><strong><sup> </sup></strong>Per aMS: decrease &ge; 2 points and &ge; 30% from baseline and a decrease in RBS &ge; 1 from baseline or an absolute RBS &le; 1.</p><p><sup>c</sup>ES &le; 1 without friability</p><p><sup>d</sup> ES &le; 1 without friability and Geboes score &le; 3.1 (indicating neutrophil infiltration in &lt; 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue.)</p><p><sup>e </sup>ES = 0, Geboes score &lt; 2 (indicating no neutrophil in crypts or lamina propria and no increase in eosinophil, no crypt destruction, and no erosions, ulcerations, or granulation tissue)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Disease activity and symptoms</em></p><p>The partial adapted Mayo score (paMS) is composed of SFS and RBS. Symptomatic response per paMS is defined as a decrease of &ge;1 point and &ge;30% from baseline and a decrease in RBS&nbsp;&ge;&nbsp;1 or an absolute RBS&nbsp;&le;1. Statistically significant improvement compared to placebo per paMS was seen as early as week 2 (UC-1: 60.1% vs 27.3% and UC-2: 63.3% vs 25.9%).</p><p>&nbsp;</p><p><em>Extended induction</em></p><p>A total of 125 patients in UC‑1 and UC‑2 who did not achieve clinical response after 8 weeks of treatment with upadacitinib 45&nbsp;mg once daily entered an 8-week open-label extended induction period. After the treatment of an additional 8 weeks (16 weeks total) of upadacitinib 45&nbsp;mg once daily, 48.3% of patients achieved clinical response per aMS. Among patients who responded to treatment of 16‑week upadacitinib 45&nbsp;mg once daily, 35.7% and 66.7% of patients maintained clinical response per aMS and 19.0% and 33.3% of patients achieved clinical remission per aMS at week 52 with maintenance treatment of upadacitinib 15&nbsp;mg and 30&nbsp;mg once daily, respectively.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Maintenance study (UC‑3)</u></em></p><p>The efficacy analysis for UC‑3 was evaluated in 451 patients who achieved clinical response per aMS with 8‑week upadacitinib 45&nbsp;mg once daily induction treatment. Patients were randomised to receive upadacitinib 15&nbsp;mg, 30&nbsp;mg or placebo once daily for up to 52 weeks.</p><p>&nbsp;</p><p>The primary endpoint was clinical remission per aMS at week 52. Table 7 shows the key secondary endpoints including maintenance of clinical remission, corticosteroid-free clinical remission,<sup> </sup>mucosal healing, histologic-endoscopic mucosal healing and deep mucosal healing.</p><p>&nbsp;</p><p><strong>Table 7 Proportion of patients meeting primary and key secondary efficacy endpoints at week 52 in the maintenance study UC‑3</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>PBO</strong></p><p><strong>N=149</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>UPA</strong></p><p><strong>15&nbsp;mg</strong></p><p><strong>N=148</strong></p></td><td><p><strong>UPA</strong></p><p><strong>30&nbsp;mg</strong></p><p><strong>N=154</strong></p></td><td><p><strong>Treatment </strong><strong>Difference </strong></p><p><strong>15&nbsp;mg vs</strong><strong> PBO (95% CI)</strong></p></td><td><p><strong>Treatment </strong><strong>Difference </strong></p><p><strong>30&nbsp;mg vs</strong><strong> PBO </strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission<sup>a</sup> </strong></p></td><td style="vertical-align:top"><p>12.1%</p></td><td style="vertical-align:top"><p>42.3%</p></td><td style="vertical-align:top"><p>51.7%</p></td><td style="vertical-align:top"><p>30.7%*</p><p>(21.7, 39.8)</p></td><td style="vertical-align:top"><p>39.0%*</p><p>(29.7, 48.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>7.5%</p></td><td style="vertical-align:top"><p>40.5%</p></td><td style="vertical-align:top"><p>49.1%</p></td><td style="vertical-align:top"><p>33.0%</p></td><td style="vertical-align:top"><p>41.6%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>17.6%</p></td><td style="vertical-align:top"><p>43.9%</p></td><td style="vertical-align:top"><p>54.0%</p></td><td style="vertical-align:top"><p>26.3%</p></td><td style="vertical-align:top"><p>36.3%</p></td></tr><tr><td><p><strong>Maintenance of clinical remission<sup>b</sup></strong></p></td><td><p>N = 54<br />22.2%</p></td><td><p>N = 47<br />59.2%</p></td><td><p>N = 58<br />69.7%</p></td><td><p>37.4%*<br />(20.3, 54.6)</p></td><td><p>47.0%*<br />(30.7, 63.3)</p></td></tr><tr><td><p>&nbsp;&nbsp; Prior biologic failure</p></td><td><p>N = 22<br />13.6%</p></td><td><p>N = 17<br />76.5%</p></td><td><p>N = 20<br />73.0%</p></td><td><p>62.8%</p></td><td><p>59.4%</p></td></tr><tr><td><p>&nbsp;&nbsp;Without prior biologic failure</p></td><td><p>N = 32<br />28.1%</p></td><td><p>N = 30<br />49.4%</p></td><td><p>N = 38<br />68.0%</p></td><td><p>21.3%</p></td><td><p>39.9%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Corticosteroid-free clinical remission<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>N = 54</p><p>22.2%</p></td><td style="vertical-align:top"><p>N = 47</p><p>57.1%</p></td><td style="vertical-align:top"><p>N = 58</p><p>68.0%</p></td><td style="vertical-align:top"><p>35.4%*</p><p>(18.2, 52.7)</p></td><td style="vertical-align:top"><p>45.1%*</p><p>(28.7, 61.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure</p></td><td style="vertical-align:top"><p>N = 22</p><p>13.6%</p></td><td style="vertical-align:top"><p>N = 17</p><p>70.6%</p></td><td style="vertical-align:top"><p>N = 20</p><p>73.0%</p></td><td style="vertical-align:top"><p>57.0%</p></td><td style="vertical-align:top"><p>59.4%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure</p></td><td style="vertical-align:top"><p>N = 32</p><p>28.1%</p></td><td style="vertical-align:top"><p>N = 30</p><p>49.4%</p></td><td style="vertical-align:top"><p>N = 38</p><p>65.4%</p></td><td style="vertical-align:top"><p>21.3%</p></td><td style="vertical-align:top"><p>37.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mucosal healing<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>14.5%</p></td><td style="vertical-align:top"><p>48.7%</p></td><td style="vertical-align:top"><p>61.6%</p></td><td style="vertical-align:top"><p>34.4%*</p><p>(25.1, 43.7)</p></td><td style="vertical-align:top"><p>46.3%*</p><p>(36.7, 55.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>7.8%</p></td><td style="vertical-align:top"><p>43.3%</p></td><td style="vertical-align:top"><p>56.1%</p></td><td style="vertical-align:top"><p>35.5%</p></td><td style="vertical-align:top"><p>48.3%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>22.5%</p></td><td style="vertical-align:top"><p>53.6%</p></td><td style="vertical-align:top"><p>66.6%</p></td><td style="vertical-align:top"><p>31.1%</p></td><td style="vertical-align:top"><p>44.1%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Histologic-endoscopic mucosal healing<sup>e</sup> </strong></p></td><td style="vertical-align:top"><p>11.9%</p></td><td style="vertical-align:top"><p>35.0%</p></td><td style="vertical-align:top"><p>49.8%</p></td><td style="vertical-align:top"><p>23.8%*</p><p>(14.8, 32.8)</p></td><td style="vertical-align:top"><p>37.3%*</p><p>(27.8, 46.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>5.2%</p></td><td style="vertical-align:top"><p>32.9%</p></td><td style="vertical-align:top"><p>47.6%</p></td><td style="vertical-align:top"><p>27.7%</p></td><td style="vertical-align:top"><p>42.4%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>36.9%</p></td><td style="vertical-align:top"><p>51.8%</p></td><td style="vertical-align:top"><p>16.9%</p></td><td style="vertical-align:top"><p>31.8%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Deep mucosal healing<sup>f</sup></strong></p></td><td style="vertical-align:top"><p>4.7%</p></td><td style="vertical-align:top"><p>17.6%</p></td><td style="vertical-align:top"><p>19.0%</p></td><td style="vertical-align:top"><p>13.0%*</p><p>(6.0, 20.0)</p></td><td style="vertical-align:top"><p>13.6%*</p><p>(6.6, 20.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>2.5%</p></td><td style="vertical-align:top"><p>17.2%</p></td><td style="vertical-align:top"><p>16.1%</p></td><td style="vertical-align:top"><p>14.7%</p></td><td style="vertical-align:top"><p>13.6%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Without prior biologic failure<sup>+</sup></p></td><td style="vertical-align:top"><p>7.5%</p></td><td style="vertical-align:top"><p>18.0%</p></td><td style="vertical-align:top"><p>21.6%</p></td><td style="vertical-align:top"><p>10.6%</p></td><td style="vertical-align:top"><p>14.2%</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Abbreviations: PBO = placebo; UPA= upadacitinib; aMS = adapted Mayo Score, based on the Mayo Scoring system (excluding Physician&#39;s Global Assessment), which ranged from 0 to 9 and has three subscores that were each scored 0 (normal) to 3 (most severe): stool frequency subscore (SFS), rectal bleeding subscore (RBS) and a centrally‑reviewed endoscopy subscore (ES).</p><p><sup>+</sup>The number of &ldquo;Prior biologic failure&rdquo; patients are 81, 71, and 73 in the placebo, upadacitinib 15&nbsp;mg, and 30&nbsp;mg group, respectively. The number of &ldquo;Without prior biologic failure&rdquo; patients are 68, 77, and 81 in the placebo, upadacitinib 15&nbsp;mg, and 30&nbsp;mg group, respectively.</p><p>* p &lt;0.001, adjusted treatment difference (95% CI)</p><p><sup>a </sup>Per aMS: SFS&le; 1 and not greater than baseline, RBS = 0, ES &le; 1 without friability</p><p><sup>b </sup>Clinical remission per aMS at Week 52 among patients who achieved clinical remission at the end of induction treatment.</p><p><sup>c </sup>Clinical remission per aMS at Week 52 and corticosteroid-free for &ge;90 days immediately preceding Week 52 among patients who achieved clinical remission at the end of the induction treatment.</p><p><sup>d </sup>ES &le;1 without friability</p><p><sup>e</sup> ES &le;1 without friability and Geboes score &le; 3.1 (indicating neutrophil infiltration in &lt;5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue).</p><p><sup>f </sup>ES = 0, Geboes score &lt; 2 (indicating no neutrophil in crypts or lamina propria and no increase in eosinophil, no crypt destruction, and no erosions, ulcerations or granulation tissue).</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em>Disease symptoms</em></p><p>Symptomatic remission per paMS, defined as SFS &le; 1 and RBS = 0, was achieved over time through week 52 in more patients treated with both upadacitinib 15&nbsp;mg and 30&nbsp;mg once daily compared with placebo (Figure 2).</p><p>&nbsp;</p><p><strong>Figure 2 Proportion of patients with symptomatic remission per partial adapted Mayo score over time in maintenance study UC-3</strong></p><p><strong><img alt="" width="797" height="387" src="data:image/png;base64,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" /></strong></p><p><em>Endoscopic assessment</em></p><p>Endoscopic remission (normalisation of the endoscopic appearance of the mucosa) was defined as ES of 0. At week 8, a significantly greater proportion of patients treated with upadacitinib 45&nbsp;mg once daily compared to placebo achieved endoscopic remission (UC‑1: 13.7% vs 1.3%, UC‑2: 18.2% vs 1.7%). In UC‑3, a significantly greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg once daily compared to placebo achieved endoscopic remission at week 52 (24.2% and 25.9% vs 5.6%). Maintenance of mucosal healing at week 52 (ES &le;1 without friability) was seen in a significantly greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg once daily compared to placebo (61.6% and 69.5% vs 19.2%) among patients who achieved mucosal healing at the end of induction.</p><p><u>&nbsp;</u></p><p><em>Quality of life</em></p><p>Patients treated with upadacitinib demonstrated significantly greater and clinically meaningful improvement in health‑related quality of life measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) total score compared to placebo. Improvements were seen in all 4 domain scores: systemic symptoms (including fatigue), social function, emotional function and bowel symptoms (including abdominal pain and bowel urgency). Changes in IBDQ total score at week 8 from baseline with upadacitinib 45&nbsp;mg once daily compared to placebo were 55.3 and 21.7 in UC-1 and 52.2 and 21.1 in UC-2, respectively. Changes in IBDQ total score at week 52 from baseline were 49.2, 58.9 and 17.9 in patients treated with upadacitinib 15&nbsp;mg, 30&nbsp;mg once daily and placebo, respectively.</p><p>&nbsp;</p><p><em>Crohn&rsquo;s disease </em></p><p><em><u>&nbsp;</u></em></p><p>The efficacy and safety of upadacitinib was evaluated in three multicenter, double-blind, placebo‑controlled Phase 3 studies: two induction studies, CD-1 (U-EXCEED) and CD-2 (U-EXCEL), followed by a 52-week maintenance treatment and long-term extension study, CD-3 (U-ENDURE). The co-primary endpoints were clinical remission and endoscopic response at week 12 for CD-1 and CD-2, and at week 52 for CD-3.</p><p>&nbsp;</p><p>Enrolled patients were 18 to 75 years of age with moderately to severely active Crohn&rsquo;s disease (CD), defined as an average daily very soft or liquid stool frequency (SF) &ge;&nbsp;4 and/or average daily abdominal pain score (APS) &ge;&nbsp;2, and a centrally-reviewed Simple Endoscopic Score for CD (SES-CD) of &ge;&nbsp;6, or &ge;&nbsp;4 for isolated ileal disease, excluding the narrowing component. Patients with symptomatic bowel strictures were excluded from CD studies.</p><p><u>&nbsp;</u></p><p><em><u>Induction studies (CD-1 and CD-2)</u></em></p><p><em><u>&nbsp;</u></em></p><p>In CD-1 and CD-2, 1021 patients (495 and 526 patients, respectively) were randomised to upadacitinib 45&nbsp;mg once daily or placebo for 12 weeks with a 2:1 treatment allocation ratio.</p><p>&nbsp;</p><p>In CD-1, all patients had inadequate response or were intolerant to treatment with one or more biologic therapies (prior biologic failure). Of these patients, 61% (301/495) had inadequate response or were intolerant to two or more biologic therapies.</p><p>&nbsp;</p><p>In CD-2, 45% (239/526) patients had an inadequate response or were intolerant to treatment with one or more biologic therapies (prior biologic failure), and 55% (287/526) had an inadequate response or were intolerant to treatment with conventional therapies but not to biologic therapy (without prior biologic failure).</p><p><u>&nbsp;</u></p><p>At baseline in CD-1 and CD-2, 34% and 36% of patients received corticosteroids, 7% and 3% of patients received immunomodulators, and 15% and 25% of patients received aminosalicylates.</p><p>&nbsp;</p><p>In both studies, patients receiving corticosteroids at baseline initiated a corticosteroid taper regimen starting at week 4.</p><p>&nbsp;</p><p>Both studies included a 12‑week extended treatment period with upadacitinib 30&nbsp;mg once daily for patients who received upadacitinib 45&nbsp;mg once daily and did not achieve clinical response per SF/APS (&ge;&nbsp;30% decrease in average daily very soft or liquid SF and/or &ge;&nbsp;30% decrease in average daily APS and neither greater than baseline) at week&nbsp;12.</p><p>&nbsp;</p><p><em>Clinical </em><em>disease activity and symptoms</em></p><p><em>&nbsp;</em></p><p>In CD-1 and CD-2, a significantly greater proportion of patients treated with upadacitinib 45&nbsp;mg achieved the co-primary endpoint of clinical remission at week 12 compared to placebo (Table 8). Onset of efficacy was rapid and achieved as early as week 2 (Table 8).</p><p>&nbsp;</p><p>In both studies, patients receiving upadacitinib 45&nbsp;mg experienced significantly greater improvement from baseline in fatigue, as measured by FACIT-F score at week 12 compared to placebo.</p><p>&nbsp;</p><p><em>Endoscopic assessment</em></p><p><em>&nbsp;</em></p><p>In CD-1 and CD-2, a significantly greater proportion of patients treated with upadacitinib 45&nbsp;mg achieved the co-primary endpoint of endoscopic response at week 12 compared to placebo (Table 8). In CD-1 and CD-2, a greater proportion of patients treated with upadacitinib 45&nbsp;mg (14% and 19%, respectively) compared to placebo (0% and 5%, respectively) achieved SES-CD 0-2.</p><p>&nbsp;</p><p><strong>Table 8 Proportion of patients meeting primary and additional efficacy endpoints in induction studies CD-1 and CD-2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:600px"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="3"><p><strong>CD-1</strong><br /><strong>(U-EXCEED)</strong></p></td><td colspan="3"><p><strong>CD-2 </strong><br /><strong>(U-EXCEL)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment Group</strong></p></td><td><p><strong>PBO</strong><br /><strong>N=171</strong></p></td><td><p><strong>UPA</strong><br /><strong>45 mg</strong><br /><strong>N=324</strong></p></td><td><p><strong>Treatment<br />Difference</strong><br /><strong>(95% CI)</strong></p></td><td><p><strong>PBO</strong><br /><strong>N=176</strong></p></td><td><p><strong>UPA</strong><br /><strong>45 mg</strong><br /><strong>N=350</strong></p></td><td><p><strong>Treatment </strong><br /><strong>Difference</strong><br /><strong>(95% CI)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Co-Primary Endpoints at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top"><p>26%</p><p>(19, 33)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>22%</p></td><td style="vertical-align:top"><p>51%</p></td><td style="vertical-align:top"><p>29%</p><p>(21, 36)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=78</p><p>14%</p></td><td style="vertical-align:top"><p>N=161</p><p>47%</p></td><td style="vertical-align:top"><p>33%</p><p>(22, 44)</p></td></tr><tr><td style="vertical-align:top"><p>Without prior biologic failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=98</p><p>29%</p></td><td style="vertical-align:top"><p>N=189</p><p>54%</p></td><td style="vertical-align:top"><p>26%</p><p>(14, 37)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endoscopic response<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>31%</p><p>(25, 37)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>46%</p></td><td style="vertical-align:top"><p>33%</p><p>(26, 40)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=78</p><p>9%</p></td><td style="vertical-align:top"><p>N=161</p><p>38%</p></td><td style="vertical-align:top"><p>29%</p><p>(19, 39)</p></td></tr><tr><td style="vertical-align:top"><p>Without prior biologic failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=98</p><p>16%</p></td><td style="vertical-align:top"><p>N=189</p><p>52%</p></td><td style="vertical-align:top"><p>36%</p><p>(25, 46)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Additional Endpoints at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission per CDAI<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>18%</p><p>(10, 26)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top"><p>49%</p></td><td style="vertical-align:top"><p>21%</p><p>(13, 29)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical response (CR-100)<sup>d</sup> </strong></p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top"><p>51%</p></td><td style="vertical-align:top"><p>23%</p><p>(14, 31)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>37%</p></td><td style="vertical-align:top"><p>57%</p></td><td style="vertical-align:top"><p>20%</p><p>(11, 28)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Corticosteroid-free clinical remission<sup>a,e</sup></strong></p></td><td style="vertical-align:top"><p>N=60</p><p>7%</p></td><td style="vertical-align:top"><p>N=108</p><p>37%</p></td><td style="vertical-align:top"><p>30%</p><p>(19, 41)<sup>*</sup></p></td><td style="vertical-align:top"><p>N=64</p><p>13%</p></td><td style="vertical-align:top"><p>N=126</p><p>44%</p></td><td style="vertical-align:top"><p>33%</p><p>(22, 44)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endoscopic remission<sup>f</sup></strong></p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>17%</p><p>(12, 22)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top"><p>22%</p><p>(16, 28)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mucosal healing<sup>g</sup></strong></p></td><td style="vertical-align:top"><p>N=171</p><p>0%</p></td><td style="vertical-align:top"><p>N= 322</p><p>17%</p></td><td style="vertical-align:top"><p>17%</p><p>(13, 21)<sup>***</sup></p></td><td style="vertical-align:top"><p>N=174</p><p>5%</p></td><td style="vertical-align:top"><p>N=349</p><p>25%</p></td><td style="vertical-align:top"><p>20%</p><p>(14, 25)<sup>***</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Early Onset Endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission at Week 4<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>32%</p></td><td style="vertical-align:top"><p>23%</p><p>(17, 30)<sup>*</sup></p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>21%</p><p>(14, 28)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>CR-100 at Week 2<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>21%</p><p>(14, 28)<strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>32%</p></td><td style="vertical-align:top"><p>12%</p><p>(4, 19)<sup>**</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviation: PBO = placebo, UPA = upadacitinib</p><p><sup>*</sup> p &lt; 0.001, adjusted treatment difference (95% CI)</p><p><sup>**</sup> p &lt; 0.01, adjusted treatment difference (95% CI)</p><p><sup>***</sup> nominal p &lt; 0.001 UPA vs PBO comparison, adjusted treatment difference (95% CI)<br /><sup>a</sup> Average daily SF &le; 2.8 and APS &le; 1.0 and neither greater than baseline</p><p><sup>b</sup> Decrease in SES-CD &gt; 50% from baseline of the induction study (or for patients with an SES-CD of 4 at baseline of the induction study, at least a 2-point reduction from baseline of the induction study)</p><p><sup>c</sup> CDAI &lt; 150</p><p><sup>d</sup> Decrease of at least 100 points in CDAI from baseline</p><p><sup>e</sup> Discontinuation of steroid and achievement of clinical remission among patients on steroid at baseline</p><p><sup>f</sup> SES-CD &le; 4 and at least a 2-point reduction versus baseline and no subscore &gt; 1 in any individual variable</p><p><sup>g </sup>SES-CD ulcerated surface subscore of 0 in patients with SES-CD ulcerated surface subscore &ge; 1 at baseline</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em><u>Maintenance study (CD-3)</u></em></p><p><em><u>&nbsp;</u></em></p><p>The efficacy analysis for CD-3 evaluated 502 patients who achieved clinical response per SF/APS with the 12-week upadacitinib 45&nbsp;mg once daily induction treatment. Patients were re-randomised to receive a maintenance regimen of either upadacitinib 15&nbsp;mg or 30&nbsp;mg once daily or placebo for 52 weeks.</p><p>&nbsp;</p><p><em>Clinical disease activity and symptoms</em></p><p><em>&nbsp;</em></p><p>A significantly greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg achieved the co-primary endpoint of clinical remission at week 52 compared to placebo (Figure 3, Table 9).</p><p>&nbsp;</p><p><strong>Figure 3 Proportion of patients achieving clinical remission in maintenance study CD-3</strong></p><p><strong><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAusAAAGvCAYAAADi2JvaAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAMf7SURBVHhe7b0HmDVFmb6v7uq6qz91TURJkhFFFAMqQcSAAWUVUBD/omIgKKjgKioriyigZEyIBEmCIMqCCQXBCIIiqCCKBAVkAcmwqP2fu2ae4f1eqs85M9+ZOT3zPfd11dXd1dXV1dXV1U9Vv1X9oMYYY4wxxhjTSSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmI5isW6MMcYYY0xHsVg3xhhjjDGmo1isG2OMMcYY01Es1o0xxhhjjOkoFuvGGGOMMcZ0FIt1Y4wxxhhjOorFujHGGGOMMR3FYt0YY4wxxpiOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzpK58X6Jz/5yebJT35y86AHPajZYostml/84hcTe2aXv//9780//vGPia37ue6665p77rlnYqtpbrrppuZXv/pV8/vf/77529/+Vvx03DXXXNNccskl5RjBPuIGLY0xxhhjjIFOi3WEOiI9un//939v/vd//3cixOwhUR0F+8knn9ysv/76zeWXX162r7766mbjjTduVltttWbFFVdsDj744Obee+8t+84888xm1VVXbdZYY43mWc96VnPRRRdNxsUyu9tvv70566yzmq9//evNt771reab3/ymnZ2dnZ2dnd0i684444yiiXDoKtxpp53W/O53vyt6ar7SKbGee81f8pKXNMcff/zE1jj0sp977rkTW7MHAlpLes8//elPNw996EObpzzlKUWkwzbbbNNssMEGZfuLX/xiSeuFF17Y3HfffUWo77777qVXXeEQ/2oA4GJj4LOf/WyzxBJLNGuvvXazzjrrNM9+9rObZz7zmXZ2dnZ2dnZ2i6RDDz3jGc8oS/TRuuuuW/QVy/lMp8T6Bz/4wead73znZM+5etYR7TjE7yh71mXW8r3vfa959atf3RxwwAGlkNCiu+uuu8r6qaeeWsLcfffdzXrrrdd85Stfaa688spm+eWXb26++eay72c/+1mz+OKLF7MYifMo3Dn2//v//r+SF8T961//urn00kvL0s7Ozs7Ozs5uUXVRD2HZgKZ63OMeV7TUfKVzZjD0pNN6Uu85Ah6BjmjHf1Q264BYxyG66V2noNCAQFAjvFdZZZXm5z//+UToptl8882bQw89tDnnnHOapz71qRO+43buiHcKmBoBLOmBB0xn3vKWtzT77rtv2TbGGGOMMQ8Es+Fll112Ymt+0kmbdQZn0pNOz3pXoNcb1BMOiO0VVlihueKKK5qrrrqqrGOLLhgQe8ghhzRnn312MZcRCHsK1o9//OOyrTjf8Y53NCuttFL5vPOwhz2smMJE4rmNMcYYYxZFpMng+uuvb5ZeeumJrflJ5weYjro3PZIF+wUXXFB61i+77LLmjjvuKGYw//M//1P2/d///V+z0UYbNSeeeGLZT7jbbrut7PvlL39Z7NER+KD4jjrqqPIlYa+99iqDVPfff//iD7FgGmOMMcYsaqCXpJmki2688cZmmWWWKevzlU6LdUCo08uee5lnGxWQWFB++tOfFnMWzGHgda97XbFlx0SG0cnLLbdc6T1HuLN+4IEHNrfeemuz8847l4ER+Mf4Itttt12z5557Tmy5V90YY4wxRkgX/eUvf2me9KQnlfX5SufEes1GnQGl+CPaRzG4FCgUtOK0hPPPP79ZffXVJ6duZNDDWmutNTk6+aMf/Whz5513ln1HHHFEMZNhqkemb/z2t789WdCwWSdOxYvN+pvf/Obmv//7v8s2WKwbY4wxxoxjsT4iNPsLIr02+wuDTvHDpn22oVBEh7BmUAM26szeIqHNYNPTTz+92KnrZ0na95Of/KTMm37xxReXbQaUSqQrXqDH3WLdGGOMMaaOdJHF+iyDQO83rzrCfRRiHRDVmr4xE8W2kJ/EeEZ+LDUjDFisG2OMMca0I11ksT7LdOmPpRkKBU7CW6YrERUchdU2xLDyl18OWxPr+VzGGGOMMYsq0k0W6yMAwU5vOkKdqQ+7NBMMDpEuoR5FttbjtpbRKR7W1ZuubZaAWOenSHGAqfYZY4wxxizqoJvAYt0sgARzFM4qLBDXM732CYWRWI8968YYY4wxZhyLdTNSLNaNMcYYY9qxWB8R73znO8sUjbJRZ4kpDCYxDD7tiknMTGOxbowxxhjTjsX6iECQI8w1+wtTOLKNDTu27Ij5RUGwW6wbY4wxxrRjsT4ioljnt/2sMxtMnKqRnva5gApRjV77wGLdGGOMMaYdi/UREcU65jCs05seoZe9y73rFB65Gr32CYt1Y4wxxph2pKUs1mcZCXR+jCThHn+SxLrEfBfpJ8IHxWLdGGOMMaYdi/URgsnLZz/72cm51qMwR8B35SdJkSjSaXCss846zWabbdZccsklE75Nc+ONNzZveMMbyr6ddtqpuf3224s/x+r4OM+6f4pkjDHGGFPHYr0jYO4S7dXZ7mKvun5u9P73v79ZaqmlmlNOOaXZfvvtm7XWWqu58sorm/vuu6951ate1Wy44YbNN77xjeapT31qEewCIU4cQDz33ntv6Vnfa6+9ip9QwTTGGGOMWZSxWDcDo8Jyww03NCuttFJz5plnlm16zhHnJ598cnPLLbc0Sy+9dPOrX/2q7Dv11FObJZdcsrntttsmj0ewax1xv+22207+wVSNAe03xhhjjFmUkSayWB8B9KQzqFRmMJi+YBbTNdOXzHXXXdcst9xyzemnn16277rrriLWDzvssObCCy9s1lhjjSLC4Xe/+10pWBdddFHZVq965B3veMekGYyFujHGGGPM/VisjwiEOjbpiPTs8O/iLDBRSO+6667F9AXzlfe+973NYx/72Obwww9vzjnnnGbNNdcsYYBeeIT9D3/4w3Ks7NG/9KUvNR/60Ieaj33sYyX8AQccUPwJUxP0xhhjjDGLIhbrI0I96vSkY5suh19XB5dG7rjjjma//fYrg0gPPPDAZpNNNmmOOOKI5oILLmhWX3315p577inhaJQsu+yykwNQJcR33nnnZu2112422mij5hGPeETzmc98pvhDbBQYY4wxxizKWKyPCAQ5P0OKIM4R64h29ud517vELrvsUtJPmi+77LLSy37GGWc0t956axl4+pOf/KSEO+6448o2du0UNtmrY8POscwcs/XWWzd77713CS8s1o0xxhhjLNZHxic/+cnSe44ol5MZDL3RCHb2d5UPfOADzWKLLVZ601/84heX6RsR39iqM23jM5/5zObggw9uVlttteajH/1oKWgS6zKFAdbz1I3GGGOMMWYci/URssUWWyxgq46LveldtF2PYpvecIT6DjvsUAadAgWK3nWma9x4442LTfrdd99d/OOUjcI/RTLGGGOMacdifcQgxrFbx2Vhzl9M49zro4bCogITe8cF+2r+gL/24yTcLdaNMcYYY9qxWJ8H6AdKvRxmKSwXBol1iW4ta8hfwpywmMjE48Fi3RhjjDGmHXQTWKzPYaK9ey+3sGJdSHBrXchf4jyHYSmRLyzWjTHGGGPakW6yWJ/DINbpOY+DVbPD/n0YYh0hLjEOuWc9CvEYLgt4/TTJYt0YY4wxph1pJ4v1Ocwgtu3DsH+X2I6iW0v1mEu8x/1ahxzOYt0YY4wxph3pKIv1WQbxzPSNvZzmXO8SUXhnIS4kyKG2P2KxbowxxhjTjrSUxfosg2lKza48u+mI9dqAU6aJHMYfUWsCPW6zHnvPc9iMxboxxhhjTDvSUhbrswxiPdqZI8y1jqNXnf1TnWedv4pmwS83HeFfQ4UGMY4tekYmLoSzWDfGGGOMmT4W6yPigx/84KQQx+SFedYj9ILTGz5VJPRxUfizHEbPugS6hHh02q91lhLubVisG2OMMca0I11lsT5CENL0iEcQ1tOxWScujsEmPjYA4p9RF5Y2Ea7CNBUs1o0xxhhj2rFY7wD0smOmop5wHFMt4jfVGVyIS+Yziodt4pqqSU0NCoxMX6666qrmi1/8YnPUUUc1f/rTn4qfCtTpp5/efP7zn2/OPvvsst2GxboxxhhjTDsW6x2AXnSEtWzL5egdnyr0qkuYI/TpnVd8Czt1Y+Tqq68uad5www2bDTbYoHnRi17UXHPNNWXfgQce2KywwgrFjGfllVduTjrppMmCxlIOJNb33HPPsm2MMcYYY+7HYr1DILBlvz4sYU1DAAE/rPhUYPbee+9m+eWXb2655Zbm2muvbdZYY43mhBNOaO66665mmWWWaY488sjSA/+Rj3ykWX311YsoBx0v7rnnnubNb37zAj3rsok3xhhjjFnUsVjvEIjq6DBfYTkVEPzDGEjahgoMveWrrLJK6U2/+OKLm7XWWqs566yzmgsvvLBZaaWVmjvvvLOE+9WvftUsueSSCzQWohDnT6bbbrtts9dee034LDhI1RhjjDFmUcZivQMwuFQ26tlNVaxjmjLMwaQRCouE9B133FHOtdxyyzVLL710s/nmmze33357c/TRRzdrrrnmxBFNc/3115cwP/rRj8pxctddd11z5ZVXFvf6179+UqzHmWaMMcYYYxZ1pIks1kdIzV5dbjpiHTMaBppiUjPV4wfl/e9/f7PuuusWsX3ppZeWdYT6D37wg+YpT3lKKVgIe3reEesXXHBBOU4Fbuutt24WW2yxZtVVV20e/OAHT85cw3562y3WjTHGGGMs1jsBwjpP3QhxLvbpgmBnkCnLYc2zDtio77vvvmUd9thjj2bjjTdufvOb3xRx/uc//7n406OOKNe2jj/nnHOar3zlK83Xvva1Zv31128+9alPFX/13FusG2OMMcZYrHcCepWxT0dQRzededYR+MwigylMNq0Z1tSNsMsuuxQ79R//+MdFkK+22mpFsGMe87SnPa3ZYYcdmssuu6x59atf3WyyySaT0z1KjEe22267BQaYWqwbY4wxxoxjsd4Bhm0GE4+nEUBjYNiDTm+++ebmHe94R7PUUks1yy67bPP2t7+9uemmm8q+8847r3nqU59aetiZ1vHyyy8v/jWYJeZNb3rTAgNMjTHGGGPMOBbrHQCBjahmGR0949MR6xxHD/sw51UX9Iyrl/zuu+8uA0VxrEc0peNtt9024VPHP0UyxhhjjGnHYr0DYLZSE9Zt/r1ArE/nZ0qDQoGR3XnNVIV92j8IFuvGGGOMMe1YrM8zGKg6rMGkNdSzHgV5FOhRwONXE/QRi3VjjDHGmHYs1jsCgz8xeYmO3/VPVXTLDGYmTGAgi3KWctqGLOjbsFg3xhhjjGlH2spifYTQGx4HhUY3VZt14qqZwQzrz6ZZmNechLq2e2GxbowxxhjTjrSUxfoIoTecaRpxrGub5VQFNkKdHnmOXdhpIGtE8Z3FeK99bVisG2OMMca0Iz1lsT5CENYIaYS2/uQJzJU+VYir1kOPG5ZYzw5yTzrb9LDHbS1jOIt1Y4wxxph2pJks1kcI0ywydSOmKohtbM7ZRmBP9UdGHI/Ij73qw+xZj2RBHoU56/fdd1/ZD1oqDPvAYt0YY4wxph2L9Q6AiJYwZ2Aowlq94VMdKNpmmz4TNuugdS0l1LWUn5b4yR8s1o0xxhhj2pFusljvEIhqBPzCzOiiOFgOQ6SLLMCFtrVfohxnsW6MMcYYMz2kmyzW5wkIc8xg1DOPYMcWftg/SqLgILTvvffe4jBrkQP23XnnnZPmL/KXYBcW68YYY4wx7ViszzNkn57t1LFlH8bc6yown/vc55rFF1+8uGWXXbZ5/OMf36yzzjrNbbfd1lxyySXNM57xjGa55ZZrNtpoo+aPf/xjOSb2rEvEW6wbY4wxxrRjsT7PQJQz17rWEevYqzNoVcJ9ukhow6WXXtoccsghzZe//OXmK1/5SrP66qs3b33rW5ubb765edazntVsu+22zZVXXlnSsNlmmz1ggKlMYwYR6zpGS2hbHzVzIY3GGGOMmTtIQ1isdwh6wKcrrOlRR5gjkuOsMtMZrFqjJjoPP/zwZv3112/+9Kc/FRG//PLLN9dcc03Zd/bZZzdLLLFEKWDA8Qh19bJjQvPmN7/5AWJd51FYwE/+cT3un23iOZWmmC5tx3VjjDHGmEGRdrBYHyEIa8Q0PeCIdIlrhPZ0UHzRDctmXeJZBYcGwCqrrFIEO9DT/pSnPGVSQF999dXFTOb8888v26B9Ahv7Pffcc2JrHAlbnUfLTBTBbWFmCp2TrwYxT4wxxhhjhoX0hcX6CEFc0yPO4FDszGVrHm3OpwrCnzj5ydIwetQjUWzvv//+zbrrrlvMXwDR/vSnP72sw3XXXVds188777yyrQK32267Neutt17z8pe/vFlsscWagw8+uPgjfGUyA3fffXfprf/tb39b3GWXXVaWv/71r5urrrpqAYE822KZ85FWlnKk76STTmpOO+20cs0/+clPmq9+9avNySefPPT7YIwxxpj5j/SNxfoIQaxjZ65ZXCTQ8Z/qtIv8YAmhHqFXPftNhyxOb7311iLU//M//3MiRNOcccYZzcorr9zccccdZRthvdRSS5WlChvLL3zhC82OO+5Y0kujRGKdfTQGJNh/+MMfNiuttFKz9NJLF3OaJzzhCWV9ySWXbF70ohcVMxqIAn+2UD5onXQfffTRzYYbbthsvfXW5csI7g1veEPzspe9rAh4Y4wxxpipIK1hsT5C6AGXuQqCHRDYCNlBxLrMZ3CIQ3rTtR39h9WzK5HKLC/MAnPmmWdO7GmaG264oYhzepLpFefaVlhhhSKqJWhBBQ+R/ba3vW0Bm3U1CAAzGuJg9pn3vOc9zdOe9rQysHXfffdtTjzxxBJmlCYo+Zq0zfLDH/5ws8cee5TrYSDtKBoUxhhjjJnbSONYrI8YCW6h7UHEusS4BH+bi/FPlyhO6UXHXh2BLhCl//Vf/1V6w+ldppf9mGOOKfs4Tk4FDxFfmw1GwpYGwQ477NB85CMfKT3Uq666avOhD32o9MofcMABk2kBxTlbcL7olBalgy8OXJe243UbY4wxxgyCtIPF+gjBBEY26wtD7KHPbosttpgINTwuv/zyMm1jFMzAD5COOOKIIqq/9rWvTfiOkwUrYv1Nb3pTs9dee034LCi6//rXvzbf//73i+03vekvfOELm29+85tllhkaNAo7ShHclgbEOg0X/HEW69NHeah1Ef2NMcaY+YjecxbrIwTbdKZZHIaZCuYzw+hBny2m8lMkGjVbbbXV5GDWUROFotaj3+67717Eur4SyN8MRsxLIb+4Ly+NMcaY+YTebxbrIwQRWptakZ7j6fa2I9ijw0ymiyJ+KmKdXvott9yyuf766yd8RosenmhjHwUjPesf+9jHJrbGsaAcjJhPfJHQV4mcz1rmrzvGGGPMfEHvOov1EYJQx0xFUzjKTWfqRoQ/vfQ1UxiL9eESBaME5e23395ce+21zY033tjsuuuuZYpKHi5+GHXbbbeV8KY/ytte5DCDHGOMMcbMNfR+s1gfIYj0mrjGTVVgDzOu2WCui/XsaHhtsMEGzVvf+tbycygcf2jlvnz961+fONIMghpAQN6yrqX8aktjjDFmPqH3m8X6CEHIMWVj7FWfbs860z3Su56pzb/eBeaLWJeQ/M1vflME+3e+853mda97XUkvA2JPOOGEMiDXDIYqJlD+9iMeY4wxxswX9H6zWB8hbbbp07FZZ4517NOHIfxng6mKdcyFuiLWARGZe3oFJjB77rnnxNY4FpSDoXxiqfxl5iAGF990003F3Aj/W265pWwza5AxxhgzH7FY7xAIcwQ1y+kOLJ1pMxgKjJy2RdyXHURhq2U/sa5j4dRTT12gZz3uA22zJH6WWu+FwtVcL9gf487H7bLLLmWAqba11DFsK52RvF1jkDBzmZhXWr/44oubV73qVc3mm2/e/Md//Efz8pe/vDTeWH7gAx/oe5/N7BPLab6nbfuMMcYsiOpIi/URgjDHDCaKakwpajPE9AOxTs86y+gYdDrsnnW9cDUbilzcJ+JLGH9NZ9hLrOulrvjpWefHSPoJUzyHwijezEyIAMWpc+f1973vfaVnXdtaAutxm7h0vSKHieuQw89H4n2jrFxxxRXl/p900kmlXF9wwQXlL7cM4J3veTGX4d7E8so6z4qWEJ8dY4wx96O60WJ9hMhMJZurIEamOvc6Ar92TJv/VOHlKgEV14VeysCSbVx8EWsJg/Ss06O69957l4Ga/DGV3urrrrtuIkR3ef3rX18GmkZyHrDMIiWuQ8zHWp7PR3SNygtduzjrrLOaN77xjeUPt2JRyJe5SL53rOu+al37JdyNMcbcj+pMi/URgijXoFDWEevYqw/aGz6IEB+GWKew6MUaX76RXv4qbIoHBrFZ/9KXvrSAOQ/uM5/5TPPzn/+8+d73vteceeaZJf9OP/30ss7yjDPOKAM75fCP28NyildLzouQ/O53v9ustNJKzWKLLdb89re/LdM26prbiPuVR9FNhamG7yIqS/H6tSR/Eet/+MMfyvZ8uN75CPdFz35e17Yc2+5dN8aYB6J60WJ9hNCjjjCXuQpmLBKlgwhsjmNgaRuY2QxzgKkKDTOfvO1tbyuiCbEKvHTvuuuu8ufOrbfeujnwwAPLCzi+lEFxDGIG8+Uvf7nkxT/90z81j33sY8v6Ukst1ay22mrN8573vGaTTTZpNt1002LPvNFGGzXPfvazm6c//enNWmut1ayxxhrN6quv3jz1qU+dnEpxJhznWXPNNcvy+c9/fknbQx/60JLW5zznOSV9r33ta5sddtih/Cxp//33b0488cTmhz/8YXPVVVc1991338RVt6P8iLCd/aDmN5eolRWW8mO2HUyi1LPelg9mbsB9Va+676MxxiyI6kWL9RGD4JZAlxvUZr12bM0N02YdO+F11lmn2WabbYr4XHLJJUsvNwVq2223bZ72tKc1BxxwQLPyyis3H//4x4soBxU4vZjbxDrhJMwOP/zw5vGPf3wR7dgoY1ry8Ic/vFl++eWLIEcIv//97y898Oeff35pRPzqV78qXycuuuii5sILLyy98DVHfMN0xIlt/YorrjiZ74973OPKNdCgonHzile8ojTIVl111RIOgU8D42Uve1kZPPme97yniHkG1GICdOutt5Z8WJRQOWGpdZUHoKxttdVWzZVXXlm2B2nsmNmHmXo+8YlPlOfzox/9aKkTaMi/973vLc+8vjhx/+I9N8YYcz+qFy3WOwDikl52RN1UTFZmU6yrwNBD/IIXvKD0ouN48R5xxBGlICHcf/CDH5Rwn//850vBIgzH5hfxIGYw/AmUXmmBGEfwcj1HHXVUGZxLHtCbrl70Zz3rWWXGEOaXpwebgYmcazZsYvfaa6/m3/7t38qXgIc85CGlYYFggXvuuacIFPKJBg9mHAj8r3zlK2UwKg0Rvg5wDXwNWW655Yo5Db326667bskHZpnBDOj73/9+c80115RpDO+4444SdxQ98wGVGYR6LD+YwfDlxj3r3QaxzrNNgx7H87nTTjsV4Y6j3ArfP2OMqaP60WJ9lqHXHGHeyw1quoJQRbAStuaw5x7WbDAqMAjK3XffvbyI6RU+7bTTihhmiQkIc2IDIpmCdckll5Tt2guZ3mbNR679Mdw3vvGNItj1u/5zzjmnXK9AyCFSaRBQkNn/qU99qjQCXvjCFxbhu8IKK5SeeEQvPdgI3qOPPrr5yU9+UmzKMUXBXEjp7gfpyw5Iw1e/+tXyFeA1r3lN+TESQhw/fV3oBfFwLYTFMU3lj370o9IoIb/pTX7Ri17UPOMZzyj5zDXRO48IovHE/g996EMlPPebLwy/+93vSsOA67vzzjsn09pGvJ4okuNxNT/1fEd//Gr+LOO+SAwTXWxoMS4AsU5jReg40y10/yiHNDYpl/Iz3UL3Jd6b/IzGfb6HxswOetYs1meZYfaGD/J30mH9wVQFBsH46Ec/unzOxmyDHuBvf/vb5Zf6CGLBrC2x0YHgIg62+asnU/BtuOGGzX777Vf2A/t5QbDEIV6/+MUvlhlhMH/gWn72s5+VuG+88cZyTL8ec6b2w86Zz/A77rhjEdHrr79+sTfHVIc0b7zxxqXX79BDD21OOeWUci7Ebr+fMCm9GUTzHnvsMbE1Hi666Cfa1mvQMKCh8a1vfas57LDDSr7QM08jYYMNNmjWXnvtYmqDY517xow6iH7Mck4++eRyz9RgQcz3a1AovXLxPuEURsu8Hl3NX35C/txf0sa0jfwIiTESzLn/61//uqSbnyXF40z3oOHOc3feeedN+JiuoectP9fRibhujJlZ9LxZrM8yiPU4HzrCXOs4BC77hyGwh0WsrLFJ54c0Yueddy626j/+8Y+L8JU5Bj3WCPlf/vKXC1Tu73rXu0pvMKYdj3zkIycHyMYwrEsEs9xnn31K7zFCHRhQ+va3v72ItxhW62oYtME+zI0Qu1/4wheKLS3mPa985StLzzUil2tB1EvkMmCWXnJs42t/zcQU5cgjjyxzrHP/cPTyIyjjCxBi2qJfdtEfiEfX2gb7r7322mJHjw395z73udLY4a+qb3nLW8qgXL6IcH3cB2z/aazQW419MaY8Bx98cPkqwCBY8onGQS9IX7xGpVHphngNORzIT+tx3+WXX17GSNCg4gsC5YovLFwPX3hiWNM9JNYH6YAwoyE+e3L5WWUp5G+MmVn0nFmszzKxpxuTlzybC+IuiuGuoAKDKQmzcQhEIC9iXsjLLrtsc9lllxV/pjJcfPHFJwW1jkdIIgBxfBonDyL5BQFMyUhvKnmDEEdcMrgUu9cYVuug9ZpfG9iAcx2IVMx6MJehh5zrwxYecYvpCev8PROxiP0tIh4bdNIUv44wfSM9+yKnRcv4IoxhQNvZ5Zen8qofNDQYnImYp3edLwmYziDSMUviunStmNswHoBGy6tf/eoimDEj4isFg2AZwMv97UdMZ7yG2KiKS60Les8x6SK9NKwY4EyaKWOYCuXwpltEMxjTbfT8qT7RsxWXcsaYmUfPmsX6CKEnXfOsCwTpMKdbHDbYhSNCEdmarYUeXHrUsRN/6UtfWsQrPcv0fqtir4lJTDfiANMcRtsIQ340hCkEcVFoMVFR3JhJsASO0XrNRIZ9hInhtGwDm3kaGTREaGgxr/q+++5bGhAIWwQ8JjWPetSjikh/8IMfXJY0VjDBIW9wEqf9zkfalHalVSjdMQ59zYgoTLzOfvB1APGNnTvmMZgC8cXkuOOOKwNlaZzQUMK0RoNguW6211tvvWKGg5inAYqwpgGDrTzXojT2Sov2EbZ2nUDe82UlNoJMt7FY7zY8Y3reeFb1vFKv4k+9oDqWbWPM7KF3oMX6CKGXHVEXzWAYEIrfVGaFiSD2eSmyxA2LKPpoYNDrilBDsMsf0xdMSRBx9NLSIwpReCkslT/mM/yVVNTCAeIfYfznP/95wud+6AFHFGPbDjpWccWXC+txW+fATwJRxPUaHMugVMQoUywiSPjqwL2LbplllinClvx67nOfW75KMKiWdDP4loGSssfuNwhU+1jKaRtIM+u8bPN1ajtfl44dBPIIkxhdM2MHMAviCwSmQvS8Mw6Bgb2UDb60MBBWc9BzDz/84Q+XqTaxX0bM0wji+unxv/vuu/umh0HHDHImv6HffTKjx2YwcwO+LPIcM+6F+0XHC7Nv8VUN87k4WYDqGmPMzKLnzGJ9hCCmEehZ4A06z3qEuLDjVRy8GIlnOnG10VZB49dWcUcxFcMgdJm1hbnYM4pPx9KzjtBDHArFRa8+phqHHHJI2Y7E9MZzK26WeX/0E7XtGB4QsAy6XWWVVcoPnGh0ISqZYpAeeRo1TGGHWH/xi19cvjwQlukZGezKVwl6rrHPp3Fy9tlnFyGMKGUwbczHDPvi9cS06biav5YxDMRtrU8VhD0NTr4sMN3kBz7wgfITLRo0jFfAZp4vEuQBPfPkFeXhIx/5SJlRh/EElGFMbRB7angyDz3TY2LGM9MoP2aD2TzXIAwzPdw/etY9wLTb0MinvvnpT39axokg1vmCSKOauggxD10rq4sig9wD36f5ge6jxXoHwLRC9uvT7VHXlI9aqheLxsB045xJ6Flvm2edwikHCHLMYCTWo9BkycuET7WAHTvCTscqTM0tDDkOzoMw5yWH6KbhhKkG11mDFyNhMRfhvtPjzOBberQkZhnoyoBXxD1fKsgrZqxh/njEPMf3G/yp69e6ljH9+Vq0HfdH4j5R8+sFFQ/zzNMQY0YbRDqz9TCAFFMbrlt/iGWdHj7C0DCjMbrddtuVfGCOf2YXIh5misFMC7HBwGaEB/eA8kBjapjk643beR9kv377oeYnon/bcTX/uGwjHl8LK79++1XeuA/9zGBq8ZjRQb1C/XzMMcdM+JguwfsD9Iz1grB+vuYuuncW6x2Al1h09Lr2erHVQJTL/p11jqcRMKx51odNL7EeBSYwCJJBt7JTj2JTlRZgRsHMJ4g9THJA4eJ69JsJGHTLgE0x1fPxUMo2/thjjy0CXb3yDPZEyGvwJz3yzOTCTCmY19ArjZ15r2knVcGTJtZjfuZ98o/7IPrLZf/pwhgBGpjM/qOBvnw5YQpKfTnix1N8rqdHnhltJOxZYoaDH88R5jeEo8HDAGDyEPMrxlMwAxAz4NAI4H4xjSgNJ/KcqUj5KoDwv/TSSyfn46eMDZN+eVXLz7gd/UH75Nrur5Afy4jCx/3R5TDZPy7Vs96rHlJYM1p0H+hF50sYA7lNN+Fe4TBPYlwRnRf8lJCph1nnqzr1aHxHmrmHnkmL9RGinxZJgEQ3VYFNjzpxye4doaK45lrPOkRRoQGm6llX4VVlBYSnUqJ3lnngNSuNULhIzW8Q8nlzPExnyawlMYzCxfDahkF6P+gdxm4f8cgc6VTKCEt65ckfeuTpjce8BDH/nOc8p8zugjilEUOjh4Gj+grRRk5HTG9eykXydhvx2LzMYDaFEI/PyJve9KZi886fbRkMi8kMAp+84fnhT6/MGMO88oiOgw46qDRoEOiUExo5/O2Wz/0Ieqa0ROQj+pkNBxMdbO9xbNMIoJefsQeEp1HIsQyspRFAA4BGEw0r8hvhzwuTL0P0+PMlAeFKpUvP5aD5NCzi+ViPLvq1rUc/UfNnPZZzyhxfjJhlCWrHmG6ge2Kx3m3iO4UxQLz3mWaYCQ+e97znlfFD1E2YE4KftbmL7p3F+gjhAYviI7rp9IbX4humzfow6dezjnjlhYGwRGxhs84sJfRs6m+jqqxYAuv0ymLjzfHYTSNwCa9wOmYQcdwLjpUjLtLJIEnMcBBsCGjSz0BMnT8jv7gvruu6+sH5EX8M6GWwJqYf9AhTiTPvO7OnIEL5myuDPhGhzJdPecGchDnkEf70HjPQlTwkn8m/XrRdU80/QxjdC23ne6L7BZgLcQ00SBgTwLz7DGYeZOrIiM7DPeEaKR9cL/eOX+RTIZKHNAxpGGmqUcxqsLlmGlG+XiDEmSEHYY75EmWZgXjkKTPj0FimcUHjCbFPAwrzNO4BDj8aVHwlwWaf8LxkecEibHnZ0qDgB1vYDTNfPuY+mPpQN9CbhtkVvf2km3uP4zood5RDyoSeF+4l1z1omRom5B/Pb7+e9VGkzdSxWJ8b8NxQh/Hs865RncE6fuzzszW30TvRYn2EMBtMnroR4lzsU2UY9u+zQb+e9YsvvriIHk0V+MQnPrGYQWDWgMDMQrImRBAx9DQwnaDCE4Z1HgA9BFOFOOKxrPMZkt5WerERYQg1BBfpp2c1wvGKI8eTryHvF1rPaWmDMOQR4vO73/1uGaiJXT2CFwFMmhGRCEpEMQKfP9Ty0yh6hem1pgeb4xG3MwXprF2bbP+ZDYaZKRinAPIH5WskxjeTxPMqHTo3jpcmjUieSZ5RxhxwLXwZ4SdUEv7bb799eS4Qt9wbyg8z7CDkmV+eRhY9/zQCGJzM/aIhwDZljv18IeDZYTAvXw74AkG81CvUDYwRoMFBuTzrrLPKlwgG7F500UXlCwV/h+XLFGmlAUejhbTTEOA6aJhSlgaF+EgTXzoys3FvzNSRWOdHb6Z76H2Xnx9MMPl6aOYPuscW6yMEQU2PGi/Q6OIA0YVBM2h0kX5inRc8ohxTBQQLggThgQBmejGJbxVkiSW25YfdNsKTnk96GkHhJKimA/FLrKjCpKeTrxgIYV5ymEVgc86fQDXNYEwbsF5Lt9ZrfqC0a1vU/AT+OlcN8ocGEjPRMCMNXwcwraGnmDKKmMch7DfbbLNiSsIsL1wzvb2IPaahjOK5jZhG1uUi0T/uQ+Bi2iOxno/rR6/w+VwgP/m3hYlLobDZf2Ggp5xGKD+24hnhCwplDuF9zDHHlHuCCQ4/8+LF/e53v7uY5/CJnMG72I4zWBdbf75OIKJpDOuPtjQEWMfkhzERNHb1/wTMfYiDRh73n3N8+tOfLvUYPbA0PLCVxWyNLxCUC0x/+CrAVz6maSXtMzHg1wwXxDp1r8V694j1vOoX1e08l/yoT7SJejN30L2zWB8hwzSDoYee42KPPEKK3rRhEB92VRAiVwR5P+QKo5dYJxy9t7zoEcFMe4hYwAyB3j/Zoys+VVT5nGzTO0hvsLYlEmrHxPhyXJEYrgb26nH++Bq180LtvL3SAlPZr/W8bIP9iHB6X2l4MNiVnhv1yse/nWIjj6Bj4CYvDAaFMkCU3lo+y/aC8yjfo8Mv9uJig0mvf7ynWmod8nrbPtErPNT8oN9xIvvXjpOL5O1hgejHhAiTKRqTmPkwMJmedoQ29xoB/vnPf77cR0Q5vf+UbRoBfG7np2Z8AWDgLgN46c2nDCD++QpAo4oysvTSS5cfhfGioZef8sExHEtDgilP+XRP3Jj8cD5MuEgD95uyxzgNzOAQ+4M0CPsxSL7mexKX0R9qfqDt7J+p7a/FV0PhctipHh+h8Y5Y5z5EesWX98V4ex1npkctT3fdddfSiAbn/fDRuyjnadxmPW9nvcFXajpVqFd5p/K1k6/d6CEmNojaQsdYrI8Q9VqyjG46M7gwWwo98tn0hfiGaQ6jgoiLIiqaluQwLKMQg3496xRmromedExLeMnTO4g9L5VRLPyKsx/0/NFLiADQMbVlr/jYFx/YGFbr9PxLrJNOXft8A7MIyhZzMGNTzgBWTDoQ8vTeMhiTLyLYZyPg+EKCQGMALuGolDCz6JU3ymMEJY02Gp/0+jJzC40I7Rcxr3OZA63HZVyP5SouRd5elCEvMImhIcaLRPb9CGtmpWBaTZ5ZOhH0V1966xHq3L9PfepTZUzFO97xjlIuEPcIfgbwEo5efn3RoUGIiQ+NAEyC+DJAo406gt5+Gg7ExXPHCxCRSUORepQvRgh9GifDEPo1YrnQMw/4az2WR4WP6yLvz8dFJ3rtA8UBtf3yU1rVsy6bdfkrDHWg6vZBUPxmZqFnnUavGT4q+/lZ0Hp2IF3Es6J14KsodRX1FHUYnV58GUXb8EVe8YKOsVgfIfR814R0m38vEOXZ/l297cMwqVGBaaO2nwKHvxxo2a9nnUFxvPyxl2XAHz1qrCPQsJ9VPBALdi/oseOHOthht8ED1S8+9uva4rbA9pgHkQc0hpsv9Lsm7h33S+KNnnUaSPQcMF88QgsBxt9dNXMN5hj0ytNry6d3vqBwnxGD3BPMK7h3j3jEI8q0jazn8k6a4n1gOztQ+rUdiX75OtuOMXX4uvL4xz++CPWHPOQh5b5x/2jMCp4R7jE9uZQZXkgM7kVcM4CW2XP4kkYDgEYhDTzqR3qi+MJDrzz/NcBEjsYgQp5GIuJeg3pZ4hhYrRl9eDnSMOCLHaZBxIHQ4SdtfE046aSTyrkw76IMk7Y4YJf6S45yIjcT5UNxtsU93XPH8KwTh0CsUz/XBpgSVi6idMR4RC28GT4W6zNLLMMq07ls520R/SXegbqMDkn2aTKAiI6xWJ8nYOuOMFfvPC8ptnHDsF2PlTCiGTHFoEN6rWL8vFh/9KMfTc5zzjEUTIgFuJdYhxi2jUHFsNKAQ/grPbyQpjtaXudkmY+n9xchofRpOVfh+tquIfopL3pBPIgzzcTCj52wt6Yc0JPHPPL0qFJ+l1tuudIrj6DCvIKyrB5aHPbZCLs468Eg5OvQ/dPxtesYNO5FAeWXnqOI8g7HvaGXm94iGmT0fDPzEA1u0H2oxTMonIfjecFRp/Cyo2whrHGUC555xD5TR9LAozF4wAEHlHRh088YE2bywZSHAeyIeUQ9aWYQL0Jfg3kpj+yLYp/xKYyLwZSHLwZ8AWLsB18XqB/5SsiXIcYZ0AjB9IjxNDQANIMUaedaFhbFwZL87VWutS0/8pCOHc3XTaOafxAwwJyZiGg8K5zuXYwvEuM1s0cW674HwyPmpcp3fBZAdZnCsq+tnhSYwTA+L5LPBRbrI4bKkc8giA9eBgi96YprxRMdvVDDgAKDo/DxiRpTneWXX75ZbLHFyoAy4AWFwEJYMUgNW1OhY1Ww28S6wrUtdTzbWsqvF4TTQ0N4BKN+gS976kFFA3HF82td0KPYz2Z9LqJrja6fv2A93rt+9wwBjg01nwmZBhNhlMs2PfMMkmTWE8oSPbYIJcQ/Zjk0GunVRxxyjwctJzH9tfVFldr1t/nF3iF6xzFZ4X6IfFy/e0N4OW33Y5AwvUD484JEaDN/PwN5EbJ8maNzhLqagdiY4GCKg+BnpiJM7WTKo4G7zNbDEqGPSRhfAJjdimMw9dN0r4h9zIfo2WcwNYN0GUeAeKY+ZWwBHSJ0hpA2xvaQzmFAnYh5Gr18mKoxuxCNERo0mLbRsBYxb3VfohNx3cw8FuszRyzf1FdaBxrevKvizwjpIKCOQGcw9g4UPh5LpxPPHMgvIj+L9RGCUM8CBEfP+HTR1I3TMaVpg8KiwomtFSKdXirMHHiJIaywB6WxwZ8gEb20FDFtYD0er5dyr551hY0vfB1HfKwrDGjZC8IoHMfqMy+9uPS8RfrFF8+rtPDJnrnK+dpAvDx8fLZnujryqV+cXYa061rb0H5dp/Il+tXi0b5IrdHEXPs8G7FnHUGBOKdxhDkE4xoQS8xYoykOWSKMEIuY4CDo9adSbOwRQfy0hzI8CLX0znd03+J6dpnoT/4yhkE/RdL9jWFimQD5K0zcFipb/cJEclhBOMWn5cJAbzn1CgKXgfJxqk7KrAaTUR55mSPWse/ffPPNSxlmus44Uw/CGaFPA0Bz8vMlIP6QS0KN+p8vB5RxviIg/Pk5mH7MRZr4OkqdHevYDF8RGAQ3HWL+ta2b4WOxPrNIz+BUZwBT4z7qUY8qX9IAcU7jHB3AM8q0yOgB0DG6NzSQeTeB6p5437RusT5C6AmnxwLRLsdnWnqtpzvPeowLR8XOclgwPzOzOzBrAz1C6j3nZUSB5LMuYOu5+OKLl8++kAtgPzMYiC/NWuEF1lX4exHjUXim/+PhqonDfhCP4mLJPOu8YHlxMgMG4pDBsNjR8uv6uY6uV9TWFSY7iPcyonuhsHkb8KN3nDzG1IDpOBE7tS9QNMIoczw/NJ746sPAHT41Ioz4koLI4blQjyeCnh56BCX7mekEEwl6UBnsQ8Wrcr0oovuge6Jt0c8vi3WVBe3vdSzE7ViO2sJF/7gOtW3I8UZq/qzXtqPfdKAuorccoU8HACY01KXU4djQU5fQcEX0Y0+OvSuCWj/nwpRMJj00WhH7iHzEPg7hz/NDQwCTM75KEZ4vA9jtM9iXr4L08tMgJg4atXxRYElPP6KfKUPp5efe5l7+hc0DM30Q69RdwvdieMRnPObrF7/4xfKVl+eLzjpAGyHSBZ1JNJqBY/WeA95NiPUcr5CfxfoIqQ0KhekIbIl89TpGt7BiPRYuKnIGiWF/irDBDIaXCT03vAgE9qqYxOjTtwqchDGVOq1OBnRFYmGtFdyZghcjLzUaIaBrZpnToX3KE7YRjog6PlEjLHGs8zLjE5kZnJivOf8RLMwmEj83xv39wI4Z21sEBl+J6GmkwcnMIdhX8yMoBhzSc0l54GsRjl56ZiLBxIH99IQSHuFE+adnfirpiORr1Hr2F7Wwom2f1ln2CtMWbmHgGaABK7G+MAwrTTPNKNJJBwg2+jQsebFTB9EhQf5TNzHOiLJKnYxpDQ1Zevn50sTneqbU5OsUvfuPfOQjy7uDQcE0aCn79LTjZMOPP4N2ZeJDo5eefxoImAFh/0+DgGeGdx0NNv7RQIcGYgaBwnOkAfmkg8YHjRCm7eRLBOkkvTS+uQ4a4tS1XCfXC3OlTPRCz1u8lryu7dq6HFM31t6puEj2Y131LmhfDBPfeTVqccbtYVKLd5DzKUwM13ZcL3/BxAk0flnybNB7jsklZpt82cLCgA47vuBqXFXOQw0wbUPns1gfIXlQKA6hjuieqt06x0aBHt0we9YRtQgcxLZ6xxHtVKpU1gKxjsjB7jhC+KWWWqqIn3/9138tP0yBtgdjJuGh0TnpJWKGEV5Ysadd+/FTZRWPU7oZgEVvOg8dPVT6oROta3qjzGAoP2MeU84QIFSCvMSp/Hh540dPusItLMTDfcaEgV5CBDgNLYQ9vYmYFPCJGUHD4DuECYMQMQvTYFieAWyRCUNPPnaMPH+IDBoYNBS4DiruXiYIEeWF8iXS5heJeSkUn6iFGRbDFOtmZqAs4qjXjz766CLS9f7giyEdDzwP9PjzbmJJmcakhq+TNHj5ksUc/fTAI7gRKwhwhDimPvpBF+8LvipTX/Is81WLHnwG7SJ8op2/Ggda8vWW5413Cw0F3iOElcmbTIT4mzRfF/hqQOOaLwc0DjCdo3HABABMHYq9MF+LabjwFY33GKadjHWhocNgYN5lPLtyPMM48oE8oR6ivqAuou7Q4GYGOlN3ka8z9WxlyGMEu9B5taR+y++3HAb61Qeqc3J8EI9T/PLL2yLuJ27Fr22Rj2tLZ80vQ5hBj9V54vVSNqjrGSPFfcbigAYx5mV8uVpyySVLuedr1bLLLlsEO3GoPOi6EOsyg4F8fm1brI8QHvYsshHq0xkUSs9IrZce/+ma1ERUYOihib2a2AtTMVJIqVBl+8s2ZjBxVhigBcoAKsQtlap6sqHtwZtJ9NDwADJbg+zX2da1KF26hrguEPt8DkOY0zPFVHLcD0ww+JRtBkf5rbJADzgvXRo/2PM+8YlPLH9XpYedyjC/LAYlniOuTxWeY8o7veyIE8xoECM82wy25vMoIgOBgRCh3NOIQzhgzsNxmJFhWoDwoRxSMfPinw61a9I6LpZnrUdimLxvOlisdwPdT93f2r2nIUlvOOKCzovHPe5xRXTw5WlQhlFmBINeEcMIZjqKKEuYGvCDPN4lmAVhHsc7hal56QDjncR7b5dddilCiQ4UevOpk6kzmM+fgbM0uOkB5RlF5PNFgAY4wp9GOI0B3mn6eoDDn8YBzzHhOZY49PWABgjPPp1SmCWRBkz3aLDwrsPkgUY/ZkWIPAYtM66JBj1fEGj00FjgC4hmW6P+47oZqE3dwBgohCJ1BMJQ/w+ggUBaeR/PBLn8ROSnex/DiuyX90ViOIjn0762Y3o5lXuBn9B+hc1Ef8LRcbPEEkuUe8kYkUc/+tGlAcj7gDoeE1+FpxwyEJ17BDoPYLPOeBURzwNat1jvAIhpDQrlRk8HejGocIgnOgTCMM1g+HkJlQEVBxUJn0cZVEqFyqdR7CcR6PSgxAGmEAsg0Jqkh0PEh2i2iA8NaJ17wadaelgAfzmh7ZxuXha9bPFNO8rLmNdUUtwPXm78RZOePnqseUnzspsu8V6CzhnPzVJlJPppfRDonaeRS0OO55SygQ0jFTRmAZgL0KOIEEDYIwDoFaT80RjhRUBDkK8K9PzxEqdXk968fuQ0RydqfqLmN1Us1rtBra7L9x3hhwjmi6imbuT9gWDUsxmfh1oc0Gs778uwP6d1puE9Rc8471+EMKKYa6YRrj/70vlCw5qeeMazILwxhdOffRHl9GrTCMe8h/FofGHlK5saCzwHjBNA3CPoeEfyDmW6UBoKfB2gIaAvBtQH+NEw4MsD5kU0DqgDiYfGB18OMN+jccAXkcc+9rGlcUD6qDvouaX+oM5krAP1CF8S+AqCWSFfDWkkyNSIa2cAMnmhaUVnEu5zLh/RL28LttvKSTxGLpK3I7XwEP3IE+py7gP1N/fnn//5n0tDkPJD/c2XVcEXe+p7Gp9AedPzxP1ByEOv81qsjxhmbEFU0yrn4Z5OrzrMpBkMhUUPBT3IVBL69MjnRdlkUwkg2LH1pfLh5cwxKmxxnUJL4ZVYV8GdbZQmPTxKH5UvFZ8Gh8pf4WNYLXUNCKw4yMcMjvK3DT4l0lPGy0T0Ct8LnSsen/3yvlo5jcfUykU/EEhMD0hvIQ0SXqz0tvBsUCfwQsZUAEGvXj1e3DyHmBTwIkAoHHTQQaX+4HmnMc1n+KkQr0MMeg29sFjvFvE+R6d9QA8gAhOBJ2LZ7kcMx3p8bnIcOWyEbbm4Hde1DdEv+kfa/GcD3jM8l3zBiA0DnhHerRpTwJc2fTlgSmS+RNNI4H7w0y6EInUEYpwGAwOC45g1voYwQwmdazx7NLxkbkSnHnUJDQHe4WoQ0FjQD8MIyzF8yeSrpr4W0ENMQ4QvBrznaMzRQUePMvUPjRjSqcHI1EVcEw0fzIr4Ks+1D2u60RqD3v+2MIP4s+Q+IqDpqKTjkvyn8QMIcL5OcX/Qd+Rx1BIxLhpVNOrY1jOmfaB1i/URQku2NiiUF/RUQazzELKMjvgXVqwDhUgVLg8cDyIFk4IawZ6dFns0/VAhjCDW6XGgVwJi4Zwt4kOhdRxppSKlR6XNJjqHj2GwidQnsOhvBkP5pryL+UtPOiKCil9MN4/zeeK2/IB1pUHruLxPKJzQuvxx+Zg2CMPLjU/fvPDoAeOzOQO6+ZzOVxwaLwh3XrR8ttene3rs6OHh0zwNYwQ9Y0TIQ2yQsZufKeK1cS4Egwabm9GgcpvLHdtyKtfUewg9RCHIHxRPDcWj9UHCZXQcrhZOftkNGr7mF11MM9ttX4cVNvpFasfMFAjBLNbp2KDRRWcaZkS1AceY3PCeQyNQr1A38I8KviIwewnmRYhJBCcNApkW8e7GlI+eZOy2EffUN3TU0QDQoGOW1EV8NZTpEDqFLwocw5gF4qBDgq+MlDnqKpkQcU7epTQE6MTA5AR9QWOGRgDXwldGxhDIxGQmabuX6CA6LukkAXreabhw3dTLmMPGBgrxKC7GTWCJALUyrHWL9RFCaxUzFezreBhwCHUetqnamdOjVptXvc1/OgxSMWU0iC4fS2HmoYzmIuxvi2cm0Tl1/pwGzA2oRPhUpU+CvdKJKKJnvvbgmd7kvCIPQf58jqZSxH4VtH+6KN7afcplNoeJ27V9kNOXw4nsVwtTg3Cy62W8BT11mKFhvkUvPT07fJbnxcpnd16gDNDDhp6vYLxY6W3jRakZbvhETk8RL3nKPqKec0xloBzhcByLKKAxgRBQfWC6icqrxLomABAIV9D9zesibmt/zS/CuRf2eY7k+KHm10YO23Ys/toX16FtHdhuqx8UNh8D+ThEHIKXMQbM9Y37l3/5l2Jmyn0cFpyX5xfRSa8ycdORoIH4pIOOPL560rmAiKYu0pcD6gEaEHT0YU5EZwNfBzCjRQNR/zA5A2O+EO90NmLyo0YAdRfCXw0AtBNOsxPhR30WzYao8zA5In+IV18HmM2Or9+MGeJLBeZB+hcBZoakl8YN18U1xgHEcuQBjvzAaeyAnhHQgOxe8HWCThWI915o22J9hFAYa4NC8ZdYZ9nvZkcISyuZ5VSOm20o1Dw4c8G2m4qHHgB6BGq9kbnyRKzLDCY/eKY/bZUVqGedFwCQ787j/pBHvER42SK8eYny4uSzOmWVZ5FBd7zgeDHyAtQMN3wyp/eMMPR00dtGLxyCni9odAbUPm/z+f4xj3lM8/jHP7552MMe1jzkIQ8pPWZqaC0suu+9ykutbOAXn9e4zbqOieugcPKPcYDCxmNyvHFfpHZs2zrE8LX1SN5PmpQuXQ/EYykjNIrpzQTtU3jFE4/RuvbHfSL7xXC18OaB5HyiB5dBwYhQenIRq6zTc13TF11HZULllHoLh2ag/sLpiwENAr446geEGnBMnjDYn04zhDmdoHwNQLDrPwSMvdMsRLzbyTfyT4OJqfvUIGCdhgBfBwhHA4L8Ravx5ZJ3Eo0jZuPhyzoNEAY80yCRSRDp42sA5k446k7qQsYhMDOeeuUzut8W6yNEPemIazkeLgqOtrXeD4S5euVxHEOv+nRt4GeauSDW48uIT/k8XKpEECXaF3ubwGJ94VAex7zTOj3r2GlL8OlLh+nPoGWRcPSOYbaiGW742QovOwbJ0XDl065ebNhj0gNG7zx2srykEHn4qz7Sn2cR/vSi8Tmelw+f5zX9HWKfxrB67lQGBk13l6ldR/SL5V3+Nb/sIOZTzUWoq+QXl1pHCKknlHnRER28W+I5FEd00G+95sz0iHlIj69mLuOdypc0wI/naD7lc7yWYV8XZZ/6h3qJDgg6IzATio0A6rVoFkS9yOBezFgwR6SBi8UEdSHPT5yaFIHPuADqRb4SMJEAwp+ODMbHMYtYDV2nxfoIoVWml1kvN4hYp/DQAtRSx3COYZnBDJOui3UeEF5QoKXgISbtbQNGLNYXDjV+oljRPaBnHbE+DJv1RZGcV2zX/HrBfsQ8X/2Ymxp7TAaYUeZ5cWlQm2ZIoEcdR12GCQ6fpJlFgd56zWrBi43BbDQGmJaTGS54xnA0EuiRZyAtLzRekPReIfqx2ee8moGJH8LgmCZPjk/tvGAZ9MWXBOYAZ4n9K4PicfyAh+kJWfJyxvFJnJ4wxuFokByOHjC+TNBgxOxIZgB8Kkcc0evHi38uwmd77gEzXPBFhK8r5C2CUGUlOsjbUPODmp9o8zcL0iufEI08g0L5rTp1rpKvWdss4/s5hmO9dpz8tJ7DDBPShskMJjJ0TDCRACaK1Cn8l4Befek85mlHW2SUPov1ETJMsU5c+uTFOsdoAOsgx882c0GsgwRjfKjp3eW+0LKuYbE+fciv2HMXK2JAQNGDgWmScB4PjvI1O+1TeddSKFz0a4OecXrJsZl/+MMfvkBdRs8TghiBzAwXCGY+FWNaQ68VA8kQ/tjaMxsOn7GZhg6BznSXfNJWLxZjSJh7n8YBAp/P2zQSaAxgp8pnbswD6NXCaT5tvgqol4uefs2tTY8XTl8M8JPDNIiw9ITpGOJhoBzxsuQcND407zaNEEyLaIiQNuxw+QxPWul9I+1qjHAtzAiB+QINEhyf1GmQ4KhTaITQGUNvN/lE44OvGDQ+cPzMiDyPjQ4G4skOV/N209hANNDY0A9+EAJAI4TxDPGekdZeg/dymaiVm0htO/uZdmJe6TmlcciSMoTtt/YB/rkenatwLXJxO5LD1Gg7RvmZncjbkbivLUyEsUGML4jPGvVabugrLov1EUIl3G8g6SBhgEocYY5QZ8lLSQXAPevTQ6KRpdaBFxf3hJay/OIDZrE+fcgvXBSL9KIj1hiIQ2XGQCKJN3pMzcIR8zou433IYbQu8jYg/LDjZCA5PeqIV3qTpgpx6xnEYU/NM4ij1yoOdJPjxUYvMUsNeNOgN0QqS+pFOUzc+Bsn5m6XXnrpZC86vWA4RC52pizpZcdEiFk0EMMMTGOaPYQyZoc0RGh8IKaZ6YHefWa92meffUrdwFzcTHuHGOeLAQKdupCGDA0PhD0CH4fop8FBwwPbVhoGDJrjqwWORkOcl5tnA/taBtyxlNM2X10Jg9OgPPxpnBAf8TA4kfeG/mJKjx9fOkgr9TWNKmYMIZ/IX+pyOcpJLCtm+MTnj7yOS0xhZU6Rw8x12sqU8iPuj341pzC5rMb9UAsjtE/rcpl4vJY8K9QZNLKpH2ngU28w2DX/P0PHWKx3CF4aC9MLXuupt8369EEYCD2ItYqPlzI9ZvqzKz3u9AaCHjQzGLnyA8Q6n3YROTSCGMGP6OGlRM/iXDU5mG3IT8q0Xh6xbGqdZXy5RPDj+BxW63Gf4uDeIILpnUXYar9QeiDvm4voWiBeD+tyhOG65agL+RpBXmlds0ywlIsNFDVSsLGNM1VonaVmsdBMQZotiF51etexS+dzPD3uzIFPA4Rp8ZZaaqkF3iEMNqbnHzMlGgp8WUDg408jjCUNBr4uEIZ6neeTryP0HtK44Xw0kDg/ogOzAI1PmA/3fRTk8gR8dZLNOlCmFGYuU0u/rn861I6L8eX9cV+N2j78cn2gbdb13mLGJRrs2p+vVXFbrI8QiWt6aRHpqhzpFZ8uxEUvO/PjDrtHXYVGyzZq+7Nf18U6Dwxp1jKmX/7aR28GLyzmwMaPB49KU8fkY2vUwi7qOC9mnl55HMsk5VpoO+7Xeg3EIT2z+ilSDqttxVnblh/E7V7rgxCP4XzxOqEWZ7x2Ef3ivprfVKjFNQjTPR/CnkYwPfwIA3rr6e2jvo4gNBDeCH3G7jD7BmZL9L4zMwZfBRiTgE0ucWiGDXru8eOLAR0cnAvzHsYQ0FDAxJCfg8Xp8/hSgqifLm15gf9086kLxOdD8O7hiw1ofy7Tc51+90z7+4VrIx5XiwM/5SnrciJu99on+PqG+VIbCm+xPkIQ6whrRttriiBEexwg2gt6zTm+lxs0rn5QYGLloAKkZSy8eYnL++dCz3ovdB1cF5/7+RROTxaD7ehV4jM3c7fSI6Y8UD7EbYi9iywVRn4xLMjfmLkAYp1Bi4gw0z1U12BexN8nMdthLAEmNogIbOER4ojzWA8NAiIb8yPEN4ORqROxt+cLGWZsiHu+ujCVnsx7EPeMHaAHHz966xlUTo8xf8vkeBoQpBFTAmbsoIxhe58bFb3I9Wom76uFl1/0r4XL1I7LtO2PfvldwP1Sz7qOb4vHTB29m/MXi5jHtfUcjnc+X8mAjlWJdZ7B/LVJ6xbrIwSxzqBQTbkoUY3/IHOk18xeam5YYh2XKwdRK1ygwq3jtJzLYl15Ea8LmLcau1REO5+kmbGC2UsyHJMFeoxPSzm2QUuO1boxXcdivftQnyAUeB9hk86UnQhlhB/z5WPqh+0/4XDUS8MEcx0aA9jBU07o/ECMkxZ6HnlPMHCSwbmMfWAwr/6WyZKGBTPYIOzp2Uf80BjAHJFxLVwPA23prWfmnumga9e6ltE/gl8tn3J4bbf5R9jWewFk/qJwcTaY2rvDTJ+cn7Vt0BI/XHzXA34//elPi/7ZfffdS0OVcsysSww6Z4rIHB4s1kcIPd8S1Ah2oLecQaWDinVMZlhKuGsdR686+wcZoNoLFboIhYleDj5hqsLAJpGZGOgRYdAEolXHER6n7fkg1kEPFS1tZrfgM67gJcegM/7cxiwWmhs85qWEt+KJeRTDQQyX9xnTVSzWuw/1SaxTqJ+ZpYae8EwOOwjUW6rbdCxL1WeDQHg6QRAt1KUMCqZuZaAvHSWY49DjjuhhYDN/7WWOa+zpNZCWJb32DNRl0C4/tOE6aZTQ0cL1MraCwcW8v/oxSPp1zcqDiPbJibwN2ta++O7QvijW5TeVPDbtKK8jyuMM/tJFwHHqjQcapnwV4mdO3DPKKQKer0/6n4vQusX6iJG9utD2IGI9zhSD8OdzSoQ4+MQ4DFT4VHCYFoy5k7GPw49PNxtttFHp2aAA0khgUJIGUWTmsljnwSMv9DAqX/jUyz2h94ZPslSaPJS8BPjxAX8yU3hmU/jOd75T8kHxRFQB4/Sgg/yMmStYrM8NYt3CIFVmp8GsD7SPeijWTb3oFUb7tJ8l9WCMO+6bCsSD+SHCHsFNT7p+g89gZ96vdIrxsy9663lHYkNPJxM9nAyalWPGHKbrZEYehD2/w8eEh9l+EFbMFES8nINBs5wP8wbeh7qeQeE6Cc9x+ZqVH3LRj2tlsC73BuHHNXF+0sI+hTULh/Iwv6/xl0kL6/G+k//cC1ErD2i3173udRNbD0TntVjvAIhqCfRBRHoNetLzr4WJa5g26yo0vHyZRoz5iJlCj8KIQGWKLz5jAnP9LrbYYpO966qExVwX67qWmC8smVGB6+JzFr09wAuCAVj6/MoXCD7bkn9U9MA+prVjX8wnofPoYa+FMaaLWKx3H+oV1WssEevUYcyBD7m+6Vf/1PbjJ3+dT+eM+4T2C4UFltrXdjzU/HpBeN5n2NkzYQCz2fBTrd12260IdXrr+SslPfOY3yDmmVyAXnvqcwbP8nWZhg7vxgMPPLBMyccXVzqx6Fyj155xTjQgoqAelHi95AHT/5Em7P9JB+niywIDfPnN/VTzwNSJ5U+CncHPdMZRLjC1ivcSTYTFBNMN8wUo3rN4T7BQ4I+nUNuvdYv1EYKYlr26bMtp8U9nukV6dLMZDPOt4zeMWWFUiLAtJG7sAPl5yTbbbFNa9CeddFLplVAPML+s5u93TNulnoJYAAG7QgYuzSW4hthy1nXF66NiZ05wkJ9gG9tQphxkCkI93JjQcK8YnAqE43MYdpaEqbXmjZkLWKx3H+qTKBKo5zEPoQcZ8M+uFzGuGLbf8bV92o77auEg+sWwWkYn2vz7gahnthoGuPITKjpkmE+fKWZ5tzEolt545tDmJ1yY4yDoMcPRjDjMkoSwpreedyqNI2z1iQ9zHMQ9Jj905ujdmqGDJ/5XBbfsssuWuPjCm8WfmT7xvY94pl7jXvJFg0YSmgj44sI94KsNP0Nj0DRmLiLeE8oMYp3tmlbSusX6CNFsLXnWFsTwVAU2wp/j4gOLm47wz8TCw6BJptwC7NXpbYDDDz+8VEKCgsVnRMQmqJAzpyimM9hwU3HR8yBiAZ0L1B4oQHBjN1mj7RrpbWEGGcyLAIHOYKpllllm0tSJY/kpC6Y1GcXLMq7HyiUuIa/H7VER01lLX3QirpvugVjnZaSpG0H3LL60fB9HB/dBDjAhoWed2WGAeyMH8b71Ix4nsl/b/uwPbWFF7biaX0b7p3NsL/hKgainHkeAYw7J+5J3H72q1Pu8R/kZFnb0CHtMb+j80vz19Jwj/JiakXcnf/bFjIeZerB9xkwnvvcZbMs0nNMhX2/t+vvlR+0YqMXTFtcgdUObPyzMvri/LSxfSviKQg860Nji3gGDnJn+VGBBgLWB4o5xUgbomRd5v9Yt1kcI4lqmK6wj1nmg6RGfrukKx8t+fdjzrPNjC0xdENlUHvScL7HEEqX3hU+GtB5lu4XpBwULEQp68PhVNpUSlRNCNIv1WEjnKoj1qfzBtNZrjh8VOhWzxDl/V+Sz6w477FC2gXB8SgW9aEHrxKW8j35a9lonbh07m+iccko3yE/EddMdYrmh3sAmU2ZhcZ/uZ34GzOyjewEyg2H+c5HvmRkePBPkOX/F5t3J+Ce+RDG2iV52vrzSa4tpDV88EInM1oM5Je/dRzziEUWkP/jBDy5jyR7zmMeUMNxDen3pZEMUMgCXgbg0nBGZCMC2HvsatXvfrzz0OqbNX+taysV3ASiMULi4Hv0y2b9XOO3TUvcLhxhnhiKeFxpJfDWhMYVJLP8cwMSVL+oxHoEZDR2g2V/I32J9hCCqEeYIdZbxU9YgQpswEvWIdNazI06WC4MKC6KR3vTtt9++2MfR6n/84x9fWozYbiHcdS4+wSHsEe8cr5cx2/rTHhVJtFknXFuBnUtMVaznMMovXLSB4w+E9JhQ6Qr+loqAp1IXjAfAUbFFYaSKLvrLqcLWdl6fTXRepZd84Ho0By1pZV2DqkaRRjM4fMbnZRTNYHL5i/fbjAbVC0AdjRkHPbdC+3SvWJqFY6p5SH3HOxSzGMQbtvWXXHJJs+GGG05qBxzjxXbZZZfSsUPnGPvRAnz95n2xwgorlK/5rPOzKgbXIjaZJAJxyWxuNAyYcx8BylSamLRia8+7mzTwbop1MvX0sJ7hmC+xbmAdx7kURvunc27FkWkr37XzkP/M5vLwhz+85BV5w3t6ySWXLH/x5Ss76/pqDvyVW4OUGd9AjzwTTtBBx+xG8RxKh8X6iFkY0xU+ixEeoV6LR25hxbqg0ETH5zsqdAlDest56Jk7lEqAFmM8Lj5gPNyER/yD/LWcy0xVrIMqh+j0wLJO3gFLreNP/vG5lE+hQKueipmGEPuB8FSwQJyKN58z7hPaN5soLYJBy3wmRPBR3hiww1gJXirk9Wynz/SHlzgvHXrwGFxHLyDT4vF7e+ojNbJyWTSjhXuAyz3rujfan+sJs3AoX/M61LYj3AveuZjC8LUboU5vOp07hFXnDaIah8jmfYDwRoAjGJn1h55gvuRSv2K2xtdzJpJA5POOQdwj8hlQyxI/9nHeV77yleU4NAECn0GvDG7FVIT6G1M4BCrnZFIFzHYl+qkLpgPXlsth9NN6zi+IfqzXwoi4TxqGJXlJPcc5yF/qOnQPg0mZFY/OWEHnJr3shAc6LvjayNgG8g9rBUyceM8h4vWOB53fYr0DTNd0BVGPYJe9Og8Oy+gWxqQmQ6GhYOph4PMcL2A9bPTGUGnwkNOipAALFXJBQUdw5Z71+cB0xbqIFQxLHHmsMLoH2o4PNp/k6B3hE6juCy16yknNZpil4tG6zqn12UTn0/mBl47+WEj54i+H/KSFH6bwVcd0Dwa2MXc1zzgvJF7kDKSjscUv5hGDsZyBlmb20b0Q1N3cM8wvzOyh+xDvR1yH6A/xucHcRR1gqr+1XBh4l6AzMMVEaGJKQy8wpjkIdMQozzoin59WYXvPjDnY3iNEcZjrMAiTXmTeUQhTyhgDckkzA3Sp44kboc97i0GZv/zlL4tpEF8RmB5TgneqxHwiP+Qi0a9tn+IhbUyTSV0HmBUhphmnx9cMdICgDqRzEt2TiX8wraF0WKx3kEFNVxD49Jwj9hHuNaHf5j9VVGAkDGPBz0JcqHDX9vEy4FNbnA0mxjmXmapYj9fNOsdIaLOu/Sy1X36s6xxaYnagKSGB3rFHPvKRpcVOGMxH+CsgM9bQwMooTsU32+g6da0RXhSUm3h9o0qn6Q31AuVYjXa2eVnhxz1jG6f77Ps4WrgvjCtAMJ1++umlV5W/gDKuimnpEGvcI+5XW51vpgZ5KZS3ehYGdRyjeBC+mtxA9yjeLxzIX9vxvJCXU4Xj+MpLTzqTIiBg6Vihx52pMDHlxIQTUxtmxGNAJh1M2HozoBZRj8kOprYIfjQRDQB68Jl4gV5oGgl09tFgoPMGky2m2uSv4fTo05tP5xW999Mh5k9ckpfAFwO+NtARRscRPeUvfelLy3VznZi+8JWBwcBcC6ZEQBxyQEcUHRkQ/YW2LdZHAOIZoV0T0VSMg5quqDedeOIPkiJt/lMlFiDWY0GOFYH8tF6rJIDWMaKLAaeQ989lpirWCSMXK802/7aKFf8M++iNYICL5nlnfAEvYsoZlRkw1SY/ceKTKCjO2UbXFZ38Abs+emf5pAq1azbdRPcQWOfexbIc95vZh0Y8nSf6qye9nny6RxxhgkbvJlCn+7kbDm1lvvY8aJtlzP+4jfiNM5FpXzxWyzZ/OdG2Hf2GAR1HCFLqdgQ+/yyhvucLPlND8xWf2eTQTlwnP11EKCOQMbPjiysinx58THQYfIvwxywUk0lmZ6F3mzF3TK9Mbz7xMQ8+Ah+dROOCr36DQjp5TjgP7089I8C4Pb4uMHUn6aejIuYZoh4dxBTOvNN4/tjO+apti/VZBmGt+c9Z0lsBLGWDPqhYJzyOwksLjxYq69HFKSG7BL1tc/WnSDw8qhzjgyU/PkVSYWpffvimwzDiEKSTz5nMOKDPcoh0yh2DkuTHZz4+0SHuIaaBdbmI8iC+CGJeaT0Tw/cC+2cqNhoXxpjhwTPIewhzAxxigk/8rPMlK5o1mm6CiFVH0XyH9xTCWmUWbYUpCgKadxu967wvjjvuuDLrHD359MjT+MRUF4FNrz0DbLE1X2WVVYqjFxxTHQaJ0tPPPOmM38Dkhc5FevGZfpOvBXR20cjga7bemxH28/OrGoh0Ghb0wD/qUY8qtuvMqpfRe9FifZbRz4vkEEP0pkvA4xDgEvG9QITHuNqcxfpwiSI0ClGBXTU9VPgNIkC7AL3vfKakwiPNDEKiB4JKRLbutPqZJ5jPf22iG+I1a7221OdE+Q0i2Kl8qTipHI0xxtzPoiTWpwrvFnQHZjE4Brgy7TGdUWqU8jMjvkJjCnbQQQcVU1Hs8fmyhJ09M+YwiQY99wh8/b0WkY/fM57xjDIzDANMseHHjAyBj6kL71fepfS+0/ilJz7qNGbW4/0K8f2qd6LF+iyD6YrEOJ9dokhnXfOuDwpC3D3rswsPD04PFEuEp+zMMYPRH0y5zl7CdrbpJ4ZBYeg54P7IVIapOymn9EpQ0RGOwZ/M+oHYhxi/8kV+bOPYll/cNwgW68YYU8di/X76vVOm+u7J0KvPe4jZX5g6GTOdT3/606Wzjo4u7PDplcdMh156hDw96Qh7evSl/ZgXn+VSSy01KdYjSqfF+iyDWI+CHJtzblTsTUfED9KzHpnpAabDZq6LdQlPPeiISAb3YAPHaHjuM380Q7gjZrsE6c8uXw9+GSonXgaM2levOAOFKL/Y5wHH8Sky/wwLdIz8oovn7oXFujHG1LFYr6P3jNA7R+idJD+FzUtgPW4PCl+m6fiiZ50pM+mt590px4+s6NWHfD6wWJ9lEHGxp5ttTGEig84GU4PjoluYuGaS+dCzjtNDzvzRjHJnxhV+0Y2dHCPEEezY0HWZfC04YFsuIz9mj6AXAft2wG4Pez8G9cjWnS8O2Jirlz2eR+ugZS8s1o0xpo7F+v3k94neOVoX8X2U98svvgPbwgmFz34ZBrbyLuN9yfz4mNtgYprRsRbrswziHAHNEsenkLitnvapCuxs9x6dxfpw4eGR0/ZcoZbWfD258sLJj6UqLrZBf1nFH0HOX/MYyCN/bPWw82Pu/TYUVz8s1o0xpo7F+v3onSVq6yx7+ef9Efz1LgSFazsm72f2F8xJeS8yowzrtUGqOs5ifZZBkNcEdXZTFdi94rVYnxl4iKJNNvSqILoE6aqlTX5ZkOdKqXasQKRTEQlmmlliiSXKlwfBFFr0Jsjci/ipqOJ5avCZkNlgmGLLGGPM/WCKabE+GPk9lt95NQgTj8txQPbTtvzyfv55onnWIe4DbVuszzKIagaCIqBrTj3krE8FZpmpDU4d1jzr0CakKEyyR87EBwCnbcR6/ilSLqRm/pDvLSPlEeuaghE7PubCxWxIFSJL9TToeP5uxzN0xRVXlG38tU/rOI6NZTL6s4S4DlrPS5G3TTsxD8lnEddjGOetMYOjuoulHNCzzk94IHckmW7CO48549vQPbRYn2UGEc/TEdjYvWNCM1OzwcQXKjbYzBFKi1AzhbAPAc7k//vtt98D/tZFZRIrD0QYYj32rLcJfjP/YLAqM8noJfOzn/2s/NDi3e9+dylHlBN65Jn6SgOksedjwC5fZJjrNg/CVjmL6yzl2NbfM4XKnPZrPTr8FZeZGjHPtK581Tr42TdmMHhmVCcB44b4wQ820EwvyE+tmFiC9z+/6nfd1W0s1u+nU2J9pphpMxhVEEzaj/0xs9e86EUval784heXKf3gYx/7WLP88suXLwc0Evj9L3BsriwYGY0pBMcIVyiLBvE+a53GG2Xr6quvnny58HMpyi9TSOLH512NlsfO7/DDDy/imzlyNW2mXmCgeLSU0zbE7RgO2IYo6LXP9CfnF+vkaVt+x7DGmDrxecEh1un0YtpAOjFw/IIfP4l1010s1u9nkRHrcaCq3HRManrBwEHiRcAwyA9xfuaZZxaxxTyhtO6BioKfBdBLCipwqjgQ6/Ss88MAwT73sM1/9JLJYk3Ij99OM38tvfD8sCIOUKWXndl2+FMdP6rgpxPAcUwbyWw8HCc/objlQGWSspfDqhEQw8cwZvqQjyoD2jbG9Cc+N2ZuY7F+P4uEWJ/JedapGCRo+PMW5gcIoUMOOaT8rYt5tfkzF+IcEQ74UbBYili5EB8joGUGo/hdAS0axJcNSxxiGf9ag42fLu22225lNhjC8Hc5ZpnBXIzed3qSgH0M1qHh+J3vfKf4ETcNw1122WWBc/JFiMGwrKv8CYWDeIzSHfebB8K0ndjPbrfdds2OO+5YfvWNiRNf0zBt0k+01EAiX/M9MMY8kH71j54jhesX3owWi/X76axYr9mmI66HNSB02MRKgF5OCg7mMLx4jzrqqGbNNdcs++H6668vAwj1q3rZCtNb+pvf/Kb0fm622WbNJz7xibIf/MJeNIj3mSXlonbfYzi47LLLimBn6sYDDzywTHXFfmae4cuOKjVEPHPWYlIDN910U5mNhoblX//61+J38sknN494xCOaD3zgA2Ub+AJFvHfccUeJC8fvqGmY5l530xvqBOoInm++nj3lKU8peU2jivEu3DM1ylQGjDH90fPCMjZ2tVQY+WnbdBOL9fvplFhHiCMKcJitMDBU29F/Or3hHIt4pqcRm3EaA1P9E2qNWAkI/BA+/HqewS3YzfELXRUszBaWXXbZ8rOgCIMDMZ1B2COWGKRqFj3iiwS0Lv9Y3mJYBp2+/OUvn5xFphZHRPFgu6m/qsKPfvSjUnYxn9FxlE2ene9///tlm/L9ute9rtlyyy0nX4o8T9jQM3VkPJ/MZdrIaYvbrGs7hwNdQwwHtbCi177ZhgY6eaiGextdSrMxXSc/L7meyM6MFt2DfC+wUJBYr90n+VmszzIS44iCXo5wU4HwtXiwLx8GKjD8av70008v60BPJwNNMXdBnF9zzTXFH0FDbyYFTFCZIHIQTTRGXvOa15QR6yKKMmNqYAbDPOvD/CmSyh0Cfp999ik98WwzWw1ifZNNNpkU44zJ4LnClIMwuFNPPbX8CEoNbOLj6xFfAmplWsfJnyXh5KI/joZC3C8UNh6jMHEbtA1a17Ex/Ezwu9/9rvmP//iP5rzzzpvwMcaYRQPq1ljX5joXsf72t799Mkyui7VtsT4iEKlZWMvROz5VOCbP364524dpVsMA06WXXrr0cDJNI4WHzzjY/tIIwQ6dHjQEDmYuKnxyAn9ak/EHDrmQGpPJfzBdmDKjY1lSHiPax3loYKpnHeFJmT377LPLNg5bbJ5b9RxTqTJ92itf+crJqU3x++hHP1qOi9QGsIK25de2TrqVdvlrW/tiWK0LHTOTWKwbYxZVqF+juVKGDlDG8kRinax1i/URgn36VHvQ26AHvfZTJAT0wp6DwqICw8AxetMZwIc5C1Mv6rfymLw873nPaxZffPEiVGqmCgIbY8wO9t577wmfBc9jTI3vfve7QxXrqjxj2VPFGpHQZRkrXPww+Tr//PObu+66q/hhr02jlt4SDaREpCPoGWypuPij63Of+9xJsxv8L7jggknRH88jYrpIJ+AX/VnXOeK2/HQcxHAzhcW6MWZRhjpWDviKu/nmm5cOy+c///nNqquuWjpbsTY44ogjFqiTtW6x3gFibzhuOgJbPfWashFHPPSsD8tuXYWG3kBmhcFMIPoD4oR9DNIDhEEUFRIgiPU3velNC/wUSfuMaQOxvtVWWw1FrIOEeVwKCVkt5UDLjOJBuONUpjGt+fKXv9xcdNFFZRv40+Biiy02aVbGc7XKKquU/xjo+pix5rWvfW2ZihKIj8GZVNz97OQFx+i6WCpNWs40FuvGmEUV6txcV6OR6FzFQoH/i9DR+a1vfau8C5iWOKJ3jcX6CJGZisxfopuqWEeQI9BjHMRN7/2waBMq2m57+UexoEKLWI9/MCUOOWPaGHbPel7W1oEyLD/Wta1yHf1xQvvxU9lXvOzjS5X8CfORj3yk2MOrl56fQCHomd1G6GdRVO7A8VTyJ5xwQlnXuWhMKx6dU7AtP8Ln/cPEYt0Ys6iiulYuvh/kB9E/ov0W6yMki+vopirWBfbp9LIj0ofRow4qULFg5W2IfnGf1mNh5GdJmMHop0j5GGNqZLG+MKis1coeZVUitrbEgY7DQQ6jdYXRegwL2i+0jaCnUc/gVe3nz62YmdEjA8xas+KKK5Z6Qz+Cuvjii4vdPIOXOA+QZ9/4xjcmp6+cLSzWjTGLKtTbqoNVr8sJ7Ye8T+sW6yOEqRVrdua1+de7RixMkLf7gVjPZjBTjcPMT3LFFZf86GiYs8HUylz2YzunI5L31dKfwT/vq4WNfjoGxxzzgvPROD/yyCMnz42QX2211crc5urdZ3wJgv6MM84o25iq8XMpBr6qYc9zefnll09u5zTlbc6nc2pfDnPFFVeUWXXi1I2EkRNxu7YvLiGHIR21Y0x/2vJV6237jTGDoWcmPj95WUP7LNZHCHOsY1dOT3h0zJE+SM86L2hMXYgjz8uO2Ef0dxX1rEexbowqMpxEIKjCUs96HLysfWZcsCLOMTPD9vHGG2+czB8GsvJXUaaUBCp/Bjc98YlPLAIdmIKVwU6777775LgT4sG+Xnke7wuwXbtX8qNu4ksA/2IA7de9q23LEQfLiPy01H6dT9v5ONMb8i/md85PypXz1pjZRc+axfoIGYYZDFM2tpm70BjoqmC3WDdtUDnVBAJgw80AU/2d1CxIzLuIRNg999yzQN5iooLJDM8jkK/PetazijjXMZ/+9Kebhz70oaXnHvDfZpttyk+lmAlHfhdeeOEDBD1fAPbbb7/m1a9+dTF5o/EgOL/CKd1yEPeJuA7aJq5ILjemN+QVjjzXUtTuk/PXmNlBz5nF+gjRjC0so6O3fNCe9X4DSOmlH5bt+jCxWDc1oljQOjMMMZgS0w7+OMr0oJiP0VP805/+dAFhYcbzUHkiYaV16CW0OI5eeR0DCHoEO38iBfbxHwWmnVQvPUKdTgYEvODevOxlLyuz4HAMP5SiEUA8nD+noc0vXg/L6BevDadrUxgzGDG/WAfltRzEdWPMzKPnzWJ9hCC0s/kKtPlnEPb9RP0gYUaBxbqpQcUkwaVt/gbKzEHMXc5ctPwtdPvtty+268zTb/HwQMgTXC/BJVcLA3kb5MdUlPHrBj9/YorJAw44YPIYTG5WXnnlsi4/xDxmN+pAIJ4vfvGLxbyJGWwIx9SUCHoaDUqb0Hr2y9sSnmYwppJf+Z4YY2YOPWsW6x2AFxeCmuVUesER4oP0rFusm7mCRIMEgUXX9FDesZTL/toW8s+NpXgvYnjAT73bQuH48+v73ve+yUH0P/vZz0qP/Bve8IYi0oGfg/zbv/1b+VqieE455ZRm7bXXLgIe8Gc+Yr6q6CdTnIOfseW0CvabwSHvaBx9+9vfbo466qjyNYTpQL/61a+W7WOOOaa5/vrrS7jojDEzi54zi/URgjCnpzDaqQ9i2iKwR+9l5kI8xDuVBsBsYbFuaqhiikIgi4IsxCwaFoT8kJNwVh7JT+vRX/tqx0QntB3Dywl633nG3/3udxebdf7QiigEwjGN5Ne+9rUy+FTHnXrqqc0aa6xRppkEBroyQPUhD3nI5A9D+FkUM8zssccek9NVIuRPPPHEyZmCdJ1mMGj8YO7EmJCdd965jF3gj4rcO2buwhxK98h5a8zsoGfOYn2EaOaXPAMMPeaDmMEQBjGOjTvCneMl+Bl4yj7iGjYUHn64wl+4MrxYeUFrwBqosIEqeV7Y8adI4BeAMfMPBrBuuOGGpde2H9QVDIJFjLMEes/PPvvsYi6jnnXqvmWWWaYMXNU0lgj1Rz3qUWVAK1Cf7LvvvqU3n+kj5cfMNzVBz7nZjn7q7Y91WCQfLwd5H8T4auGAbe2PDv8cVvsWFsV/6623lkHAmDXxO3QmKaBBhZ9+3mVGi+43y1w+dR+1Lv9cbszUiXmsZS1fs38tfG0/xHUhP4v1EYKQ1idi2ZYz5eKgA0wBoa+e+Zob5nztFBpejNgKL7vssqXgMCsEf2EEBpRho7rCCis0z3nOcyYHpHFc/FwNiHV6az7+8Y9P+IyHi2GMMXMfhDX27HGe9TYGef5Vn1AX0TnANi8/BPlb3/rWyboTP6b5XH755SenjeSF94hHPKLUT/QkA9NVbrvttmXAMnAcjQIEa6y3tGQ/LvuzlKuJ8rjkeKHt6K+w8o/biruGwi0s/PmWL5+Yw5juEctXPzQWxAwH8lLPpcj3Q0v5x/As5eLzrcawtoXWLdZHCEIbYY5Q13zpEtmD9KwLej84Por0YdqqU1goVMAgP15+CHHNyfyJT3yiVO6sv+c97yk9Yptuummz0UYbTVYUHK84QD3re+6554SPKxVj5iNT+YNpv+e/JoJjvSK0DxNAevZ1HF/86DGmntJxJ510UvP4xz+++dCHPlS2Ybvttiv16EUXXVS2GfSKcD3hhBMm46YOox5Ug6GGzgtKM+fFP27H/VqPYXAx3EyhuLkmOmWwVzfdI5YBtMJZZ51VGqSMCzn//PPLOo1PvlAR1l9FhkN+nnkmdS/0XAvtk5+eZ6gdq6X8hLYt1kcMQj2KbNygNusRXkqIc7lhowLDCyt+zsbmHgFPhcEvzxmEBLyYl1hiiZIujlWBVaGkV+stb3nLA8xgtN8YMz+YiljvheoG6pO4Dqo72I77IworFBYzD+o1BsQKTGnocKBDAjCbWWqppZqll1560sQPgbTmmmuWga86H9OLHnrooWUArc6HTb3s6uPLPKK0REfYeJ1yom19YVA8EuuaW990B90jljgam4wz4G/FfDHC5IyZmPA755xzSlgzHPLzqHWI+3L9E8PEddUHtWOEwlusdwBMVehlp4d8Kj3qs40KjSDdyy23XPP1r3+9zNbAi0thsFvHVIaWPuCfj7fNujHzn2GJdYh1iOqLWLfgh5Of/OO6eriin5AfYWQfzza96MyMgtmi4kcIIY4OP/zwSb+3v/3tpcNFIglb7x133LFMN6q/ydI4OO644ybnqM/oGgTHCPlHv0ib/yBwrI53z3p30T3Sko4vlVXKGn8fBsoZ++J9NdNHzzgoT3Pesp7DiRx2UHSMxXrH6OLMLbVCxqdlxDhTs2ECw9RezOAgGICKuQxTs4Hi2GmnnZpnP/vZzfrrr18+PR922GFlf3w5GWPmD8MS66pDVFewjC9GEcPEY6JIz/tFji8eI7RODzudEpjIKBydE4h36j/gSyOCnh9I6asjdeIjH/nI0hOqdBx99NHlKyt2/cSDP736v/zlL8t+hcvEdEHeHhSOi8fyJcBivduonEQoU9G01AwPPR/K8/i8MAD+2GOPndi6PwzmR/ifdtppZVtQJx544IHNQQcdVBruTJOKFtp///1LQz/GrXWL9RFCLw29MHEQKCYwzOzSZbCHW3LJJRew8aRnHZt1emQAMc9nY83CIM4444zmM5/5TBH366yzTpkqzBgzfxmmGUx8YWo9LvWSlHgGlloX0a9fuNoyUzuWtOAYgI9Tmhi4+p//+Z/FjAbw+/CHP1zmm+cvr8BL/hnPeEbz9Kc/fXLmGo7DtEFmkhyHqKaDh55/+U2HfJzEOo0I0y10r+KSsgV0njGdqZhueTAPhLyMjmebfP/5z39ezOO23HLLBcIBk2487GEPW0ArwY9//ONSJ2JCvMEGGzSrr756MSlmditmvdL9BMVlsT5CmF6RgaDZ9IUelq6aw2AP/5jHPKa0CBm8ghjHPpOCxFRqiHBmaeC34k95ylMmp18DvUiBwsgMDNEMRoXSGDP30fOOWGc2GI2lkT9LPfOL8rPPtWOuQD7xlZJt8gbhhWBWBwgveL5GMouWQAT80z/9Uxn4CtSrTGF5yCGHFAFPPCyxx9esXcr/XjCF48te9rJimil63S+25YCwciIfE+MTpD/GFR3UjonE/TFc9FOaamHxy/t1jJbaH4+NflrXMcAyXpuI2zEOwur4uD/GHVGYXXfddVKs52O1Hf3jMvtrHXS+7L8ooTzUEhDWq622WvkrMzNPgfYxtfXzn//85rGPfWyZhAO0j6UcPerMYqXtjPws1kcIolxTNwr1ts/EINGFhd6eF7/4xaWlSCGkJ12tRl4IDMpi6sZXvOIVZd/JJ59cjouFUA89n5CzzXqtoBpj5jaYiiA6maUiksWL6oZFCa49igCIYkCwTf3Lj6J+85vfTPg2xUyFH0aplx5hj9nNP//zP0+Kc0xpMFFEyCluTGwQGnFQLZ0smPQQB/EydSMDFfnym9MD+NXSKb+4zOv9XC0saZfLYVSWQPuji8fJxbC91uMSf6FtllrXfvlHP4WTf/RTeNC6BLuc9uuYuK5t7hcdZULHCsWjJeeI/kJxRj9gO8a3KJHzhCUNY370hvnRi170ouIPfJlC3yHSmXnqve99b/En73JeI9bf9ra3lfXoL+RnsT5CNEc6NxVHLzvbuC7ZrlNYcAhyBpNik0khZI70j33sY823vvWtyQJI4eUTL34RPeAqeBbrxsxfeFnRWGeWlYMPPrhZa621ii0tPcCYerAfeObzy2tRQvVirB/lImxrFpqMvl7qGOpe7GAFf32lA4U/yGoKP+4F7xmZuSDSqcsZCPulL32p3DOEHPb1DFi89tprSzhs8Zl95JprrinbQA8in/t5PyjtfG3Fga5N5waJRFG7Xh0XiXGAyo6Ory0Jo3AS9dovf5YSxyC/uK7j8jrIL67Xwiq8wmqftuP+6Md6jCvuA23zNUZiXeF0zfLjGDnI8SqM0Dr+Wmp9USPmWcwjGrZMVS141mQWgxDfbbfdyjr5FssZMHuUetYh5622LdZHjP40Gt10pm6cafo9nLFCEGzjKJhaVxiLdWPmL8x88q53vau8sHgRIQJ5abHNjCmYWcQ6YVF99rnu+OLOeaJ9cZ2lXIQwGfkhttVAgl//+tfNF77whckf1+knSJguUidz/wBx/LnPfa4IfqABxuDYAw44oGyzn17Dpz71qZM/vaJnfr311mve8IY3TN5n7HrpkGIAHeBHXMx5f8kllxQ/oCOIhgTXRhjSxfSRTInJNo6OLAb08SWAbaCxQUOCBoNgH+lTmIjij7Ad/bQ9qJ/QNu9EIT+Fi+fXu7PNxXdrPC6uaxkHmOJHGIWLTvvl4jmiv1z2XxTRtSs/lbeASS+TZgA97diwv/71r2/e/e53F2sDOmIZZKpjFAdIrLehcBbrHUBTNyLSu2qrrgIDbQ+2KqdYiCEeK2piPR5jjJm78CwjqhB9LBFwLBFULHP9AYvq8891q/6MeVATabGOZTsu5Y9TXOxTHKDjM4ThXtFLTs86Jo2ERSQz4YHMZbCr33777ScHC3McvfAbb7xxc/nllxc/BPLaa69dzAL0l1gmIHj4wx9efjYldt5559I5RU89IL4R+ZhWMpgWOA/TAzPmQV8WSB8/AWR+e+AcxIVA0uw5zLxDmjC/Ug8/5kPrrrtuMf8R3/ve94rQitNoYmrEF4eYp9/5zncm59znmvmaQV6wVP6SPtJCvqmRoHUc4KcvEKD7Ec+ldcjbwLaOF4qXa2YQcu0+K64YH8fFuEinwkT/2vkWRXK+ahst88IXvrCsI9Yp+5ieYc/+6Ec/upRznqmcr+Ce9fvprFjHPh2RzstrLkDBjAWJbTn8cSq8rMdKQYVUx7tn3Zj5S79nOdYPuV5ZlGi7bvJGdWmuOxFU2gfy1zLXwTEs68p3ofgFYRhYyk/r6BmUzbqOi4JOLprAsI2IxbEOLJmQQANogcYBZjb4sR9//rp56qmnTqaZ+cMZMKnxT8B4LkwOCAu8Sz7ykY+UrwKy5+dcCHNm3NA0mkyJh8in91kwCw+DdjHfFDQ0VllllSLGgek4aWi89KUvLduA8MKPiRbENtts0/zrv/7r5NcKzot4RoipocFXBBoQZ555ZtnmmjEh2nfffUtDCbh2BhPz9UCNHfKS+8AXEuUzXxNoRBGGcSGYWnzta18r4w0whUHcAY0gwijfgWPZViMClMYYDtjWfRR5e1GAfJBTXgnuKeUNuH88D9wzyu9rXvOaMuuLnhuF0TrPGl8bIec9yM9ifYTwWZDKo8s/QgIVUFABY1sVKsRCRpi4rXWWWqcw89k1zgkbjzHGzG3icw+xXmAZn/e4viiivMl5pPoW2I75pG3C1MLJr9c2S/mBwiDmELqYygiFAcWRQZBk/5i2NmrxsR2PrYWJ1xDBj2vQTDqAeGJKYc13D0yLyRdt/VQIEO5MLyxBRs88HUsxLxi7tckmm5SpiAUNG6YjvvLKK8s2ov3lL395yUcaJMAXhic84QllzBdpJ78YE/DgBz94cpAwooxpO5ldTT3+LOmdJS69d4844ojixzgQ5ulWg4N0k1bi45rpacdUScdhAoV4jOPKvvvd7xY7a75okHccR5x89eBdDQxYppHxq1/9avK+kJecJ3Y4cv0XXXRRiQMIix8NqAgND+ULEC7eByAtOteg1MpDP9qOif5aj0utMwW1GoHRn0YSDSdmZ4J4rNhnn32azTbbbGLrgSisxfoIoWe9Zp9OC7rrve2xsEHe7gcVCmI99qwbY4wZDbEOx76dnmL/FGlB2t5z+NM44K+h2gamNkakSnBiw4/g1QBdwiFsMYVAjCkeTH3otVd89NJjQoS/esMR2Jtuumkx5aHxoOk72Y+pD18S6FVncDdfBdT4oPedLwB8VRCML0H4Eycg2jHjiLMKIcoJwzgDCXFMoPBjXAEgvplalP+wyCSJxg4/QuR9T3qAmaFe8IIXLGCShOkRPdQ0qID0kka+mlAeyRu+IOy9994LfGnhPIyh4EuI8p1rp/GidNLg+Pa3v11MVLgXhCMtfMFAa+n+4Ec8aqAQjnPn+6p7wLb8ItmvFga498wWg307ea/zRnSsxfoIQagzwJQedsxh5BiM0MWpG9sKpfzzei8s1o0xpjvEOhuBgnCyWF+QmEfxXRd7f7Wdw8Ztkf3ycSBhKOJ+iUh68RlbcMopp5R/nSBoZf5DT3j8ek/vNV8EaDAoXfS2o0ckzBGNagDwriYMPeE0IOiRVy89g4oRm4hg4Dh69fnBD8IaZArCtJL60oH5E18O+IunwIznIQ95SPn6AJyXHytibqQBz4wdoHHAPwAEZlL46Z8A9GYznSl++srBeAN+PMSsSGowIN4Rv/R6k+9cEz3kNG4Q8UB6GdNAQ0lfZDA9etWrXtV86lOfKttAuhhAzw8jBV8+GEuhQdbkDeZOX/3qV8t+xngw7TV5SDppmJCmjO63xfoIQaRToGqui2I9oodc61PFYt0YY7pDrMct1tuJglrvQTnBOuFwQmEQhdovP5C/hLDCxDiEwoKWiEnMKTDZqX2Zr8UDOp/I27mxkEGE6lqAdzvlB3QNpEcNC7aJkwYEfgpD+rEq4MuC0oqNPz3nul6ELz3QNEAAP4Q4vfKaXpSwNDSYeUjnpHcfcyPmNFfvNTMU8d8YvjQQD07/imEfINb5AoBZksx4SBMajUHPgmms8YuNj+c973nNv/zLv5RrAhpESyyxRPPc5z63bDPmAkGv/GYwNw2tDOkCi/URglinBRp71bvcsy5UsLUe4SHTg9YLi3VjjOkOsS63WG8n5lN+/yG8stjVO5GwCh+X0clP71BEbdxWPBn57bLLLsVsREjkKg6lLcaj/XmdMPl8ik/+MTxL3usini+CfySfQ2S/fJzOHf2jXz43eamGB2HYj9kOaSY8DiFPzzt+CsOzQCNB5yEOhHs0jeHrASYt6rWHCy+8sPS465zEiRjXjzAZWExvOl84OC89/HGgsyB+sFgfIW226V20WVeBgbwulx+aXlisG2NMd4h1tsV6nfxe03Zc4iT+or/8tC20T0uJTPnJyZ91LfGLYTA1ie9UhdV5QX4s8dc+nU9xRuK2wuMn/7yuuEANDvlrn/bLX+u1cDEOhVMYiGG1nv3lR1zRH7SMaL/OUQsTzwVsK3wkhwO2GcAru3y+BNAoyOg4i/UOgDCnJ51l10R6plZg8Yv+tTAZi3VjjOkOsd5GrHuA6QNpe7fpHSgnPy2j4IvCLa5rGcEv+tfCxjh23XXXB/zBNB4Ttzkuin2IS6UZ4jEKHx1oXWFY1uJgGc+bxTNOx8Wl1hVG6xnixgnFrWU8VuHkX9snlIYcLvpF/7heC4MfINaxsmhD4S3WRwjCHDOYaKfOII/aDDGjJhYywSj0Y489dnLENYNTGFCBLRfTQMk2rAZiHdu6OHUj5HMYY4yZWah3JSgQTwgV/kD65S9/uezHDyQwFvV6muvvlQe1ffKL+9riwD+H67cN9KxLrOteQQwr5FfbF8WlqG2LuC5qfpCPGyScqB2b/cSg63Ebeu2vbQutR78aOQ4GxjKVJs9cW76DxfoIkX16tlOnldXFuddjAWLUMiO1GSVNIaMyZz5XBmLQ2Fh11VVLixFU+OQAgU/POqIe4j5jjDGzC7NoMP8308gxswVT9zFPOB1KCHd+OEQdLUFhRovemfF+MKNKFOsKY0aH7pHWcbHXnmk7+QEZEE5hhe6fxfoIQZRrsAHriHXs1flRUhcHmKrQ8MMIRkyvsMIK5WcLFC7mJmVuVU15xOdTfv+sP6fpWC3pWWc+1mgGo94bY4wxswf1Ml9CmemCOap5/yDOGSSnbWbGiHW5GQ3K/5qwwwwmf63O5hxm9uBeoWtYch9qzw5z1Uus19AxFusjhB51hDlCneUzn/nMSZOYrvWsUylQaHA0MEgfveLYNSK8md+V3z2zDsz7qj+wcQzH50qDXnmJ9VohNsYYM7NQ9w4i6FSPg94HZnToXjDVIVMTMs5gxx13LL3rrOOnzjKFNaOB/NczI6fOScxgoljXfqF1i/URg1CXQJfrms16LDzxoadSYMYACh3zhSLWBT9kWH755Sd/EqDj+Xsbfy2j552/munHAuxXYTbGGDN7qI7PLouMGNZ0A/QCJqjve9/7mnXXXbdZf/31yxdvTJeYy9uMlvi80CjOOocpG9/61reW9ZoG0rbFegfA9IVedlpYXbRVFxQkUOFhMAumLIh1piDCxlGtxT/+8Y+lZ51fBxNex/CZbqONNip/NHviE59Y/ogmFL8xxpjZRfV0rK9VJ7OM9bPr6tGhe6P79LOf/ayYptIJxt8xcfxF9HOf+1wxZQLfr9ERn6e4LrhvjAtpQ+Et1kcAZiQMKMX0hZs0F6ZrjE4gvBHrtBavuOKK8ncu/tIFp512WhmAys8CQMdi98jPBJhPdOutty5//hIxbmOMMbOPhF2s7+My+pvRwD2ayn3w/Ro9ugcs+QOr5lbfdNNNm7XWWqusMynHGWecsUDjSsdZrM8yDNTJZi+9WlVdIj/w9KxjBsPAJAT7K1/5yvIJjlb+mmuuWfa3QXjstDzPujHGGDMcLMy7h+6JLA8uuOCCZocddmje8573NHvssUfptMR0iSkcTzjhhAXGkFisj4gPfvCDkwJdUzay3fXedRFb9EceeWRz4IEHThbA6667roh3zF/oddfveDkm9wT4p0jGGGOMma+gd6R/cCC7daavxrGNhqLTEyc9JaSZLNZnGQaUItIFIj1P1YgNe5fEu0S2HAUtFigVpho6hvBaB4t1Y4wxxsxnou5hiX5Sz7m24345oXWL9VlG86lHsh9TOOYwoyYWJrUQVai0zTLuUyGkYOawFuvGGGOMmc+oJz1qIhxoO65LIwntt1ifZRDmiHGWcppjXfswi+mSWFdhgbyubQqYCpnW5RRO+8Fi3RhjjDHzGekeaSXpIWmiuF96KaJti/VZBkGugaW9XNd61lWoYoHK63Ebor/82A8W68YYY4yZz6B5oi6KlgZRFymM/IS2LdZnGcQ6g0sR4zXHtI7Zhn3UUIhkY8U6UICi3RXEfbi4HZdgsW6MMcaYRYGofyDrJGA9boOOs1ifZZgNhgGkvRgkTFdQgZODXNhqWKwbY4wxxrQTxToz7c1nOiXW5yMqTCxrLcMaFuvGGGOMMQ8k6iqwWDcLDeJcBUrU/CIW68YYY4wxD8Ri3QwVCpIKk3rU2e7Xu26xbowxxhjzQCzWzdDhh0cabDooFuvGGGOMMQ/EYt0MFQqSChNceOGFzde//vXmsssum/CpY7FujDHGGPNALNbNjECBOuaYY5qlllqq2XDDDZsVVlih+f73vz+xd5wo6hHrb37zmyfFetyXift6hesKcy29cxXn7dwgmseZ7qL74/s094j3zPdxbtF2v/K2xboZChQk5gA9+OCDy/ZOO+3UrLXWWs29995bCp2czGXwjz3r7Isv9fjjgOiPE/jH7S5AmpSuuG4WHuWpyobztrtwX3RvfL+6j+6P1uP9ivfM97A76B5pXU5+PHfx2TPdJD5nctFfyxtuuMHzrJvpo0rgO9/5TrPSSis1t99+e9m+6KKLmiWXXLK55pprynYuiPSsv+Utb2n22muvsg3aT5wqoG3EfUpDF6iludd1mKlBXio/u3TfTW/8DHQf1bm4qdS/Znbpl/e6h3JmbkODC2688Ub3rJvpo8rgyCOPbJ7ylKdMbtMKXG655Zof//jHZVv+iPnbbrutueuuu5rXv/715QdQFEYK4i233NL87//+b1nefPPNzU033VR67Fm/9dZbJ/0VjmMI0xVHenB33HHHZBp1HXYL7ygLf/3rX4sjX7t2/+3ud3oWeAZwen5rYe264XimVGfxrFFX86yxT/dO95R1Le1G4/SM6Z3IkueM9yv72Y7h4rF23XA8Q9w77pueJ5491rUPd8899zRXXnlls8QSSxQdNV+xWJ8FEOtrrLHGxFbTXHvttc2yyy7b/OhHPyrbEutvfOMbm6WXXrpZeeWVm8UXX7x5whOeUMLhh727HJ97oot+WucYuXjsqBzp4FpYJ320guXflTTOZadyQoVF3ipfnbejc/EeRMc+3S/uFc+6nt8cNrocv93sOe6T6izuHc8Z90R++f7FY+1mzyn/cfF+6DmL9xEX1+1m38X7FR37eM7o1GRdz5c0hPxYcg+xVHjWs55VdNR8xWJ9FjjvvPNKoaM1CBdccEGpOP785z8XoS6ThV//+tfN2Wef3fz0pz9tLr300uZnP/tZc9ZZZ5XBqLgf/OAHZb+22f/xj3+8WW211ZpvfvObzc9//vMS/nvf+14Jd84550yG7YL7xS9+0bz4xS9uNtlkk+aSSy5Z4FrsFs5RFvbbb79mxRVXbE4//fTy1Yb7T1mohbcbnaPcc1+oF0455ZTysjnssMPKbFG18HajdXqOuG84ni2es5133rnU2YTRc+Y6bfSO+6V3H+/Dc889t7xPN9hgg2bTTTct7x6Fw0SV92o83q4bjnv2pje9qXna0562QN3I/eR5033+7ne/W/QPnaDzGYv1GURCnM84COoPf/jDzW9+85tmm222KRWHBrgsDF/5ylea9ddff84UVB6+d73rXRNbZpiceuqpzXOf+9zmd7/73YSP6TrUB2uvvXYRDWZugAnMeuut1xxwwAETPmYusMUWW5SxYGbu8JGPfKQ8a8ZifUZBiEuQM786duv0yLzgBS8oveCZLNx7CXnt+/KXv1xmlrniiivKNsTBUF1js802a7beeuvJtOmrghmMeE/z/T3xxBOb1VdfvfRIgMqAXPYzM0fMZ+W11uMARb42PfnJTy71g8jhtW1GA/kf75k6Xz7xiU+UbdVhLDXgzYyG+KzkdwtfdLfaaquJrfv3+/kaHeR9fr7i/dhtt92aZzzjGWVdYeP+6Bf95yMW67OAKnA+v2Gi8Ic//KFsTwcKZCzYfIY9+uijy2AnUOOAMLmy6gKnnXZayQM9XF1MY5eJ9x8nP+BnW1/60pfKgClQmFheVBa7Wj7mE8p/3QP5xXxnsPnhhx9e6oQYXk74Xo2WeE8Y0HbUUUc1P/nJT8o290b3SmHMaMj3A/Ts8OXxW9/6VllXGN+v0RLvl9bj/cPkhQ5J3UPeX1rXMXLzHYv1GUQFD4ZZmIiL6R1jIdW55CfR3hWULrnsZ/pTK08xD3X/473XevTT0sws+X5xDyI8w1C7H/Lr2nO8KEL+6x7oGcPFdYh+ZnQo/3l28vOnewTa9v0aHcp7PTe6NyzjerxPWs/3U/vnKxbrs4AKlwrVwqB42gomAiCep0sFmHTFtOVt059YQbGM91d+vRgkjBkOMZ/zvRqEeK98z7pFr/vhezU6eGbuu+++ss59yPeC/Rnfr9HCPandF8E7T+R7pXus9+J8xmJ9BqHwxMoDVLimg47V8Zi+fOELXyh/OmUWAsF+zjvd88wUSg9pZUBdvBbTH/KKSkn3Vnl3+eWXN9/+9rfLOjDn7Oc+97lmjz32aM4888zm7rvvnthzvwCMx5uZgbzGaR24NwcddFDzX//1X2UGA8H/B7Bb/+hHP9occcQRkwPGdY90vJl9eOaYtedjH/tYWQr8mW0Ef+6pB3Z3g1y/MevSD3/4w8ltzaK2//77lx8UmtGh+6T30sknn1wGbuO4P6oHr7/++uYzn/lMs+eeezbf+MY3ih+ojlU88xmL9RkkFh4VqGFAXLwomFmFgU7vfOc7m1VXXXUBwabC25UCrHQwEJa5UV/72teWbTM48X5qyWwiDFhmSkz47W9/22y00UbNC1/4wmaHHXYof8495JBDSpkxs0987in7z3zmM8tMUO9+97ubf//3fy/CnGeZl9Aqq6zS7LTTTs3znve85j/+4z+aP/3pT+X4YdYdZmpgn04Dinuzyy67NCussEKZIpUOGBrE+G+33XbNK17xinLfaDj7Xo0OPS844Jlj3m6eK+4ZnRdMBcg/TTbffPNmzTXXrE72YGYenpN4r5jKmjqR2V9e/vKXl/ca4/z4gRXvt2c/+9nlGXziE59YnkGhOOb7c2exPoNQeKKT3zDgh0r8CEAzf7z97W8vhZsKiXOo8A7rfMOAgY9MW8kD+da3vrX4dS2NXSbnFYN1EQvkJ9OSAQKCn0P88Y9/LNuf+tSnyixEv//978s2OM9nHuVxzOdjjjmmWXfddUsvESDQuVe8jF7ykpeUgVTwq1/9qohCBp6C79fo4I+JT33qU8sXTKDhyw+R+GfGlltuWb6QAH9XZCYm/jptRgfPid59PGfco3/9138t0ybz9eptb3vb5LuHdyUNZ/4WbkZDFNnHHntsmdmOqVHpwOCZ4h4xKJh3GJ0X8OlPf7poH/70rrpRccxnLNbnKJi+xD92IdwWW2yx0hNEwaWww2wXYs4XGwqsC34iQst4xx13bF75ylcWv9lO31yH/NK9Pemkk0pPEQJhww03LH5UcBKDgMigJ+mqq66a8BlH98fMHDF/eQ74NTbiT/ApnmnJeCHxItKAU8wp6A1kxhGILzQzu3BveHbuvPPOYjJBj9973vOe4n/dddcVwQCYmjEFJ6ZnZnToOeH+8L5BnPPlg3978G6k91YzpwG9tZ57fXTE9xDvscc97nHN6173uubpT396c8IJJxR/pkqVUIeDDz641I+aZGNRwWJ9jkJFRE+6wC6P1iZCLYrl2SaKc6WDJXOAk156fLfffvsy520MY/qje6o8u/fee4v/7rvvXnpsM/yZj8rv85///AJ57DyfPdrymUbW8ssvX56LCF+f6GXHTIxGGcf7Xo0exhrQwfCYxzym9ADyDAmEPPN3I/zovTWjh2kaed/wDL3jHe8ooj0+Rwi9D3zgA+UZRMCb0RDvCaaB/IcGm/RPfvKTzaMe9ahST0b4Yykmv0xRrGdwUXmfWazPUXbdddcFBBq/4eXzLJ/U9YKXm210Xj1MDBLhE/Gb3/zmMqiOXmBaztgKjiJ9c5mYr8o7fhzxnOc8p6xrH5Xcwx/+8PIFBlShLSoVW1eQ4Bb0+B155JFlLAE9RKD99KjzTNN7i5kF6J6Z0aKvWZgfPuEJTyi/Owd611/96leXsQgIevAzNlroOecrMyaX1IP84Rtzl/PPP7/sv+2220pPOyaEtlcfHTwjsUOCdXVAAXqBulB+X/3qV8sYA35GFp+x+G6bz1iszzFUQI877rhmjTXWmHyJYKusT0NAwR3FS4Pz5QeH3nR6pUjvOuusU3qnsCNEZMJsp3GuEvMp5jE9RM9//vPLOjBoERs/2UALjqG8jKJcLGqQv3LaxlSCgVEM/uXHYBH+ZPrc5z639AJGOC4+S2Z2wXSJsQVXX331hE9TBshT315zzTVlYCkDFRGAwvdrtNDo3XjjjYv9M+MNGNNDx8U+++xT7KExe2EQfvzrtxkNqiN5ZnhvMaBUINYZaE8HB+acNIgx/RR6j7HU+nzGYn2OocLNpzt65973vvcVe3XE2Yc+9KHJAqtws/3iiOdTWmgZ87LjD5vYnvEAIkzoAVkUHrJhoXyS4FZev/e97y0VGZxxxhmlIUSvEgMamcmCig4xwfHxWOf7zEHe5jzm8+6//Mu/FEGOPfpee+3VHH/88eVr2Etf+tLySZ5G+N57710EomcWGT184aAHlgHcfILXp3oGbHMfMTNDuDOQm8GmF1xwQTnO9200kO8aZ8A9Yvma17ymdBbxvmGg6b/9278VM4vDDjusmBAy/aYZDbGOpBedxhVf3w899NAyyJ73GV9EMInZbLPNigkaU6XyzPEu07Es5/szZ7E+h1CBVG86pi8MHmQqI14cGjijcKMovJxTIlLnz+ngpca0gmbq5AoKmKFCg6QYKc9ANxpy9AA+9KEPLb3umq9Wx6sMmZlFDSMEBCZJfP3C5pLP9P/0T//UbLrppkVUMF3Zyiuv3DzpSU9q/t//+3/Nox/96DLvuhktPCuYSjB1HPcOczMGmmL+whcShPtyyy1XRDv3E5FhRkd+1wDibt999y3jCTBZ4jnjvmHO9KAHPah5//vfPxHSzDbcL+kFOiDRMdSBNJCxS6fe5P3Gs8eX+cUXX7x52MMeVnSPZoPhXRZF/3zFYn2OoQKpAs7sHwixaOslCDvbBVjpiuhBUlp4yBiUhX8tvKmjvIr5xpJZDjSwjbzVrCM33HBDERX03Eqccw8s1GeH+Oyxzj3ieeXeMBAcxzb3g4Y2g0u5Z3Ka2UnHm9HBlym+CqpDhHvGc0XPu+4l94x77Dpt9PC84LhPvGswQeO+MLMIzxz3Ss9hNGEys4vuk+o37hOinedKzxH3j23qRz1rbOs4hVMc8xWLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTFmHsE8+8wfLccPYHDRD3fuueeW8O985zvLNsdNl5e85CWT8TJvvDHGmOFhsW6MMfMMCXaEuECcS1BLqIsYbrpYrBtjzMxgsW6MMfOM448/viqe1QPOUrCfnveFxWLdGGNmBot1Y4yZh0g8RyFeM1dhfxbYCoPLtO2TH3HFxoIaBvHcC2NyY4wxixoW68YYMw/JtugS0TKRkYjPvers1zHEEXvhe+2TEJfwZx/nA4l37VMcxhhj+mOxbowx85Bso45gRixLxCOm2Y5iXaJaNuzsk8jutQ9Y1zZiPNrFx7QYY4yZGq45jTFmnoJoRiAjsCXKo3DGX2IbJMizk9hv2wfZP/fYx/PmfcYYY9qxWDfGmHmKer9xiG0hER/NWECCPPtDr32g86hnnXUJ+QjHt+0zxhjzQCzWjTFmnoJwloiOyBQmCnih8BLTCP7ce95rXzaLYT/nkfmM0qTjjDHG9MZi3Rhj5jH0ZEsoC4RyFNYR7ZOLJitt+9RbjpO9egy34447TjYQcDk9xhhj2rFYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTHGGGOM6SgW6yPinrvvbv7xj380f/vb35q/jy3hb/fdV/zh72P+995zT1m//Y47mvvG9hH+73//++RxgnDavuuuu5p7xrb/byz8HWPHgfbdN7bkWMF5iQ936223lXMQl85z7733Nv835u77v/8rSyjpHtsHpIvzcD7OC5PnGvMX5fgxV9bH/DmOc3BOXYvOWdzYts5nZg/uQ3Z//7uWfy/lM+8fhvv738bj1f0fX09hxrZVNib9x9LDdnE6bsJ/Msw0neLUOUu8LCfiNkbEchOdys/keljmsNN1ip96VX7UtWyzT+vZKeyMuonzlGsec8aY6WOxPiKoyAAhO1nhTlSsErYKg2hGzN4ztsSxTliWEvLAEuGsChIhTZg77ryz7I+CmRcG+++aaBxk7h7z57ycDyGuypZjJbbvDWmXu1PnGjsO2CZNgMhnneNAS8LEOMYiL+dWus3sUMrF2D2qiYl8n4fpyjmLW9CP9Exus5zYbkvLwqRxgWPvW3Bb6Yh+xohYNlhmUR73sRymUyN2vIyOvztUXuMyuxjHTDvlhzFm+lisjxAqTSpXiW8J3CLaJ4QsQpn9VHYI6Ci44c6JHu1SCU/EVbbHKkgJe44DxE45z5gjvuL+MV7R//rXv2kuvPCi5re/vWw8rrHjSU8R18QzdryEvXrRBaJfwv3uCWGuhgbbOpfOCzFdxKsw2s8yn8fMLNzr8vIfu/cqm6UsTDi2h+UUX/l6M7HkxU4aVPZ7QfmRGNDxlBm2iVv7puookxw/np7xeJTGGL8xgjIxLkjHRalc8Z9ogEqwsj5Mp3OyThlVmaUc827gOaG86nnTeoxjmO7+66bhf7+fvsYaY6aHxfoIQQzrxY9IoYKlckVkS7DQu4y5CuYnpcIfW6fSRTwTTuDHNhVj2R6LV2KXfYCgLmYuE2Huu+9vRZwfffQxzSc+uU+z996faP77v/dqjj32uOa6668v4SbjGzuWHnUqX0DAkFYc55FInzwX+8eWOp7jOLeul32Y6WhblTzHKw4zu0igji9pXI2/1Lk35f6M3atSBofhFOfYeikbY+ekLOD3x6uuao4+6qjm2GOOaY778pebL48ttc7ymLHy+serri7hi7gfW+rYGOeU3NjxXDsCg7h4FrWvxD9WJhU3S2PE/eVnoqyEdcrK+PM0Xrdpv+q5hXWKS+WW9bvvvqcs9z/gwOZHP/pxSSPPSTympHmG3Hhaxs/DtZc0uePFmIXCYn3EINipzOgFUS80ttxUeqClKmKEsXpMbrv99sl9wDaVI7CfuHC3/PWvxY/9iHjxy19e3Hzwgx9qttpq6+awwz5bRNAnx0T75ptv0XzmM58tgh2I/64JkxTZ0RMXjQPOJ/HCumzfWQJpVpoQQPLnGK6N+AhDPrCOgI9fC8zswUu23Isxx/0h//UCxumeDdVxjjFH2aCcUG6/9/2zm8Uf/4RmiSc8cdItWZbjfk9aYsnm7HPOLenheVA6Web16TilTXmhbe1TeTcGVD5URnA0SBHIlOm77uJrjcrRWBma6HEehuOZpTxSTsu5aXD+4+/ND879YfPk5Vdo3rLtW5ubb7llbD/PGHXteMOBxniOa1iuXPdYeu69d0HBboyZPhbrHeD2MeEbbccRLBLYLFXRIWIlZKmgCaewqiQVlnUJ49IrPyEwJLb//Oc/N3vt9fFSmV/x+98XP3H2OT9oXr/l65sjjzyqxItJzG0TcXE+Qfzq3ee8xM1+Xg6gc3J9hMMh8vHHTp10E554qNzHrqaEByr5v95668SWmQ3GX7bjDTyJC93DQrj3w4QywHk4H+Xoe98/p1l+mWWblcbExorLLd+syHJ5lss3q660cvE797wflWNp4FLWcaWsFrHEdSCsB3ccN3794wKIbcTN/X7j+aJ0GiNUPrSUOFXZueeecYFMuZLfsJzOi6Phyjlu+MuNzVZv2KpZ7knLNMsvu1xzwgknlvq1mDWOufvLvRqgw3Lj6eD6iXe8IT3ux7YxZvpYrI+YW8cEKRU7YoPP/1f+8Y9j6mVMrI75AcL3t5dd1vzlhhtKbw0777r7rtLr/Zvf/ra58X//t4RDKCN6f/+HPzR/uPLK5q9R5N9xRwn75+uum6w0v/71bzQ77vju5pSvnlq2IQrx/fc/oNl99w83v/zFxWUbwc7xxMMLgvj/NrbETIdz/nEs3UoznzxJF2FJp3rzeVFc+6c/leuRoC+fR8fOy3Vz/W0DXs3MM/4iH3+x0gPHfb7tttub6667fuzeXz92L28YX153w1Accf1pIt4//fm65ppr/9TcdPMtzddOO71ZYUysI8qLYJ8Q6oj2FcbEx1NWW6M559wfTqR6ZiEvEB/khYQRS2NEEakTPdw4RCplRvUpvdqzUWZ0jqOOOqZZY7XVy/Pz5LHn6AXPe355tmYb0nPnnXeV9xD5YYyZPhbrHYGe7ve97/3Nei9Yrzn//AsmfJvmzG9+q1l7rbWb3Xb7z+bqa64pfpgMnHjCCc2KK6zY7Lffp8YqwnGRjE35tttu2zz3ues2p5zyteJHhXnpr3/drLLyKs0WW2zZXHXV1cX/+ONPKCYwl1xySdlWj7heMN/81rebXXf9QPONb5xetq+++upmyy1fX+IhPr0YzvyfM5sN1t+g2WqrrcYE2HXFj4qZdK24wkrNCWPplAC/fkyU/dceH2ue/rSnl+sSv/jFL5v111u/ed973zeWD+NxaApL8eQnP7l50IMetIA7/vjjy75PfvKTZfvcc88t29NF51gYfv/73zfrrbfeA9IIpE/+73znOyd8e0O4trAveclLHnCOmE9AGNI0CEV0jDlerohU3C8uvrh55ctf0bxizLEsbpMhuBDfpq94VfMq3Ctf1bz6lZs2G2+08aRYj+7JY0J95Sev2Kyx6mrNy1+2SbP1G7Zqttx8i+JeX5abN1u+bsJN+E/JjR23RTmW5euarV7/hmbz176u2WOszKpsK49qxLzXPcn3vFc5jlCmCTsIbWUkl4WZRM+gXCxztWvG9XteR/kssVT8Smfbs1TKxNizQmcKzwx14+2339Gc9NVTSqfHQQce1Bx00MHj7sCDmwPHHMthuBLXWLwHHnBgc/DBhzQHjq1vsMGGzcorrlgaunyJWmHZ5UtdfuaZZzanf/0bzenfGHf/M1a3/8/pY47lMNzpY3ES35g75ZRTmz/84crJukRjmmqM4rmJ5TXeU9Zr/jNF23Mz158Z+U3l/WN6Y7E+YjAvobKnV/y4MQH9yU/sU8w/qPzhoosuarZ/1w7NSSefPDlvOsd87/vfb9761u2a8849r7wceFFQIX7uc18oQvmKK64oYRHff6Ih8N73F7OWWyZ6tI899tjmvWPi+OcXXli2CUcPvMT61049rfnAWAPh29/+Ttm+8S83Nvvt+6nmXe/avsQnENr/vedeY+f9/GSFzPWQrre85W3NBRf8vFTYQC/tCSd8pdlpp3eX3nhxzbXXljhoQETTF8xi6OEVPPiqrFQxxBdpv4qsH6qopwvnjy8KKjnii5UV61TQg6Dja5VlzZ88qVWMpGmQvOHLiEQ6jvtGL+H5Y/eQBmRZDsuF+C74+YXNj3/yszE/1i9qPv+FLzbLP2mZ0pNeXBDsK6/w5OI+/vFPjD0TX22OHytPJ5x40tizc2Jz/NiS7em6404cj+v4E05sjhtzXznpq82Xjz2++fZ3zirlkmdDz1obtXKY73mvciy4t4OU6bYy0lYWZgLOHcs9583XlK9F6dZLPUPYUT1LxKtz61pE7VmivqNcFNE+sX7zzTc3p47Vofvus19x1Mn77rNvs+++49tDc8RX4ty3+dSnPl06TpZb+klFpCPWVxlr3K6+yqrNSmPPzJZbvGGs7n1P+aK6w/Y7NtsP2e2w/U7NDjvsVN4RO47V8edNDG6l80bvgDZm87mJ8bKM9577y/5YBmYKzhvPobKmtM+lZwZ0Ll2HqD0zZupYrI+I8nOhsZc/piQSAbfc8tciiu83RhmfJvGaa64p5jJUepqVAtvvq6++puxnHy8JuOmmm8fcTcUmXPOUI7zoscZ0hWPhJz/5abPzzruMvUT2K9sRPtsi7vf82J7NVVddVfyI/y9/+Utz7ZiwJr7SyBiLi17+G264obycCCObeNJFbzz7iwiccFwjccg0hmvC3XDDX4oNO+nDYV8J//jH/Z+Pc+VFJaCKp18FPQi5kpkquXKnMiN9uUIetLKE/DIBrrUWB+ch/bV8yGmrkYW61mk2jTuh7ek7NQq51zqP/M763veLzTo96Q9wY/70rp83YbNOmeM4HTsUiG/iOSF+7Pc1kI9tfozURq0c5nveqxyDwsv1gzC5jPQqC8NEzwzLCGmKZa6WL6S5rVxm/9l8lhBD0Y9jokDKaStlYqJs6NlRPVbK50S4meb75/ygWecZ6zTLj4l1GrQ0bldaYYVmtZVXKbbr1Om333HnWLomGp1jdWv8Md4wHO8E/lNAvY9pJ/lB/c56L2bzuYlllfgUlnXOIbjvOU3DgjT0e27m0jNDvPE8rMdra0uzGRyL9RGhnnNE7bgguh8qPUxaMggSwrI/QmUIxCXRwrJXbwb7mKJxi9dt0Rx26GHNH/7wh+byy3/X/OKiXzQf+689m+22e0fz3e9+dyL0WJrGXjoRzpnTgch5gN8YJd1j5+PFJRSfZpkRukbNEhKJlRfLKEbiPioG9sXKkMpFfnrxRj/C4ViXf6y41ZOj/RnOnSs1bcfKjXNoHX/FGV2Mn/UYL8dzfTo279M15N4Xwil/2iDf5STWuWfjYmRckBTH9kI6xcs5yuC3Ccf9/+a3vtMstdjirW6ZpZYqg1CBLy85zVpOxzFQDnFO+R7fHk+jZs/g+lm2EcuhiPccYhiW3K94DPeObd3rfuQyAr3KAugZ0flVPljHCfzlhyPtEc5dS6POzRLa8iWGEYTL16Nt4lFecpzW8Y/plIv5nvOJ42vPUg7HdoyHffFaVC5wlBWVHcqyyo/KklztmZiOw1YeGP/x+i3fUJ6NlceuiZ50etZZPnm5cfOxtdZ8WvOdiS+l42lW2b4/XcNwXD9LXbdcL9rKR8z3GIYl9yweM9XnBnrd57wNs/nctOWJ9kcIF68FtE08ug6O0zr+MY1y8ZpZj/FyfO2ZAfwJT5haWvK1mKlhsT5iNIsFUKGxTSWPnbf8gX34lxfCmBgpfhNLiVrMUFQpcqx6MxSOWVk4noGEcOONNzZfOuJLzY477lTmV99zz/8upi877LBjsVXX30jpJSkvh7FjIaaLuBBHwH7CgmatYZvelvJiGXNFjI+F13YU5WyTfr2IcJFcucRKRRUbFbYqCvbj8Gc/sF9hFU5+qggVL5WPXgA6HgiDf0Tniih+xUs8sbIcBMLGii+mHxRvRBVqpJa+DHkvtzCCdxCne815WGepdUxj3rj1G5tttt6m2eaNY451lm/U8k0lTCk/Y46vOeWfBRNxKv6puMk0UTZ5xsbWeX4QHsoL9rNPz0GNeG9EvueE4b7J5fuSw+b4MoSPZSRSKwugMqlyHdd1TpyObYuHc/eKX2mvXUcOI4gz58lsPks41gXHxOc9py+Wo/Eycn95jmU8lk2tL6yjcUmdeuihhzXLPmmZZtmllh4T58s3yyy5VDEl4wsVg7KXXfpJY0J+6TIuhEHcpYyX40nzeDwL7+5/lnBqtODIg160lY+Yz4Thvsjle5/D5vgiKkcxHpYxjrwNOo74Ia7rnLhhPDe1a4j7I7W0zuYzAzpP2/VO5bzmgVisjxgqMb38Wad3HBCqquiAJeKhhJ+oFBEoHEulOClsxypuHGYmEsz3jC0Jh1kMFTv+si9HbP9g7GGjsv/sZz/bHHbYZ4o9sdLEMQp774QQ57zEgyO9nL/4j6VNAp8vAzoXaSUMDj8dzzWVCn5sWa537Hj8ODd++a93tcpL5H1sU3GokqiJa/ZHp8pGcAwVVa5oWI8VGChcJFdyOofCKY3Z9ToX23F/7bxA3JEcTw2Vt+LG7gX3QNvc2zJ38phjfWEdvdf0iiu+Up7Hlkxzx/kQFLfdfkcx96IslWXZvqO55a/jJmE6jvCxjCnuqTodrwZ0L9dGrYxyz2P5q4WJ9CoPNfrd21wWIJd1XrD4AeGV3vjijeEF5+4lOmKctXyJYUStTMfrm41nifUYT0xjjieWCz0rcpTF+AyNrxNO+xbOcU46RI49/sRm//0PbA486JDm0LE6/OCDDy3uoDF36Gc+W/wPYDDq2DazbpGGmM5hOj1DOK631Oc9nhloKx8z+dwAYVR+WY/H5G1QmRUz+dzMtWeGc5Be4ojHQI7HTJ0HliIzK0gMI0So4MbUaxGwUCo8CeSxZdk/Br3tVMxF8E74ybabcIhb/KkgI6XXceIcnJd1hVVPeA2EepnJZew4hBuVMDDdYhHbE/FAeVmNhdE1CFXSnEezwhBGf7RTXOX4iThwEuyRXpW19qmyYKmKRS5S81NFKKh8VBnFsPKP1OLLYdgmnTlcLwgb48nnZj9+mUHSl6HcqIdsXFSMu8l7M+HGTWIW3o3HNd7YpKxhasL6ePkdfx4WKE9j6zTqShkeC3PPvfxEbFyk53Qq7YO6eGwUGSqH+JftiTBtkO/5flAWo1+vcqwyLCiTtZd6JJeRTG1fLuttooO4CYerlTPSyj4dKwgb0127ZtJVu7ZaWc3XwPZsPEukmfNEcvpUNsoyro+VzVK2YvkpZV/LYbjxMhqfkwWemQr3p2U8ncN0pGl8ef+7qGyPuV5wH2p5H/2G/dwIhcv3una+2Xxuaucnn7r4zHAdMe9IY0x7LX1malisjwiJVFF6lScqNwaMAhUeMFOMxDngX8T3GHFAJ/4IF5zCaMm5WNLzjRjBP4r1XMETrypg0qrzADNjlOM5z0RFrBeSplzUUj88inCNmvVFvexAukgTcWsAbqRWeQnti5WC1vGPFZz8YqVLBVSriAmnsKpYCYtfhO1YiUHeBuJU+gaBsDmemBbiq1X4+QVRS3Nm/CU7/qLVvZ9Jp/OwXPCc42VJjvIy+dIPxyy4VJwsY1yDu5iOvB7DsGyDfI9lCPJ2r3JcKzO9wkOtjIhaWYBaWVc54nwcw3ZbvBHCx+dLccfz5msgXsLUrgu/fN5aOmb6WSId+d4BccR0q2zY9Xa9GMVzA7msqQzgYpkWKtsilplhPzdz6Znh/Dlfctpr6TaD88CayMwqiNLcgwwIVeY9Z7S+QNgiZiW8FSaLWsS6BLnMUpj2MYZjPw7wz4IaigCfSBth1IsvENyKg3TJhEfp4vyipH1CmKuhAUoXx8YGCeKM2WEEDz+VQazMhCox3Iknnji5rmMIH8Oosqr56aWBi+dhfw6bUcUFVLQKLz+gwmo7PhPPGStMVYw4pTGmO4YVpK0ftResXd31It43XHxJ9SrH2hfvX7yvtXJTKyP9ygLoXJTTWFYJr3WJh+hymkU8LoeL1xxdfC4yHDPqZ4nz1iBtkVr5sHug68dsPTfxPPkex/JQK58610w/N/F6o+vqMwNt4YG0mYXDYt2YIUEl1sVKiTTFF58xg8BLPpebfi96vawXFj9LZq4yqufGz8z8xmLdmCFCRd3WIzcKSEvsWTFmUOgdiz1nvHDbeggjlDeJj4V5SftZMnORUT43fmbmLxbrxhhjHkAUD7guiQBjuoqfGzMTWKwbY4wxxhjTUSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmI5isW6MMcYYY0xHsVg3xhhjjDGmo1isG2OMMcYY01Es1o0xxhhjjOkoFuvGGGOMMcZ0FIt1Y4wxxhhjOorFujHGGGOMMR3FYt0YY4wxxpiOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUeasWH/yk5/cvPOd75zYWnT4/e9/3zzoQQ9qjj/++Amf/hCWYzh2vvDJT36yXNMwGCR/zj333BKG5aDkeIeZZjN1yHvuQddYmOdzJp7ttrLOOfCX07mn8kwMk5m49rnKdOons/CoTse95CUvmfCdfTj3KM5f02HkxUzWs6O61lEzo8qBG6mCnN1UKlgq5ZmuhBZF4T9XiRXkTDHs8jDdNOslLFd7DiRacC7Hc4t477osOiXUBXX7bL8wY9meK/lWw89o9xnkHlGnK5zqacrlbMNzyLln+3mUvnN5nh1mvJtPhTiKDLazXy8ohIOGnS6kx8wdJH5nAl7+VETDZqpppszHCphKMR8v0SII78pzbqF72GXRSdmdiWdiKrSV/bkm1vN1mG4xaP1PGJ6LLkC9P9tiHcgDv29mhxmvNWpiXX6DFC5VyDMp1msiyHSbmRTrlMsuiPUsQtjm+OhPOmNvjp6tuSZgFmXmguikjpyJZ2JQejVU51JZ97um+wxa/3MfLdYt1meLGa81amJdoiM+EGzLyV/iJjrQ8VGkQAwXz6eCrONwKmD4x+NU4HVutokrn0vEFwbpZl3EuPNDrePkIjGdOLZFPF/OH4XTeXUt+UWr40Bpjvshp6EXCqM8jdem+8A5OUeMV+kTMb9w8bpB+4knXgPk9Oa4e+V3zB/lh5yuKZ8v3oeY7khbvse0xv39IC+VHmBb8UWIk/TV6HXvYx4RLsJ52/bVUNrkIN8jzlc7J+ciT2Mc8bohHhfzUMew1H3hvNE/ojjyPo7FxTT3SgMukq8136OYn4onhxExLtZjOljPZSimi2uIxHyIaYjnjmUknltO54vhhOKXi/Hm/IrlqFd+4x+P0zXFfFNa5ISOjXmWifETZ0T5q3Tp3KBjcLHs5Dzodx3AOeQf09Dr/JF8L2LexPNCTF/MF+KI58LF88U4lV6Rr01Ef44R8lMZyHkWUTidH6c8ivmWkT8u3h+O4brjOZWOGB8u5o9QXkcX0zeV/AHdY9B+5Xs8l665BuFxMY9y2vO1RZQ+zofjGgTx6JhanNFPear8jtsxnhg/xLT1uk4gDGkUSkPtfs4nHljCh0y+eSA/Fch4w7VPNywfHysShZGfCoAKONsqhJwDByrQObzgXEpbTk9E8eDigwKcS8fkODif0gKs5/MJFXCI51Pa5af8EcpPHa/z6VrlRzw4tpW+vB2PUbwZ4or7dB0slQac0qFzxHRqH+RzkT/a1rE4wTrphJwnvfJbaYv7c1ri9UO8D4TTedhWGmrxKh756TqUll5wjhxO6cgQf8w7Ea+DMJw/pkHHKJzI+aE4cByfIV0xPHHHbdbztsoaYRW3rldlSXnLMuYFx7OtcDpW+XPiiSdO+ute6bqVfl0z20pDTKfiiuHzNeT0CpUFwXZMP/ti3Bni1r54HsUb05HTqWvB7bHHHpPrHKM8Zz3fe1wkl4FaOJ1bcG4dozxR/sc8URoJq/C1/I5xQ1uYnI+6thqcW/nJcRwvF/OXMMTPUuFq59U+5W1OU+062Fa+6JrYbjt/RnEqXsWhYxU32xyvOGL+6Vw6BnQt7Itxcry2ge2Yx2yzT9esuCPsI91AXDoncLy2dU62dQ6WbON0DsIoPqVb+5Q/bHOM4lM+aL9Q/P2I55xu/ihvlC7Qs0I4xd8vTYpT59H5dTz7caD80T6WcZ19yruYhnwckCadU+nGsR63CUeaIB4DCg9Kt7Yzik9pUL6x1PXpGuYbM35FumEx85XB8mM7FoB4M2rHq9Do5hM2Hp8LFTeRcwjtV5yEY1vgH8NzHp0ro8IV93O8Co6IhSmH5/w6H4U4xxXD63x6mCDnH8fo2iA/6Lretjh0jkhOc4bj4wOodCsdOQ2An87Deswz1rVdS0++ZzF9uXzEdYj5DTlttbTm8ylNMZ9JL8eKHE+OAxRPvBcZ4iAMLsanYzOEiemIKA353sfwOU3s5ziR8y9DPsR8qeUV28qv6A/x3gu2dU6WMf3xmoiL9ZhekL/Oxf4YhmPjcfF8oP06nnWuS3CcwnNNcZ/OjZ/WY/pzfmeIV+eFmDe5jLEd9+fzxbSIfAzXQphIPg/kcOyPearrgpyOfM398ruWplq+EQdpFYSJeZfh+F55wXY+B2mJ16m04pfTretuuw7OHdML7Jdf7fw1avHG8wLXVSsbCsO58j3W+UFxxvxSHDF9ygNdQ84TiPlHmuK+nPYYF2h/PGe878Qd49f55UfYWj4ovlo+1IhxwnTzhyXbkRw36zlMJN9biNfBPp0Pcn7FfayTRlzOB+KJfjEe0PXq3mk75gnhlVb84/FA+OwXyXlDGuK11/J8PtB+94eEMi473cyICjtON0PHx/Aq7CoA3CgdF51uOPvjzczH1x4ExZELa0ZpjgVD8WVHXDp37fqBMPk4nPKj7XwxnQoryIe8nzgi7Fd+1c7B/hxvJB4P+b7lNEDtPMofnO4Zx8b7B7VrAPnjiL9ffkNOWy2t+Xy1tOdyluOppTnnUy+Im7C6D0pDJt+LSC0NOXy+trb9bbCv5jhO6Lpr6cz5CEp3LB/ZEWdbfmZ/5WV2Sk9Og87LNfQrU+RXjFOOa8DFMgE5vzOkSXHkc7Ivxpe3c1pzPkA+plZGchjI4ViP97iNmPe65l75DbU01fIthyPdvSAsxwjWe+UnxPRHl8/FtvYpv2vpU5jolBe189fI8dbyJudxLgu1c8V4Bslvkc/FesyfmOccX3O696zH8LV0kG7Fz7liPHLaH8PCIPlQg2P6pWuQ/KmdL8fdFo+I8YnaMbpWnPKg5ge6npoT/fIyb0O8XtZjvHL5WiLsj3nTLw3zhfa7PyQGyTgVCmV4vBm143kY8NPDzI2NNy+TC3I+vu1BiAVJYTNKe35A2wqbzt2WHxS8tnNB7Xw5zpwX8eGA2vXmAs+24tE96JWufg9MTgPEa9E1KEy8Zxyb8zNfg7ZZKi7iz3lTI6etltZ8vtp9iGmGHE+OA3I+9YP4iAd0bEwD4Nd2r2ppIE7SKvK1aVtwjTl/IoTtdz2KE5fTmvMRlG7dz3zNoi0/sz/xKx9r5DTovKRV623XSN7kaxKcM+ed8qLtmkDpx8V05TKW0xbzDXI+wCDldJBngvW26wbSrXPna+6V31BLU1u+6Tj8Y7muke8H673yF9jPcW1wjNKQ8ztfB2F7pbF2/ho53lre5DzOaaudK8ZTi7N2XyCfS8cC59M5IaahBvtjftfSQbqVj/3uTwwLg+RDjUHSNUj+1M6X426LR+T8hniMrlFhch4AfoTB6X73y4ccT87LvA3xelnP6egH8cW86ZeG+UL73R8S/TKOQpH3x5tRO17HUJiAG5ULKugG5oKcj88PAufSPiCetkJbe0Dll1F62BcLG3AMcZDOWPAAf4WvnQ90jYonktOfrxdygdd55HJ6Mznd+b7lNABxyo9lPIeuB2rpjX46l66bJdtcA7Ce0x/zKaetLa0xDbX7ENMMOZ7adRBPPlcviF/XBRwbt3NeZGppII5472rXRhj85HpB2Jzf8ZkiXl2z0qNyAjkfgfTJj/DxmoFt4tD1x/gg+8f4IsqHnAbSHM/Ler5G9hGO42J+Av6EJwzHxryt+UViXLXrUF4K/AgjF/MiHw85jloZqZ0nh2N/TCtwHhxh4/H5mvvldy1NbfmmtHJMvM42iEMuX2PtuvGLaRX4K00i53e+jpwvQvlYO3+NHG8tb3Ie57TVzhXTV4tTfiwjHMOxEcLhl/1rYUmT4tRxopYO4oh51nZ/IIaFQfKhxiDpGiR/aufLcbOOXxv53gLx6jpzGmIeEHctL5UvcR/oOIjxQM7LvA2E1/Vy7nztEOPMEF/Mm35pmC+03/0h0S/jtF8FSdu6GRQU7cexP/rFMPEGKjzkgpyPZ8k2/tx0pYFtIN7aww/x2AgFKJ9TBYr4OCbmifbl/ADCK2zb+eRfK+T4xQdC54/EAs+52q63DcLHc7DOOXDER9ys67pIf9xmPaadbaVBYWOaYvwHHnhgWeY8Uty98ht65Y/C5TzTOeJ9IH0xjW3xtuVBPwgX4wOlQ3B+ztNGvg4gzpgf+dqIM+ZdP3R8zm/Fl6+Bffl88XiWcVvXkPMecliR/ZX3Ma9INw6IT3GCwmu/0hDPozzUuRQWCK+w7It5oOvN8QnCKp1Kh669VsbiNWWUtpzuHAdhIjkM5HC67/G6lScsY1ht6zr65bfixl9xRr+IrjGntwZh8vGR2nUrbTGfSQtOeaI4ta38rl0H21oHwiru2vlrtN2LeG05j3NZ4FxscyzoOrVdixNUfuWvcBldS8w3UHilAwir+NgXj6mlg3iVh0p3PgYHMSzkfIh5GcNlBkkX9Msf5Uskxx3TVKPtHGzn/NC2rg3/eH7iUljWc9rwE/3yMm9Dvt6YFiBsvPZMvBbol4b5QvvdHwJkIpkml2+6UEHDqXBoPe7nhuhGyOUCKKebF9PAetvx2qaQE4ZlPLYGx2o/LheOfO4I6Ws7ti2N/c6HH+mOxLzF5fPmfCN89pPL1xDJx6iyUBo5L8fH88e05muL4SDnifaLmNfxWNYh+uGUrpw/EK+FcPnY3XbbbYFtwuR7XYsXlC9ynKuNfF5dSybmncpKjRxf7d7Xylg+Ti6XtUi+ToXVtq6ldj7SIRf9I7Xj2s7Z5p+vX2nK95K4Yzjlcc6XmMa2Y6B2XpZtZYH98XqV/loZy9cqRxy1fMhx5Gs6++yzF9jGESaHU9rzfemV13Fbrld+a5s483li3gPXFfO8jXz9Mb5a/oq2sgPZX+u16xDyw3Fe6HX+SM7LQeqnWlkgHvbF+JTGQfJb+4ijhu5rrZzX0lPL41o64rbyru3+RD/C9jtvvk7IacDlezVo/uTjaumO9wNXyz+I4fI9yPt0Xta5npiP7IvkNIroR5iclzvuuOMC2+wfNK4atbyJ27U0sD1faK8BzCKNXiwRHuia/41jD8U/brppYqtp/nHbbc3tb3pT8b/7i18sfjxYay6//AP8oRYeFgX/27fffsK3u9TuObRVqgsL8c5U3PMdntE2gVHzn68Mer2zXba7DHV0m9A23WWFbf9o1+LmExbr5gHwoqq13vGrtVTvGBOcd7z//RNbTXP7tts2t7/nPc3dBx/c3LT00sWPF8ER/+//PcAfauFhvvv//bLLmlvH8vqO3Xab2NM9EDzcuxptQmdhsVifPm1ii+e2rUduPjJI+SFP2srwTJXtLmOxbkx3sVg3D0CflDJtFfnfr7uuuXmVVZrbttqqufvQQ6vC9MjnP7+59J//ecJ3+MJ3rvr/45ZbmptXXbW5+0tfmvDpFogWykPupcR/pj4xWqxPD+4R9yoLzV4NrvlILxEeIU/Ir9yIwX+QXvn5hsW6Md3FYt1UodLmRRZdL/528cXNbZtvXjX5OGXJJYv/G0I8M2FSMhf94b4f/7i5+9OfntjqHoifXBZmqucxljsLh6mT7Tpxi0LDJ173VBomaoxGN1ON0C5DGYl5YOYONfMPu3E3n/BTaYwxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUWZNrEe71+nYonrwy9xHZaBtVgrZjxrTVaiDpmITbYZDV+oG0jBT4zUiLmfGmMis1H6INA1y0kCgfhWeK6r5RWys1cR6HOg1LBRfm2sbSEZaBmkY1gbz4cfxmoGjtp+4s392bbNR5IFg2c3H54a8aLtXs4nu23TyON+3eD2x7OMWxZlIejFo3TDTZV9pID0zycKUM2PM/GRWxDovqqlUPLzIXFHNPyTYa2Id9FIeJm3nRBC1vXQJj+slmiifhMkiUi/aeCzb8VyEUXpY5niIO8cbqR0j1CieT/TLj9mEezfVuomy0HZfuK5YNlSuLNgXpF/dwDPBvZlp8rM8U0ynnBlj5i+zItanWvFQIbqimn8gTLi3WTiLfi/k6dDvnBmJJ45pE1ja3yaoOC6KS8LGF3xcrwlv4o3bmV5ifb5BXnTpWqcjoigPbWWldl25vJj+dQN5bLFujJmvzKhY50VE5RadKiCW0Z+XmURIdHqZ1SqvGEesQKO/0HaMI59vUEEH+dgs7OTPdeV0R3RdEiU4XQtxyi+njeO0L7/w5Y/LLzD5x3TJT9vxvklksI+4dN3xehU2hhccp32Kty2f9UKOeav0a5+cUB4p7ZnaOXu9bHWNSnctrfjnfI2QB/GeEL7tnLrWfA97UTuG9VpaIxyDi/decD3an9Oa8z7e45i/ikPE8tsrzyGeX3Eo7ujyNca06ZpieOWR7qfKbYy7di+1Dxevl7A6D/4xXI0YJj4zveAcSncbMW/zvcz5FuNSelgqT3Dkq8oVLqZV8YH25zyLceFqeaZ4VBb65Z+ukeN1n2uwP8YT8yP698t/jiNMTFeMC/CLZTlfQw6f70Uk5jculm3lWSzf8bwQ9+Finhtj5hf12m/IqOIRueJlf6xIc3hVxtGPdfxFrLSo9PI5IMarSlbgn8P3grCqPFUhq7JUha/1mM6Iroulrl/pjnHEdEM8Vz537RoJA73Slc+hY1kqb5RO0shSLxu9ZJR2bXMc4QT74v6Mjle6FL/iyPGLmO6M8iceE687omvVOsdxzoj8e50zU4tH6Bp1jwahdozuRxvsJ+1aj3kQ41J+KSzpjmF1DwinsDji1DZwjOJUnmk7w7E40LUpvwbJH8Ufr5/7k++z7hlx63xAuHx+xaXr1TZh472P8dRQPgLx4KJfRufvBWlQ/uS8jfcAtE14hcXF+6PrZwkKx1LXLydY17UrjFB8WldY8o0l4Tm3zgfx/KDwoDyJ58jU7jfhdY3Adg4jOJ/OwTooH5TXELeVLp1D+RDLTjwf6zluQfrjNmHjuRR3PFeMO+83xswv2mu/IUKlEl9wuaLJFW0OD9mPbVVk0FZ5RWIcLGPFpspz0Mouhs2VNhVyjEcVdA3SFPfHF6Vgv8IQb84bwssv5wv7tN0rXTFvIKeDfWzrRQTEG8+lfMBPx8fwnDv7RTiO/ZF8TE4n+2NeZXR8dMRRg/zI+Z7DKr543f3oFV55RryDomOya8tXaLv3pCtfI3EpbFwXhNcxyo8YhjyMZQsIn/0E/vGeElbbg+ZPDqOypPvJUuvEH/NKYfFjPd4rnV9+MW0x/kHRudpgf69rVX5HSFNMX0w/kL86hvSyHs/B9XCcyHleS7P8lGfx+Bwf63EbSFPMO10XfrVrrKUhks+Z0wSKN157hDTlMsp2jIfjiRuUT7oO5a2287limkhv3Kdj5Uc4lTMR05fjBo7J12yMmR+0135DpFbxCCodXKxkauGzX96m4iIeUavc4zGs69zRqSIeFJ0Hp8qz5tdGvo5c4UOspAmruKPTfqH8wOmaeqWrXzrYR5gI51R80RGWc+XwShMvuRpKXySnI4eJaa5RO2fOK2B/Wx7GeyE/5ekg9AqvF36+H72oHUM+tOUrKN9qx9XyA3Lei3gPlB/x3PFc0eXykNH5cLqvg+ZPvg62Y5nO8dUc5+9VpkFx4jddiCPnKZA2nacN8rYtH9vyKt6j2j3lnDHOHE+836IWD+CHi/EpzyIKlx3nJGwuk7U0RPI1cHytXBMHcdWoHZPP23Y852cfjjxRHub8EaRV4aNT3LU80zW25X2/PDLGzF1m5cnuVVlDrmhr4bOfXkCCSjbGUau4Yhys55faVFD8LGsvSfnhYroy+bpqFXF8iRA2501E+aIwrOsFAG3p6pcO9uXrIE0x7gj+ObzSRhpqKE8jtfxgm7iIp1deQO2ctTQTD+FqLr7AlX/Rrx+Eb8snxRfLjuAcSgNO11o7RvnRCx2H070hzrZrqeU9xPvUlr9TyR+dR8fEstgrfyKKg/CEZZs44nWC4ovpjZCGtnsFxMfxLBX3VOEcOU9hkPhIW1u4tryK90j5FM8f8wlyPPF+ixwP6wqT42Nd+S/isRnC5vJTS0Mkn5PjcxxAHG33t3ZMPm8+nvPipzLHOkvlYds1ktZ8nyK1PNM1xvNE+uWRMWbuMitPdq54qBDjtiohUauo2vyonOQiekFFYhw5DUAF21aRR1RZEh7yyy3Gm/dl8nXVKuL4EiF9HJMhjtoLgm1dU6905fzI6WBfPi9+SlcEf+W/8ghqfpHay4ZjaufFj/DxWmv0Oyewr5anwLny8fJrOzdhCSMI21auCMt+3YdBmM4xMT3x+FqeA/4KF48FtnXfa/krv0yORygtgnuhsFO5VoXTsSrDXEs8vhYf24SP1xZRnEqb0lUL249aWWsrfxnSyXljfoPKVy1N7FP8ypNYdrmeeP6c57UyonQA51P+QI6P9bgf8FOaBWki3tr5an6RfE62CR/zSdcVrz3CdeS8I57ox/FKd8wDyHkbwwqOIR05zwB/ha/lGcewX9eR9+e0GmPmD+213xDJFQ/bsVJhO1a07NN+HZfjYH9bpQuqSBVGlb0qOVWshBOE6RWnyHFrW3GRtpjWGDaTr0vpiuFjfgD78zFKe0yHtvUC6JUu9sV7wDr7FYbj4n7QS0PxA+fW+dkXj+EcMc6M7pGOV/zaFrqunJ4aHEtY4mqDdOVzCKUh5j8of/JxbOd0ES7mUaTtGnsxnWN63XvW4/Xhr7jb7omOxZ/tnL/kQYyT/fH8QvEpf7Sd08r+mK4aKqMxr3WfYvp0TdFPac3pAc6p8xKf0qZyWLuuNjhPvgbijGkB4sx+gvA4QTilV/cjpp9tnVNp1v0D5ZtQHugY5VeOU9scG+91Th/rOY+UzpwOzq3z5zjxw9XyRWkEnYvtmA78Y5wZ9nGM0lTLK7Z13Tqn0qNthc/boLQp7lgWCK+wul6huIS2dbzyLJ7LGDN/mFGxrgo5OvyyPxWY1ql04n7QOk6VbTwmOlVeoMoXR+WWXxqqMGOY6B8r+kx8ecS0sI6L16B4M9qPI605X9iO54npieHiCyheM+s6nvVe6VJlL6dw5EWMExfJx8X8re1jiX8bOQ/awpKmtnwVMR4cx2R67c/lAxdfhjmtuHj9ut7o4vXkfMX1YzrHwFTufc4Hwsb9uobsH/MG2spuJuYT4XSNOkb7c7oyur4Iaaydu1fac37onkY/0pLLB+fP5PuV8yjui07nbCOGzdeXy6XOmf3ZrqUvbpNPyquYZ6yLHG+8n9Hl+1dLj8jpUJxtxHsW81h+uH55SvrkclyDlIl43cqfnBcxbbW8jsR05LyDeD9wei5B+3Kcxpi5yWBv+g7SVgnVKrXpwssjVq6mO3D/fW+MmXkk/OY7EurGGNM15mQNjEhr6yUZZk+CK+7u4ntjzOxgsW6MMaNlTtbAennknlX846fU6aLPk+657Sbc42E2yowx7VisG2PMaJmzNXC2d8RZwM1fos1oP9tTY8xwyDbX0S56PoHdv66xNsbBGGNGyfzvLjHGGGOMMWaOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmI5isW6MMcYYY0xHsVg3xhhjjDGmo1isG2OMMcYY01Es1o0xxhhjjOkoFuvGGGOMMcZ0FIt1Y4wxxhhjOorFujHGGGOMMR3FYt0YY4wxxpiOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmI5isW6MMcYYY0xHsVg3xhhjjDGmo1isG2OMMcYY01Es1o0xxhhjjOkoFuvGGGOMMcZ0FIt1Y4wxxhhjOorFujHGGGOMMR3FYt0YY4wxxpiOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmI5isW6MMcYYY0xHsVg3xhhjjDGmo1isG2OMMcYY01Es1o0xxhhjjOkoFuvGGGOMMcZ0FIt1Y4wxxhhjOorFujHGGGOMMR3FYt0YY4wxxpiOYrFujDHGGGNMR7FYN8YYY4wxpqNYrBtjjDHGGNNRLNaNMcYYY4zpKBbrxhhjjDHGdBSLdWOMMcYYYzqKxboxxhhjjDEdxWLdGGOMMcaYjmKxbowxxhhjTEexWDfGGGOMMaajWKwbY4wxxhjTUSzWjTHGGGOM6SgW68YYY4wxxnQUi3VjjDHGGGM6isW6McYYY4wxHcVi3RhjjDHGmE7SNP8/uyXyY3zcGdYAAAAASUVORK5CYII=" alt="" width="747" height="431" vspace="0" hspace="0" border="0" style="width:747px;height:431px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p><strong>Table 9 Proportion of patients meeting primary and additional efficacy endpoints at week 52 in maintenance study CD-3 </strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Group</strong></p></td><td style="vertical-align:top"><p><strong>PBO<sup>+</sup><br />N=165</strong></p></td><td style="vertical-align:top"><p><strong>UPA<br />15 mg<br />N=169</strong></p></td><td style="vertical-align:top"><p><strong>UPA<br />30 mg<br />N=168</strong></p></td><td style="vertical-align:top"><p><strong>Treatment Difference<br />15 mg vs<br />PBO<br />(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment Difference<br />30 mg vs<br />PBO<br />(95% CI)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Co-Primary Endpoints</strong></p></td></tr><tr><td><p><strong>Clinical remission<sup>a</sup></strong></p></td><td><p>14%</p></td><td><p>36%</p></td><td><p>46%</p></td><td><p>22%</p><p>(14, 30)<sup>*</sup></p></td><td><p>32%</p><p>(23, 40)<sup>*</sup></p></td></tr><tr><td><p>Prior biologic failure</p></td><td><p>N=126</p><p>9%</p></td><td style="vertical-align:top"><p>N=124</p><p>32%</p></td><td style="vertical-align:top"><p>N=127</p><p>43%</p></td><td><p>24%</p><p>(14, 33)</p></td><td><p>34%</p><p>(24, 44)</p></td></tr><tr><td><p>Without prior biologic failure</p></td><td style="vertical-align:top"><p>N=39</p><p>33%</p></td><td style="vertical-align:top"><p>N=45</p><p>44%</p></td><td style="vertical-align:top"><p>N=41</p><p>59%</p></td><td><p>12%</p><p>(-9, 33)</p></td><td><p>26%</p><p>(5, 47)</p></td></tr><tr><td><p><strong>Endoscopic response<sup>b</sup></strong></p></td><td><p>7%</p></td><td><p>28%</p></td><td><p>40%</p></td><td><p>21%</p><p>(14, 28)<sup>*</sup></p></td><td><p>34%</p><p>(26, 41)<sup>*</sup></p></td></tr><tr><td><p>Prior biologic failure</p></td><td style="vertical-align:top"><p>N=126</p><p>4%</p></td><td style="vertical-align:top"><p>N=124</p><p>23%</p></td><td style="vertical-align:top"><p>N=127</p><p>39%</p></td><td><p>19%</p><p>(11, 27)</p></td><td><p>35%</p><p>(26, 44)</p></td></tr><tr><td><p>Without prior biologic failure</p></td><td style="vertical-align:top"><p>N=39</p><p>18%</p></td><td style="vertical-align:top"><p>N=45</p><p>40%</p></td><td style="vertical-align:top"><p>N=41</p><p>44%</p></td><td><p>22%</p><p>(3, 41)</p></td><td><p>26%</p><p>(7, 45)</p></td></tr><tr><td colspan="6"><p><strong>Additional Endpoints</strong></p></td></tr><tr><td><p><strong>Clinical remission per CDAI<sup>c</sup></strong></p></td><td><p>15%</p></td><td><p>37%</p></td><td><p>48%</p></td><td><p>24%</p><p>(15, 32)<strong><sup>*</sup></strong></p></td><td><p>33%</p><p>(24, 42)<strong><sup>*</sup></strong></p></td></tr><tr><td><p><strong>Clinical response (CR-100)<sup>d</sup></strong></p></td><td><p>15%</p></td><td><p>41%</p></td><td><p>51%</p></td><td><p>27%</p><p>(18, 36)<sup>*</sup></p></td><td><p>36%</p><p>(28, 45)<sup>*</sup></p></td></tr><tr><td><p><strong>Corticosteroid-free clinical remission<sup>a,e</sup></strong></p></td><td><p>14%</p></td><td><p>35%</p></td><td><p>45%</p></td><td><p>21%</p><p>(13, 30)<sup>*</sup></p></td><td><p>30%</p><p>(21, 39)<sup>*</sup></p></td></tr><tr><td><p><strong>Maintenance of clinical remission<sup> a,f</sup></strong></p></td><td><p>N=101</p><p>20%</p></td><td><p>N=105</p><p>50%</p></td><td><p>N=105</p><p>60%</p></td><td><p>32%</p><p>(20, 44)<sup>*</sup></p></td><td><p>40%</p><p>(28, 52)<sup>*</sup></p></td></tr><tr><td><p><strong>Endoscopic remission<sup>g</sup></strong></p></td><td><p>5%</p></td><td><p>19%</p></td><td><p>29%</p></td><td><p>14%</p><p>(8, 21)<sup>*</sup></p></td><td><p>24%</p><p>(16, 31)<sup>*</sup></p></td></tr><tr><td><p><strong>Mucosal healing<sup>h</sup></strong></p></td><td><p>N=164</p><p>4%</p></td><td><p>N=167</p><p>13%</p></td><td><p>N=168</p><p>24%</p></td><td><p>10%</p><p>(4, 16)<sup>***</sup></p></td><td><p>21%</p><p>(14, 27)<sup>***</sup></p></td></tr><tr><td><p><strong>Deep remission<sup> a,i</sup></strong></p></td><td><p>4%</p></td><td><p>14%</p></td><td><p>23%</p></td><td><p>10%</p><p>(4, 16)<sup>**</sup></p></td><td><p>18%</p><p>(11, 25)<sup>*</sup></p></td></tr><tr><td colspan="6"><p>Abbreviation: PBO = placebo, UPA = upadacitinib<sup> </sup></p><p><sup>+</sup> The placebo group consisted of patients who achieved clinical response per SF/APS with upadacitinib 45&nbsp;mg at the end of the induction study and were randomised to receive placebo at the start of maintenance therapy</p><p><sup>*</sup> p &lt; 0.001, adjusted treatment difference (95% CI)</p><p><sup>**</sup> p &lt; 0.01, adjusted treatment difference (95% CI)</p><p><sup>***</sup> nominal p &lt; 0.001 UPA vs PBO comparison, adjusted treatment difference (95% CI)<br /><sup>a</sup> Average daily SF &le; 2.8 and APS &le; 1.0 and neither greater than baseline<br /><sup>b</sup> Decrease in SES-CD &gt; 50% from baseline of the induction study (or for patients with an SES-CD of 4 at baseline of the induction study, at least a 2-point reduction from baseline of the induction study)</p><p><sup>c</sup> CDAI &lt; 150</p><p><sup>d</sup> Reduction of CDAI &ge; 100 points from baseline</p><p><sup>e</sup> Corticosteroid-free for 90 days prior to week 52 and achievement of clinical remission. Among the subset of patients who were on corticosteroids at induction baseline, 38% (N=63) in upadacitinib 15&nbsp;mg group, 38% (N=63) in upadacitinib 30&nbsp;mg group, and 5% (N=61) in placebo were corticosteroid-free for 90 days prior to week 52 and in clinical remission</p><p><sup>f</sup> Defined as achievement of clinical remission at Week 52 in patients who achieved clinical remission at the entry of the maintenance study<br /><sup>g</sup> SES-CD &le; 4 and at least a 2-point reduction versus baseline and no subscore &gt;1 in any individual variable</p><p><sup>h </sup>SES-CD ulcerated surface subscore of 0 in patients with SES-CD ulcerated surface subscore &ge; 1 at baseline</p><p><sup>i </sup>Clinical remission and endoscopic remission</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Patients who were not in clinical response per SF/APS to upadacitinib induction at week 12 in CD-1 and CD-2 (122 patients) received upadacitinib 30&nbsp;mg once daily for an additional 12 weeks. Of these patients, 53% achieved clinical response at week 24. Of the patients who responded to the extended treatment period and continued to receive maintenance treatment with upadacitinib 30&nbsp;mg, 25% achieved clinical remission and 22% achieved endoscopic response at week 52.</p><p><em>&nbsp;</em></p><p><em>Endoscopic assessment</em><br />&nbsp;</p><p>In CD-3, a significantly greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg achieved the co-primary endpoint of endoscopic response at week 52 compared to placebo (Table 9). In addition to the endoscopic endpoints described in Table 9, a greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg (11% and 21%, respectively) compared to placebo (3%) achieved SES-CD 0-2 at week 52. Corticosteroid-free endoscopic remission among patients on steroid at baseline was achieved in a greater proportion of patients treated with upadacitinib 15&nbsp;mg and 30&nbsp;mg (17% and 25%, respectively) compared to placebo (3%) at week 52.</p><p><em>&nbsp;</em></p><p><em>Resolution of extra-intestinal manifestations</em></p><p><em>&nbsp;</em></p><p>Resolution of extra-intestinal manifestations was observed in a greater proportion of patients treated with upadacitinib 15&nbsp;mg (25%) and a significantly greater proportion of patients treated with upadacitinib 30&nbsp;mg (36%) compared to placebo (15%) at week 52.</p><p>&nbsp;</p><p><em>Rescue treatment</em></p><p><em>&nbsp;</em></p><p>In CD-3, patients who demonstrated inadequate response or lost response during maintenance were eligible to receive rescue treatment with upadacitinib 30&nbsp;mg. Of the patients who were randomised to upadacitinib 15&nbsp;mg group and received rescue treatment of upadacitinib 30&nbsp;mg for at least 12 weeks, 84% (76/90) achieved clinical response per SF/APS and 48% (43/90) achieved clinical remission 12 weeks after initiating rescue.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Health-related quality of life outcomes</em></p><p><em>&nbsp;</em></p><p>Patients treated with upadacitinib achieved greater improvement in health-related quality of life (HRQOL) measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) total score compared to placebo. Improvements were seen in all 4 domain scores: systemic symptoms (including fatigue) and bowel symptoms (including abdominal pain and bowel urgency), as well as social and emotional functioning. Changes from baseline in IBDQ total score at week 12 with upadacitinib 45&nbsp;mg once daily compared to placebo were 46.0 and 21.6 in CD-1 and 46.3 and 24.4 in CD-2, respectively. Changes in IBDQ total score at week 52 from baseline were 59.3, 64.5 and 46.4 in patients treated with upadacitinib 15&nbsp;mg, 30&nbsp;mg once daily and placebo, respectively.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>A total of 344 adolescents aged 12 to 17 years with moderate to severe atopic dermatitis were randomised across the three Phase 3 studies to receive either 15&nbsp;mg (N=114) or 30&nbsp;mg (N=114) upadacitinib or matching placebo (N=116), in monotherapy or combination with topical corticosteroids. Efficacy was consistent between the adolescents and adults. The safety profile in adolescents was generally similar to that in adults, with dose-dependent increases in the rate of some adverse events, including neutropaenia and herpes zoster. At both doses, the rate of neutropaenia was slightly increased in adolescents compared to adults. The rate of herpes zoster in adolescents at the 30&nbsp;mg dose was comparable to that in adults. The safety and efficacy of the 30&nbsp;mg dose in adolescents are still being investigated.</p><p>&nbsp;</p><p><strong>Table 10: Efficacy results of upadacitinib for adolescents at week 16</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:559px"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MEASURE UP 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MEASURE UP 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>AD UP </strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment Group</p></td><td style="vertical-align:top"><p>PBO</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>PBO</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>PBO +</p><p>TCS</p></td><td style="vertical-align:top"><p>UPA</p><p>15&nbsp;mg + TCS</p></td></tr><tr><td style="vertical-align:top"><p>Number of adolescent subjects</p><p>randomised</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>42</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>36</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>33</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>% responders </strong><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>vIGA-AD 0/1<strong><sup> </sup></strong><sup>a,b</sup></p></td><td style="vertical-align:top"><p>8</p><p>(0,16)</p></td><td style="vertical-align:top"><p>38</p><p>(23,53)</p></td><td style="vertical-align:top"><p>3</p><p>(0,8)</p></td><td style="vertical-align:top"><p>42</p><p>(26,59)</p></td><td style="vertical-align:top"><p>8</p><p>(0,16)</p></td><td style="vertical-align:top"><p>31</p><p>(16,45)</p></td></tr><tr><td style="vertical-align:top"><p>EASI 75<sup>a</sup></p></td><td style="vertical-align:top"><p>8</p><p>(0,17)</p></td><td style="vertical-align:top"><p>71</p><p>(58,85)</p></td><td style="vertical-align:top"><p>14</p><p>(3,25)</p></td><td style="vertical-align:top"><p>67</p><p>(51,83)</p></td><td style="vertical-align:top"><p>30</p><p>(16,44)</p></td><td style="vertical-align:top"><p>56</p><p>(41,72)</p></td></tr><tr><td style="vertical-align:top"><p>Worst Pruritus NRS<sup>c</sup></p><p>&nbsp;<em>(&ge; 4-point improvement)</em></p></td><td style="vertical-align:top"><p>15</p><p>(4,27)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>45</p><p>(30,60)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>3</p><p>(0,8)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>33</p><p>(16,50)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>13</p><p>(2,24)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>42</p><p>(26,58)</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: UPA= upadacitinib (RINVOQ); PBO = placebo</p><p>Subjects with rescue medication or with missing data were counted as non-responders.</p><p><sup>a</sup> Based on number of subjects randomised</p><p><sup>b </sup>Responder was defined as a patient with vIGA-AD 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) with a reduction of &ge; 2 points on a 0-4 ordinal scale.</p><p><sup>c</sup> Results shown in subset of patients eligible for assessment (patients with Worst Pruritus NRS &ge; 4 at baseline).</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with RINVOQ in one or more subsets of the paediatric population in chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis) &nbsp;atopic dermatitis, ulcerative colitis, and Crohn&rsquo;s disease (see section 4.2 for information on paediatric use).</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Upadacitinib plasma exposures are proportional to dose over the therapeutic dose range. Steady‑state plasma concentrations are achieved within 4 days with minimal accumulation after multiple once daily administrations.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><em>&nbsp;</em></p><p>Following oral administration of upadacitinib prolonged-release formulation, upadacitinib is absorbed with a median T<sub>max</sub>&nbsp;of 2 to 4 hours. Coadministration of upadacitinib with a high-fat meal had no clinically relevant effect on upadacitinib exposures (increased AUC by 29% and C<sub>max</sub> by 39% to 60%). In clinical trials, upadacitinib was administered without regard to meals (see section 4.2). <em>In vitro</em>, upadacitinib is a substrate for the efflux transporters P-gp and BCRP.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><em>&nbsp;</em></p><p>Upadacitinib is 52% bound to plasma proteins. Upadacitinib partitions similarly between plasma and blood cellular components, as indicated by the blood to plasma ratio of 1.0.</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p><em>&nbsp;</em></p><p>Upadacitinib metabolism is mediated by CYP3A4 with a potential minor contribution from CYP2D6. The pharmacologic activity of upadacitinib is attributed to the parent molecule. In a human radiolabeled study, unchanged upadacitinib accounted for 79% of the total radioactivity in plasma while the main metabolite (product of monooxidation followed by glucuronidation) accounted for 13% of the total plasma radioactivity. No active metabolites have been identified for upadacitinib.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><em>&nbsp;</em></p><p>Following single dose administration of [<sup>14</sup>C]-upadacitinib immediate-release solution, upadacitinib was eliminated predominantly as the unchanged parent substance in urine (24%) and faeces (38%). Approximately 34% of upadacitinib dose was excreted as metabolites. Upadacitinib mean terminal elimination half-life ranged from 9 to 14 hours.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><u>&nbsp;</u></p><p>Upadacitinib AUC was 18%, 33%, and 44% higher in subjects with mild (estimated glomerular filtration rate 60 to 89&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>), moderate (estimated glomerular filtration rate 30 to 59&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>), and severe (estimated glomerular filtration rate 15 to 29&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>) renal impairment, respectively, compared to subjects with normal renal function. Upadacitinib C<sub>max</sub> was similar in subjects with normal and impaired renal function. Mild or moderate renal impairment has no clinically relevant effect on upadacitinib exposure (see section 4.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p>Mild (Child‑Pugh A) and moderate (Child‑Pugh B) hepatic impairment has no clinically relevant effect on upadacitinib exposure. Upadacitinib AUC was 28% and 24% higher in subjects with mild and moderate hepatic impairment, respectively, compared to subjects with normal liver function. Upadacitinib C<sub>max</sub> was unchanged in subjects with mild hepatic impairment and 43% higher in subjects with moderate hepatic impairment compared to subjects with normal liver function. Upadacitinib was not studied in patients with severe (Child‑Pugh C) hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The pharmacokinetics of upadacitinib have not yet been evaluated in paediatric patients with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and Crohn&rsquo;s disease (see section 4.2).</p><p>&nbsp;</p><p>Upadacitinib pharmacokinetics and steady-state concentrations are similar for adults and adolescents 12 to 17 years of age with atopic dermatitis. The posology in adolescent patients 30&nbsp;kg to &lt;&nbsp;40&nbsp;kg was determined using population pharmacokinetic modelling and simulation.</p><p>&nbsp;</p><p>The pharmacokinetics of upadacitinib in paediatric patients (&lt;&nbsp;12 years of age) with atopic dermatitis have not been established.</p><p>&nbsp;</p><p><em>Intrinsic factors</em></p><p><u>&nbsp;</u></p><p>Age, sex, body weight, race, and ethnicity did not have a clinically meaningful effect on upadacitinib exposure. Upadacitinib pharmacokinetics are consistent between rheumatoid arthritis, psoriatic arthritis,</p><p>axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn&rsquo;s disease patients.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology.</p><p>&nbsp;</p><p>Upadacitinib, at exposures (based on AUC) approximately 4 and 10&nbsp;times the clinical dose of 15&nbsp;mg, 2 and 5 times the clinical dose of 30&nbsp;mg, and 1.7 and 4 times the clinical dose of 45&nbsp;mg in male and female Sprague-Dawley rats, respectively, was not carcinogenic in a 2‑year carcinogenicity study in Sprague-Dawley rats. Upadacitinib was not carcinogenic in a 26‑week carcinogenicity study in CByB6F1-Tg(HRAS)2Jic transgenic mice.</p><p><em>&nbsp;</em></p><p>Upadacitinib was not mutagenic or genotoxic based on the results of <em>in vitro</em> and <em>in vivo</em> tests for gene mutations and chromosomal aberrations.</p><p>&nbsp;</p><p>Upadacitinib had no effect on fertility in male or female rats at exposures up to approximately 17 and 34 times the maximum recommended human dose (MRHD) of 45&nbsp;mg in males and females, respectively, on an AUC basis in a fertility and early embryonic development study. Dose‑related increases in foetal resorptions associated with post-implantation losses in this fertility study in rats were attributed to the developmental/teratogenic effects of upadacitinib. No adverse effects were observed at exposures below clinical exposure (based on AUC). Post‑implantation losses were observed at exposures 9 times the clinical exposure at the MRHD of 45&nbsp;mg (based on AUC).</p><p><u>&nbsp;</u></p><p>In animal embryo-foetal development studies, upadacitinib was teratogenic in both rats and rabbits. Upadacitinib resulted in increases in skeletal malformations in rats at 1.6, 0.8, and 0.6 times the clinical exposure (AUC-based) at the 15, 30, and 45&nbsp;mg (MRHD) doses, respectively. In rabbits an increased incidence of cardiovascular malformations was observed at 15, 7.6, and 6 times the clinical exposure at the 15, 30, and 45&nbsp;mg doses (AUC-based), respectively.</p><p>&nbsp;</p><p>Following administration of upadacitinib to lactating rats, the concentrations of upadacitinib in milk over time generally paralleled those in plasma, with approximately 30‑fold higher exposure in milk relative to maternal plasma. Approximately 97% of upadacitinib-related material in milk was the parent molecule, upadacitinib.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet contents</u></p><p>&nbsp;</p><p>147.1 Microcrystalline cellulose</p><p>96.0 Hypromellose</p><p>100.6 Mannitol</p><p>96.0 Tartaric acid</p><p>2.4 Silica, colloidal anhydrous</p><p>7.2 Magnesium stearate</p><p>&nbsp;</p><p><u>Film coating</u></p><p>&nbsp;</p><p>6.53 Poly(vinyl alcohol)</p><p>3.30 Macrogol</p><p>2.41 Talc</p><p>1.56 Titanium dioxide (E171)</p><p>0.60 Iron oxide red (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
3 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>&deg;</sup>C.</p><p>&nbsp;</p><p>Store in the original blister or bottle in order to protect from moisture. Keep the bottle tightly closed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>RINVOQ 30&nbsp;mg prolonged‑release tablets</u></p><p>&nbsp;</p><p>HDPE bottles with desiccant and polypropylene cap in carton containing 30&nbsp;prolonged-release tablets.</p><p>Pack size: 1 bottle (30 prolonged-release tablets) or 3 bottles (90 prolonged-release tablets).</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>